[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 208
1. Sampaio J, Brites C, Araujo I, Bacchi CE, Dittmer DP, Tanaka PY, Harrington W Jr, Netto EM: AIDS related malignancies in Brazil. Curr Opin Oncol; 2007 Sep;19(5):476-8
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS related malignancies in Brazil.
  • PURPOSE OF REVIEW: There have been relatively few studies of HIV-related malignancies in Brazil.
  • Universal access to antiretroviral drugs in Brazil has changed both the mortality and morbidity rates of AIDS.
  • Nevertheless, there is also extreme poverty in both urban and rural areas and complications of prolonged immune suppression such as mycobacterial and malignant diseases have put a significant strain on the country's healthcare system.
  • This brief review outlines the existing data regarding AIDS related malignancies in the largest Latin American country.
  • In the studies done of HIV malignancies in Brazil, it appears that these tumors are histologically similar to those that occur in other equatorial countries and differ somewhat from those seen in Europe and the US.
  • SUMMARY: The existence of federally sponsored highly active antiretroviral therapy, clinicians and healthcare providers experienced in the care of HIV patients and high incidence of malignancies associated with oncogenic viruses make Brazil an important site for clinical and basic research in AIDS and immunodeficiency related malignancies.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2005 Oct;19 Suppl 4:S27-30 [16249650.001]
  • [Cites] East Afr Med J. 2005 Sep;82(9 Suppl):S133-4 [16619688.001]
  • [Cites] J Med Virol. 2006 Jun;78(6):719-23 [16628586.001]
  • [Cites] Braz J Med Biol Res. 2006 May;39(5):573-80 [16648893.001]
  • [Cites] Int J Hematol. 2006 Nov;84(4):337-42 [17118760.001]
  • [Cites] Pathol Res Pract. 2007;203(1):1-7 [17157997.001]
  • [Cites] J Infect Dis. 2000 May;181(5):1562-8 [10823754.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • [Cites] J Clin Microbiol. 2002 Sep;40(9):3341-5 [12202576.001]
  • [Cites] Int J Dermatol. 2004 Sep;43(9):643-7 [15357742.001]
  • [Cites] AIDS Patient Care STDS. 1998 Aug;12(8):619-23 [15468433.001]
  • [Cites] J Acquir Immune Defic Syndr. 1993 Aug;6(8):959-63 [8315579.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):230-7 [8607450.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Leukemia. 1997 May;11(5):743-6 [9180301.001]
  • [Cites] J Infect Dis. 1998 Nov;178(5):1488-91 [9780272.001]
  • [Cites] J Gen Virol. 2005 Sep;86(Pt 9):2433-7 [16099900.001]
  • [Cites] Int J Infect Dis. 2005 Sep;9(5):239-50 [16095940.001]
  • (PMID = 17762574.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA070058; United States / NCI NIH HHS / CA / CA109232-05; United States / NCI NIH HHS / CA / CA109232-03S1; United States / FIC NIH HHS / TW / D43 TW000017; United States / NCI NIH HHS / CA / R01 CA109232; United States / NCI NIH HHS / CA / R01 CA163217; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NCI NIH HHS / CA / R01 CA109232-04; United States / NCI NIH HHS / CA / CA109232-03; United States / NCI NIH HHS / CA / CA109232-01; United States / NIDCR NIH HHS / DE / DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NCI NIH HHS / CA / CA109232-02; United States / NCI NIH HHS / CA / R01 CA109232-05; United States / NCI NIH HHS / CA / R01 CA109232-02; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / NCI NIH HHS / CA / CA70058; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NIDCR NIH HHS / DE / DE018304-02; United States / NCI NIH HHS / CA / R01 CA109232-01; United States / NCI NIH HHS / CA / R01 CA109232-03S1; United States / NCI NIH HHS / CA / R01 CA109232-03; United States / NIDCR NIH HHS / DE / DE018304-03; United States / NCI NIH HHS / CA / CA109232-04; United States / FIC NIH HHS / TW / 5D43 TW00017-18
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  • [Other-IDs] NLM/ NIHMS191349; NLM/ PMC2855639
  •  go-up   go-down


2. Sasco AJ, Jaquet A, Boidin E, Ekouevi DK, Thouillot F, Lemabec T, Forstin MA, Renaudier P, N'dom P, Malvy D, Dabis F: The challenge of AIDS-related malignancies in sub-Saharan Africa. PLoS One; 2010;5(1):e8621
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The challenge of AIDS-related malignancies in sub-Saharan Africa.
  • BACKGROUND: With the lengthening of life expectancy among HIV-positive subjects related to the use of highly active antiretroviral treatments, an increased risk of cancer has been described in industrialized countries.
  • The objective of our paper is to review the link between HIV and cancer in sub-Saharan Africa, putting it in perspective with what is already known in Western countries.
  • METHODS AND FINDINGS: Studies for this review were identified from several bibliographical databases including Pubmed, Scopus, Cochrane, Pascal, Web of Science and using keywords "HIV, neoplasia, epidemiology and Africa" and related MesH terms.
  • A clear association was found between HIV infection and AIDS-classifying cancers.
  • The association was less strong for invasive cervical cancer with ORs ranging from 1.1 (0.7-1.2) to 1.6 (1.1-2.3), whereas ORs for squamous intraepithelial lesions were higher, from 4.4 (2.3-8.4) to 17.0 (2.2-134.1).
  • For non AIDS-classifying cancers, squamous cell conjunctival carcinoma of the eye was associated with HIV in many case-referent studies with ORs from 2.6 (1.4-4.9) to 13.0 (4.5-39.4).
  • Other cancer sites found positively associated with HIV include lung, liver, anus, penis, vulva, kidney, thyroid and uterus and a decreased risk of female breast cancer.
  • CONCLUSION: Studies conducted in sub-Saharan Africa show that HIV infection is not only strongly associated with AIDS-classifying cancers but also provided some evidence of association for other neoplasia.
  • African countries need now to implement well designed population-based studies in order to better describe the spectrum of AIDS-associated malignancies and the most effective strategies for their prevention, screening and treatment.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 1995 Aug;21 Suppl 1:S121-4 [8547501.001]
  • [Cites] AIDS. 1996 Apr;10(4):413-7 [8728046.001]
  • [Cites] Br J Ophthalmol. 1996 Jun;80(6):503-8 [8759259.001]
  • [Cites] Lancet. 1996 Aug 31;348(9027):587-91 [8774574.001]
  • [Cites] Tumori. 1995 Sep-Oct;81(5):308-14 [8804445.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Feb;6(2):73-7 [9037556.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1996;67:1-424 [9190379.001]
  • [Cites] Lancet. 1997 Nov 15;350(9089):1425-31 [9371165.001]
  • [Cites] Am J Clin Nutr. 2004 Nov;80(5):1106-22 [15531656.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492 [9705682.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):37-42 [9709301.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):817-20 [9714046.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] AIDS. 1998 Oct 1;12(14):1921-5 [9792393.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1521-8 [9836488.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] Int J Gynaecol Obstet. 1999 May;65(2):171-81 [10405062.001]
  • [Cites] Sex Transm Infect. 1999 Apr;75(2):103-6 [10448362.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):489-92 [11054682.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Oncol Rep. 2001 May-Jun;8(3):659-61 [11295098.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):622-7 [11340563.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1188-201 [11423251.001]
  • [Cites] Int J Cancer. 2001 Aug 1;93(3):430-5 [11433410.001]
  • [Cites] Int J Gynecol Cancer. 2001 May-Jun;11(3):194-7 [11437924.001]
  • [Cites] Int J Gynaecol Obstet. 2002 Jan;76(1):55-63 [11818095.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Br J Cancer. 2002 Jul 29;87(3):301-8 [12177799.001]
  • [Cites] AIDS. 2003 Jan 3;17(1):81-7 [12478072.001]
  • [Cites] Lancet. 2002 Dec 14;360(9349):1921-6 [12493258.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] Sex Transm Dis. 2003 Feb;30(2):137-42 [12567172.001]
  • [Cites] J Womens Health (Larchmt). 2003 Apr;12(3):227-32 [12804353.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2005 Apr;19(2):269-76 [15778115.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5224-8 [16051964.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1505-11 [16104038.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):985-90 [16106415.001]
  • [Cites] Rev Med Interne. 2006 Mar;27(3):227-35 [16337065.001]
  • [Cites] Ann Oncol. 2006 Jun;17(6):914-9 [16565210.001]
  • [Cites] BMC Cancer. 2006;6:135 [16719902.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):355-62 [16832413.001]
  • [Cites] Afr Health Sci. 2006 Jun;6(2):69-75 [16916294.001]
  • [Cites] Br J Cancer. 2006 Sep 4;95(5):642-8 [16868538.001]
  • [Cites] Cancer Lett. 2006 Nov 28;244(1):1-7 [16542773.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Transplant Proc. 2006 Dec;38(10):3533-5 [17175324.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] J Viral Hepat. 2007 Mar;14(3):183-8 [17305884.001]
  • [Cites] Pediatr Blood Cancer. 2007 May;48(5):515-20 [16794998.001]
  • [Cites] Am J Obstet Gynecol. 2007 Apr;196(4):407.e1-8; discussion 407.e8-9 [17403438.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1480-3 [17437020.001]
  • [Cites] Gynecol Obstet Invest. 2007;63(4):222-8 [17191009.001]
  • [Cites] J Med Virol. 2007 Jun;79(6):758-65 [17457908.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):301-6 [18097233.001]
  • [Cites] Cancer Causes Control. 2008 Mar;19(2):147-53 [17992576.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636 [18354839.001]
  • [Cites] Int J Cancer. 2008 May 15;122(10):2260-5 [18241034.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2590-3 [18224690.001]
  • [Cites] J Med Virol. 2008 May;80(5):847-55 [18360898.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Lancet. 2008 May 3;371(9623):1504 [18456099.001]
  • [Cites] AIDS. 1999 Dec 24;13(18):2563-70 [10630526.001]
  • [Cites] AIDS. 1999 Dec 24;13(18):2583-8 [10630528.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]
  • [Cites] J Natl Med Assoc. 2000 Jun;92(6):301-5 [10918766.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2401-8 [9635533.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Bull Cancer. 2003 May;90(5):387-92 [12850760.001]
  • [Cites] J Infect Dis. 2003 Aug 15;188(4):555-63 [12898443.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):84-90 [14501799.001]
  • [Cites] Int J STD AIDS. 2003 Oct;14(10):647-51 [14596765.001]
  • [Cites] Hepatology. 2004 Jan;39(1):211-9 [14752840.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):638-45 [14760378.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2177-83 [15169806.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2644-54 [15197808.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):317-24 [15241829.001]
  • [Cites] Curr Opin Oncol. 2004 Sep;16(5):468-76 [15314517.001]
  • [Cites] Lancet. 1981 Sep 19;2(8247):598-600 [6116083.001]
  • [Cites] Lancet. 1982 May 1;1(8279):1026-7 [6122840.001]
  • [Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1987 Aug 14;36 Suppl 1:1S-15S [3039334.001]
  • [Cites] Lancet. 1990 Jul 7;336(8706):51-2 [1973230.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Ann Intern Med. 1992 Aug 15;117(4):309-11 [1637026.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):26-36 [8478145.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 1;85(17):1382-97 [8350362.001]
  • [Cites] Int J Cancer. 1994 Oct 1;59(1):20-4 [7927898.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Lancet. 1995 Mar 18;345(8951):695-6 [7885126.001]
  • [Cites] AIDS. 1995 Jan;9(1):57-63 [7893442.001]
  • [Cites] Lancet. 1995 May 27;345(8961):1378-9 [7752795.001]
  • [Cites] Int J Cancer. 1995 Sep 27;63(1):29-36 [7558448.001]
  • (PMID = 20066157.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI069919
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2799672
  •  go-up   go-down


3. Krishnan A, Forman SJ: Hematopoietic stem cell transplantation for AIDS-related malignancies. Curr Opin Oncol; 2010 Sep;22(5):456-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation for AIDS-related malignancies.
  • PURPOSE OF REVIEW: AIDS-related malignancies are an ongoing cause of mortality in individuals with HIV infection.
  • In the HIV-negative setting, high-dose chemotherapy or stem cell transplantation is an option for patients with hematologic malignancies.
  • RECENT FINDINGS: Early autologous stem cell transplantation has studies had high relapse rates but they demonstrated that mobilization and engraftment of autologous stem cells were possible in AIDS patients.
  • Recently, in less advanced AIDS lymphoma, autologous stem cell transplantation has resulted in low transplant-related mortality and durable remissions.
  • In addition, case-control studies of HIV-positive versus HIV-negative lymphoma patients undergoing autologous stem cell transplantation have shown similar transplant-related mortality and overall survival.
  • SUMMARY: The potential future applications of autologous and allogeneic stem cell transplantation are the cure of the malignancy as well as the underlying HIV infection by either transplantation of naturally resistant or genetically modified stem cells.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2002 Jul 25;347(4):284-7 [12140307.001]
  • [Cites] Blood. 2009 Aug 13;114(7):1306-13 [19451551.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):317-24 [15241829.001]
  • [Cites] Blood. 1989 Apr;73(5):1340-50 [2649174.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2466-72 [1933784.001]
  • [Cites] Bone Marrow Transplant. 1996 Dec;18(6):1195-7 [8971396.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3561-4 [10446961.001]
  • [Cites] Blood. 2005 Jan 15;105(2):874-8 [15388574.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):59-66 [18158962.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3484-7 [18698002.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):692-8 [19213682.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2192-8 [19332732.001]
  • [Cites] Blood. 2009 Jun 4;113(23):6011-4 [19307667.001]
  • [Cites] AIDS. 2003 Jul 4;17(10):1521-9 [12824790.001]
  • (PMID = 20639760.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA030206; United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / P50 CA107399
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS427480; NLM/ PMC3537514
  •  go-up   go-down


Advertisement
4. Cheung MC, Pantanowitz L, Dezube BJ: AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist; 2005 Jun-Jul;10(6):412-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.
  • Human immunodeficiency virus (HIV)-infected patients are at increased risk of developing cancer, particularly in the later stages of acquired immune deficiency syndrome (AIDS).
  • Despite the advent of highly active anti-retroviral therapy (HAART), malignancy in this population is a leading cause of morbidity and mortality.
  • Kaposi's sarcoma (KS) and AIDS-related non-Hodgkin's lymphoma (ARL) are the most common AIDS-defining malignancies.
  • AIDS-related KS varies from minimal to fulminant disease.
  • Treatment decisions for AIDS-related KS are guided largely by the presence and extent of symptomatic disease.
  • Novel therapies that have become available to treat AIDS-related KS include angiogenesis inhibitors and antiviral agents.
  • ARL comprises a heterogeneous group of malignancies.
  • HIV-infected patients also appear to be at increased risk for developing certain non-AIDS-defining cancers, such as Hodgkin's lymphoma and multiple myeloma.
  • Although the optimal treatment of these neoplasms is at present uncertain, recent advances in chemotherapy, antiretroviral drugs, and supportive care protocols are allowing for more aggressive management of many of the AIDS-related cancers.
  • This article provides an up-to-date review of the epidemiology, pathogenesis, clinical features, and treatment of various AIDS-related malignancies that are likely to be encountered by an oncologist practicing in the current HAART era.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antiretroviral Therapy, Highly Active. Hodgkin Disease / drug therapy. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Medical Oncology / trends. Sarcoma, Kaposi / drug therapy


5. Noguchi K, Fukazawa H, Murakami Y, Takahashi N, Yamagoe S, Uehara Y: Gamma-herpesviruses and cellular signaling in AIDS-associated malignancies. Cancer Sci; 2007 Sep;98(9):1288-96
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma-herpesviruses and cellular signaling in AIDS-associated malignancies.
  • gamma-Herpesviruses, Epstein-Barr virus (EBV/HHV-4) and Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8), are involved in human carcinogenesis, particularly in immunocompromised patients.
  • Virus-associated malignancies are becoming of significant concern for the mortality of long-lived immunocompromised patients, and therefore, research of advanced strategies for AIDS-related malignancies is an important field in cancer chemotherapy.
  • Detailed understanding of the EBV and KSHV lifecycle and related cancers at the molecular level is required for novel strategies of molecular-targeted cancer chemotherapy.
  • The present review gives a simple outline of the functional interactions between KSHV- and EBV-viral gene products and host cell deregulated signaling pathways as possible targets of chemotherapy against AIDS-related malignancies.
  • [MeSH-major] Herpesvirus 4, Human / pathogenicity. Herpesvirus 8, Human / pathogenicity. Lymphoma, AIDS-Related / metabolism. Lymphoma, AIDS-Related / virology. Sarcoma, Kaposi / metabolism. Sarcoma, Kaposi / virology. Signal Transduction / physiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640300.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 102
  •  go-up   go-down


6. Qi Y, Martin MP, Gao X, Jacobson L, Goedert JJ, Buchbinder S, Kirk GD, O'Brien SJ, Trowsdale J, Carrington M: KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog; 2006 Aug;2(8):e79
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show that this genotype confers dual protection over the course of HIV disease; early direct containment of HIV viral load, and late specific defense against opportunistic infections, but not AIDS-related malignancies.
  • The double protection of KIR3DS1/Bw4-80I in an etiologically complex disease such as AIDS, along with the disease specificity of its effects is conceptually novel and underscores the intricacy of host immunogenetics against HIV/AIDS.
  • [MeSH-major] AIDS-Related Opportunistic Infections / genetics. Acquired Immunodeficiency Syndrome / genetics. HLA-B Antigens / genetics. Killer Cells, Natural / immunology. Receptors, Immunologic / genetics
  • [MeSH-minor] Disease Progression. HIV Seropositivity. HIV-1. Humans. Immunocompromised Host. Immunosuppression. Lymphoma, AIDS-Related / genetics. Lymphoma, AIDS-Related / immunology. Receptors, KIR. Receptors, KIR3DS1. Sarcoma, Kaposi / genetics. Sarcoma, Kaposi / immunology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2004 Dec 9;432(7018):769-75 [15592417.001]
  • [Cites] JAMA. 1998 Jan 7;279(1):35-40 [9424041.001]
  • [Cites] J Exp Med. 2005 Apr 4;201(7):1069-75 [15809352.001]
  • [Cites] J Exp Med. 2005 Apr 18;201(8):1319-32 [15837816.001]
  • [Cites] Nat Med. 2005 Dec;11(12):1290-2 [16288280.001]
  • [Cites] Int Ophthalmol Clin. 2006 Spring;46(2):91-110 [16770157.001]
  • [Cites] J Infect Dis. 2000 Mar;181(3):872-80 [10720507.001]
  • [Cites] N Engl J Med. 2001 May 31;344(22):1668-75 [11386265.001]
  • [Cites] Curr Opin Immunol. 2001 Aug;13(4):458-64 [11498302.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):429-34 [12134147.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 6;94(21):1592-3 [12419778.001]
  • [Cites] Annu Rev Med. 2003;54:535-51 [12525683.001]
  • [Cites] Nat Rev Immunol. 2003 Oct;3(10):781-90 [14523385.001]
  • [Cites] EMBO J. 2004 Jan 28;23(2):255-9 [14685277.001]
  • [Cites] N Engl J Med. 1989 Oct 26;321(17):1141-8 [2477702.001]
  • [Cites] Adv Immunol. 1989;47:187-376 [2683611.001]
  • [Cites] J Acquir Immune Defic Syndr. 1992;5(5):490-6 [1560346.001]
  • [Cites] Annu Rev Immunol. 1993;11:269-95 [8476562.001]
  • [Cites] AIDS. 1994 Aug;8(8):1123-8 [7986410.001]
  • [Cites] Annu Rev Immunol. 2005;23:225-74 [15771571.001]
  • (PMID = 16933987.001).
  • [ISSN] 1553-7374
  • [Journal-full-title] PLoS pathogens
  • [ISO-abbreviation] PLoS Pathog.
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / R37 DA004334; United States / NIDA NIH HHS / DA / R56 DA004334; United States / NIDA NIH HHS / DA / R01 DA004334; United States / NIDA NIH HHS / DA / DA04334; United States / Intramural NIH HHS / / ; United Kingdom / Medical Research Council / / G9800943; United States / NCI NIH HHS / CA / N01CO12400; United Kingdom / Medical Research Council / / G0401569; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA-B Antigens; 0 / Receptors, Immunologic; 0 / Receptors, KIR; 0 / Receptors, KIR3DS1
  • [Other-IDs] NLM/ PMC1550271
  •  go-up   go-down


7. Yarchoan R, Tosato G, Little RF: Therapy insight: AIDS-related malignancies--the influence of antiviral therapy on pathogenesis and management. Nat Clin Pract Oncol; 2005 Aug;2(8):406-15; quiz 423
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy insight: AIDS-related malignancies--the influence of antiviral therapy on pathogenesis and management.
  • Patients with HIV infection are at an increased risk of a number of malignancies, including Kaposi's sarcoma (KS) and certain B-cell lymphomas.
  • Most of these tumors are caused by oncogenic DNA viruses, including KS-associated herpesvirus and Epstein-Barr virus.
  • The development of highly active antiretroviral therapy (HAART) has reduced the incidence of many HIV-associated tumors and has generally improved their responsiveness to therapy.
  • However, the number of people living with AIDS is increasing, and it is possible that the number of AIDS-associated malignancies will rise and the pattern of tumors will change as more people live longer with HIV infection.
  • By contrast, the goal of AIDS-related lymphoma therapy in most cases is the attainment of a complete response with curative intent, and the benefits of administering HAART during therapy must be weighed against possible disadvantages.
  • The past decade has seen substantial improvements in the treatment of AIDS-related lymphoma, which is attributed partially to a shift in tumor type and more effective regimens.
  • There is currently an interest in developing new therapies for HIV-associated malignancies, based on viral, vascular or other pathogenesis-based targets.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / physiopathology. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / physiopathology. Sarcoma, Kaposi / virology


8. Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D: AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol; 2008 Oct 10;26(29):4834-42
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: state of the art and therapeutic challenges.
  • Despite the impact of combination antiretroviral therapy (cART) on HIV-related mortality, malignancy remains an important cause of death in the current era.
  • Although the advent of cART has resulted in reductions in the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma, non-AIDS-defining malignancies present an increased risk for HIV-infected patients, characterized by some common clinical features, generally with a more aggressive behavior and a more advanced disease at diagnosis, which is responsible for poorer patient outcomes.
  • Specific therapeutic recommendations are lacking for these new nonopportunistic malignancies, such as Hodgkin's lymphoma, anal cancer, lung cancer, hepatocarcinoma, and many others.
  • Special considerations of these AIDS-related and non-AIDS-related malignancies and their clinical and therapeutic aspects constitute the subject of this review.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18591544.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


9. Bower M, Palmieri C, Dhillon T: AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis; 2006 Feb;19(1):14-9
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy.
  • PURPOSE OF REVIEW: Three cancers in people with HIV denote an AIDS diagnosis: Kaposi's sarcoma, high-grade B-cell non-Hodgkin's lymphoma and invasive cervical cancer.
  • In addition a number of other cancers occur at increased frequency in this population group but are not AIDS-defining illnesses.
  • This review discusses the impact of highly active antiretroviral therapy on the epidemiology and outcome of AIDS-defining cancers.
  • In contrast, highly active antiretroviral therapy has had little impact on the incidence of human papilloma virus-associated tumours (cervical and anal cancer) in people with HIV, although it may improve survival by reducing opportunistic infection deaths.
  • As people with HIV live longer with highly active antiretroviral therapy, an increased incidence of other non AIDS-defining cancers that have no known association with oncogenic infections is becoming apparent.
  • SUMMARY: For those with access to highly active antiretroviral therapy, the good news from the AIDS-defining cancers - particularly Kaposi's sarcoma and non-Hodgkin's lymphoma - may be balanced by the increasing numbers of non AIDS-defining cancers.
  • [MeSH-minor] Female. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / epidemiology. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / epidemiology. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16374212.001).
  • [ISSN] 0951-7375
  • [Journal-full-title] Current opinion in infectious diseases
  • [ISO-abbreviation] Curr. Opin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


10. Warley E, Tamayo Antabak N, Desse J, De Luca A, Warley F, Fernández Galimberti G, D'Agostino G, Quintas L, Szyld E: [Development of AIDS-related malignancies and infections after starting HAART]. Medicina (B Aires); 2010;70(1):49-52
Hazardous Substances Data Bank. AZITHROMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Development of AIDS-related malignancies and infections after starting HAART].
  • In order to evaluate the incidence rate and possible risk factors associated with AIDS-related malignancies and infections (ARMI) we performed data analysis of clinical charts of HIV patients in two hospital cohorts, that started high activity antiretroviral therapy (HAART) between July 2003 and October 2007.
  • A CD4 cell count < 100/150 was associated with risk of developing ARMI.
  • TB in first place and cryptococcosis in second were the AIDS events more frequently observed.
  • A low CD4 cell count was the only observed risk factor statistically associated with development of ARMI.
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. Acquired Immunodeficiency Syndrome / drug therapy. Antiretroviral Therapy, Highly Active. Neoplasms / epidemiology


11. Cáceres W, Cruz-Amy M, Díaz-Meléndez V: AIDS-related malignancies: revisited. P R Health Sci J; 2010 Mar;29(1):70-5
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: revisited.
  • Since the first reports between the association of Human Immunodeficiency Virus (HIV) infection and neoplasia, there has been a dramatic change in the incidence and epidemiology of AIDS-related malignancies.
  • Kaposi sarcoma (KS), non-Hodgkin's lymphomas (NHL), and cervical cancer are classified by the Centers for Disease Control and Prevention (CDC) as AIDS-defining malignancies.
  • However, since the availability of highly active combination antiretroviral therapy (cART), especially protease inhibitors, there has been a steady increase in non- AIDS defining malignancies, such as Hodgkin's lymphoma (HL), lung cancer, hepatocellular cancer, anal cancer and others and a decline in AIDS-defining neoplasias.
  • Although the emergence of non-AIDS defining cancers could be a result of longer life expectancy and due to a better control of HIV, toxic habits and co-infection with other viruses such as hepatitis B, hepatitis C and human papilloma virus (HPV) could play an important role.
  • The interactions of cART and incomplete immune reconstitution could be other factors explaining the increase in non-AIDS defining cancers.
  • These emerging non-AIDS defining malignancies present a new challenge in the care of patients with HIV infection, and require optimal treatment protocols that take into consideration the interaction between cART and systemic chemotherapy.
  • We review the current status of AIDS-related malignancies, its pathophysiology, epidemiology and management with emphasis in the changing patterns of presentation.
  • [MeSH-minor] Humans. Lymphoma, AIDS-Related / epidemiology


12. Orem J, Otieno MW, Remick SC: Challenges and opportunities for treatment and research of AIDS-related malignancies in Africa. Curr Opin Oncol; 2006 Sep;18(5):479-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges and opportunities for treatment and research of AIDS-related malignancies in Africa.
  • PURPOSE OF REVIEW: Following our review of AIDS-associated cancer in developing nations in 2004, we sought to update recent publications and review data on the challenges and opportunities for the treatment and research of AIDS malignancies in Africa.
  • RECENT FINDINGS: It is apparent that the burden of AIDS-related malignancies and other virus-associated tumors is significant and increasing in Africa.
  • Several recent studies report findings on conjunctival squamous cell carcinoma and there is a report that Hodgkin's disease, a non-AIDS-defining neoplasm, is increasing in incidence.
  • International collaborative partnerships dedicated to AIDS malignancies in developing countries are feasible and invaluable for clinical strategies to address this aspect of the pandemic.
  • A departure point is the ongoing work of the East Africa - Case Western Reserve University Collaboration in AIDS malignancies.
  • SUMMARY: The burden of neoplastic complications of HIV infection and endemic virus-associated tumors are assuming increasing significance in Africa.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894296.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI36219; United States / NCI NIH HHS / CA / CA43703; United States / NCI NIH HHS / CA / CA70081; United States / NCI NIH HHS / CA / CA83528; United States / FIC NIH HHS / TW / TW00011
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 56
  •  go-up   go-down


13. Bose P, Thompson CL, Gandhi DG, Ghabach BS, Ozer H: Response of AIDS-related plasmablastic lymphoma (PBL) to bortezomib. J Clin Oncol; 2009 May 20;27(15_suppl):e19562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of AIDS-related plasmablastic lymphoma (PBL) to bortezomib.
  • An AIDS-defining illness, PBL comprises 2.6% of AIDS-related lymphomas.
  • A 42-year-old male with newly diagnosed AIDS presented with nausea, vomiting, bloody diarrhea and epigastric pain.
  • However, studies of their immunophenotype and molecular histogenesis suggest that PBL are more closely related to plasma cell neoplasms.
  • A shift in the paradigm of treatment of PBL towards agents effective in plasma cell malignancies may be necessary.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961065.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Cuéllar Ponce de León LE Sr, Miranda Rosales LM Sr, Biminchumo Zagástegui C, Rosales Cusichaqui R, Flores C Sr, Mas López L Sr, León Chong J Sr: Human immunodeficiency virus/acquired immunodeficiency syndrome-related cancer in the pre- and post-highly active antiretroviral therapy era in a national cancer center of a resource-limited country: 1988 to 2007. J Clin Oncol; 2009 May 20;27(15_suppl):e20550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human immunodeficiency virus/acquired immunodeficiency syndrome-related cancer in the pre- and post-highly active antiretroviral therapy era in a national cancer center of a resource-limited country: 1988 to 2007.
  • : e20550 Background: The introduction of the highly active antiretroviral therapy (HAART) has changed the clinical course of acquired immune deficiency syndrome (AIDS) related to cancer.
  • The goals were to describe the the characteristics of AIDS related to cancer before and after HAART in patients in a Hospital of a resource-limited country.
  • The number of invasive cervical cancer (CC) and AIDS-related lymphomas (ARLs) increased in the Post HAART era; the number on non-HIV/AIDS related to cancer has decreased.
  • CONCLUSIONS: The introduction of HAART has reduced the number of non-VIH/AIDS related cancer, but have increased the CC and LNH and improved the survival of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961054.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Ortega ME: AIDS-related malignancies--a new approach. AIDS Rev; 2008 Apr-Jun;10(2):125-6
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies--a new approach.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18615123.001).
  • [ISSN] 1139-6121
  • [Journal-full-title] AIDS reviews
  • [ISO-abbreviation] AIDS Rev
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] Spain
  •  go-up   go-down


16. Kiertiburanakul S, Likhitpongwit S, Ratanasiri S, Sungkanuparph S: Malignancies in HIV-infected Thai patients. HIV Med; 2007 Jul;8(5):322-3
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancies in HIV-infected Thai patients.
  • Of 1416 HIV-infected patients seen at Ramathibodi Hospital over a 5-year period (1999-2003), 42 were diagnosed with malignancies, giving a prevalence of 3%.
  • AIDS-related malignancies were found in 26 patients (62%).
  • The most common AIDS-related malignancies were non-Hodgkin's lymphoma (NHL) (33%), cervical cancer (21%) and Kaposi's sarcoma (KS) (5%).
  • Breast cancer was the most common non-AIDS-related malignancy (10%).
  • The 75% survival time of patients who received treatment for their malignancy was longer than that of patients who received no treatment (18.3 vs 1.2 months; P<0.01).

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17561879.001).
  • [ISSN] 1464-2662
  • [Journal-full-title] HIV medicine
  • [ISO-abbreviation] HIV Med.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  •  go-up   go-down


17. Nguyen ML, Farrell KJ, Gunthel CJ: Non-AIDS-Defining Malignancies in Patients with HIV in the HAART Era. Curr Infect Dis Rep; 2010 Jan;12(1):46-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-Defining Malignancies in Patients with HIV in the HAART Era.
  • The introduction of highly active antiretroviral therapy (HAART) has drastically changed the scope and spectrum of diseases associated with HIV, shifting from AIDS-related to non-AIDS-related diseases.
  • Studies linking HIV/AIDS databases to cancer registries have shown a dramatic decrease in AIDS-related malignancies and a steady increase in non-AIDS-defining malignancies (NADM).
  • Meta-analysis of published studies show an increase in NADM over the general population, mostly among infection-related cancers such as anal cancer, Hodgkin lymphoma, and liver cancer.
  • Among the non-infection-related cancers, lung and skin cancers predominate.
  • As HIV-infected individuals survive longer, better screening strategies are needed to detect cancer earlier, and prospective data are needed to assess the impact of HAART on cancer outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Immun Ageing. 2008 Sep 24;5:11 [18816370.001]
  • [Cites] Arch Intern Med. 2009 Jun 22;169(12):1130-8 [19546414.001]
  • [Cites] Curr Opin HIV AIDS. 2009 Jan;4(1):3-10 [19339934.001]
  • [Cites] Curr Opin Infect Dis. 2009 Feb;22(1):7-10 [19532075.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Transplant Proc. 2008 Jul-Aug;40(6):1965-71 [18675102.001]
  • [Cites] AIDS. 2009 May 15;23(8):875-85 [19349851.001]
  • [Cites] AIDS. 2008 Oct 18;22(16):2135-41 [18832877.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):861-8 [15213571.001]
  • [Cites] AIDS. 2004 Nov 19;18(17):2285-93 [15577541.001]
  • [Cites] Clin Infect Dis. 2009 Oct 1;49(7):1109-16 [19705973.001]
  • [Cites] AIDS. 2008 Apr 23;22(7):841-8 [18427202.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Sep;43(1):47-55 [16936558.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1505-11 [16104038.001]
  • [Cites] Obstet Gynecol Clin North Am. 2009 Mar;36(1):187-200 [19344856.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):305-9 [19412116.001]
  • [Cites] AIDS. 2003 Jan 3;17(1):81-7 [12478072.001]
  • [Cites] Exp Gerontol. 2007 May;42(5):432-7 [17307327.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] AIDS Educ Prev. 2009 Jun;21(3 Suppl):3-13 [19537950.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):506-12 [11330577.001]
  • [Cites] Lancet Oncol. 2009 Apr;10(4):321-2 [19350698.001]
  • [Cites] AIDS. 2009 Nov 13;23(17):2337-45 [19741479.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):6-7 [17617251.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2590-3 [18224690.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7 [18363070.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] AIDS. 2007 Sep 12;21(14):1957-63 [17721103.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):41-50 [19050385.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] Oncol Rep. 2007 May;17(5):1121-6 [17390054.001]
  • [Cites] Arch Intern Med. 2008 Nov 24;168(21):2326-32; discussion 2332 [19029496.001]
  • [Cites] Lung Cancer. 2006 Jan;51(1):1-11 [16300854.001]
  • [Cites] Curr Infect Dis Rep. 2009 Sep;11(5):407-13 [19698285.001]
  • [Cites] J Hepatol. 2007 Oct;47(4):527-37 [17692986.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Leuk Lymphoma. 2007 Oct;48(10):2058-9 [17917974.001]
  • [Cites] Lung Cancer. 2009 Sep;65(3):345-50 [19135758.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1383-8 [16549832.001]
  • (PMID = 21308498.001).
  • [ISSN] 1534-3146
  • [Journal-full-title] Current infectious disease reports
  • [ISO-abbreviation] Curr Infect Dis Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Cheung MC, Hicks LK, Leitch HA: Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk; 2010 Apr;10(2):E22-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma.
  • Hodgkin lymphoma (HL) is the second most common non-AIDS-defining malignancy among persons infected with HIV, and its incidence might be increasing in the current era of combination antiretroviral therapy (cART).
  • Antiretroviral therapy is commonly prescribed concomitantly with chemotherapy in the treatment of AIDS-related malignancies.
  • In particular, the potential for excessive vinca alkaloid-associated toxicity is significant, given the metabolism of drugs such as vinblastine by the 3A4 isoenzyme of the cytochrome P450 system and the inhibition of this isoenzyme by protease inhibitors.
  • We report 3 patients who experienced severe vinblastine-associated neurotoxicity during concomitant treatment with ritonavirboosted antiretrovirals.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV Infections / drug therapy. Hodgkin Disease. Lymphoma, AIDS-Related


19. Aoki Y, Tosato G: Interactions between HIV-1 Tat and KSHV. Curr Top Microbiol Immunol; 2007;312:309-26
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the advent of the HIV-1 pandemic, a close association between HIV-1 infection and the development of selected types of cancers has been brought to light.
  • The discovery of Kaposi sarcoma-associated herpesvirus (KSHV) has led to significant advances in uncovering the virological and molecular mechanisms involved in the pathogenesis of AIDS-related malignancies.
  • Extensive evidence indicates that HIV-1 trans-activating protein Tat plays an oncogenic role in the development of KSHV-associated neoplasms.
  • Comprehensive knowledge of the functions of Tat-1 together with the KSHV genes will contribute to a better understanding of the pathogenesis of virus-associated cancers and the interaction of viruses with their hosts.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17089803.001).
  • [ISSN] 0070-217X
  • [Journal-full-title] Current topics in microbiology and immunology
  • [ISO-abbreviation] Curr. Top. Microbiol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Gene Products, tat; 0 / tat Gene Products, Human Immunodeficiency Virus
  • [Number-of-references] 122
  •  go-up   go-down


20. Sloand E: Hematologic complications of HIV infection. AIDS Rev; 2005 Oct-Dec;7(4):187-96
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment of HIV-infected patients with highly active antiretroviral therapy (HAART) has altered the natural history of human immunodeficiency virus (HIV) infection by decreasing the frequency of opportunistic infections and altering the expected frequency of hematologic complications and AIDS-related malignancies.
  • [MeSH-minor] Anemia / drug therapy. Anemia / etiology. Antiretroviral Therapy, Highly Active. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / etiology. Neutropenia / drug therapy. Neutropenia / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425959.001).
  • [ISSN] 1139-6121
  • [Journal-full-title] AIDS reviews
  • [ISO-abbreviation] AIDS Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 105
  •  go-up   go-down


21. Smit C, Geskus R, Walker S, Sabin C, Coutinho R, Porter K, Prins M, CASCADE Collaboration: Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS; 2006 Mar 21;20(5):741-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Causes of death (COD) were categorized into three AIDS-related and seven non-AIDS-related causes.
  • Pre-HAART, AIDS opportunistic infections (OI) was the most common COD, followed by unknown and HIV/AIDS-unspecified.
  • In the HAART era, the cumulative incidence for all AIDS-related COD decreased, OI remaining the most important.
  • The cumulative risk of death from AIDS-related malignancies, OI and non-AIDS-related malignancies decreased significantly among homosexual men (MSM), whereas the risk of dying from (un)-intentional death increased significantly among injecting drug users (IDU).
  • A non-significant increase in hepatitis/liver-related death was seen in MSM, IDU and haemophiliacs.
  • OI remain the most common COD in the HAART era, suggesting that AIDS-related events will continue to be important in the future.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / mortality. Adult. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Cohort Studies. Disease Progression. Female. Follow-Up Studies. HIV Seropositivity. Hepatitis / mortality. Hepatitis / virology. Humans. Incidence. Lymphoma, AIDS-Related / mortality. Lymphoma, AIDS-Related / virology. Male. Multivariate Analysis. RNA, Viral / blood. Risk. Substance Abuse, Intravenous


22. Savage P: A new approach to immunotherapy: for AIDS and AIDS-related malignancies. J HIV Ther; 2006 Sep;11(3):64-6
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new approach to immunotherapy: for AIDS and AIDS-related malignancies.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Cancer Immunotherapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580502.001).
  • [ISSN] 1462-0308
  • [Journal-full-title] Journal of HIV therapy
  • [ISO-abbreviation] J HIV Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 20
  •  go-up   go-down


23. Arora A, Chiao E, Tyring SK: AIDS malignancies. Cancer Treat Res; 2007;133:21-67
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS malignancies.
  • Among individuals with HIV-infection, coinfection with oncogenic viruses including EBV, HHV-8, and HPV cause significant cancer-related morbidity and mortality.
  • It is clear that these viruses interact with HIV in unique ways that predispose HIV-infected individuals to malignant diseases.
  • In general, treatment directed specifically against these viruses does not appear to change the natural history of the malignant disease, and once the malignancy develops, if their health permits, HIV-infected patients should be treated using similar treatment protocols to HIV-negative patients.
  • However, for the less frequent HIV-related malignancies, such as PEL, or MCD, optimal treatments are still emerging.
  • For certain AIDS-defining malignancies, it is clear that the widespread access to HAART has significantly decreased the incidence, and improved outcomes.
  • However, for other cancers, such as the HPV-related tumors, the role of HAART is much less clear.
  • Further research into prevention and treatment of these oncogenic virally mediated AIDS-related malignancies is necessary.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17672037.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 368
  •  go-up   go-down


24. Lim ST, Levine AM: Non-AIDS-defining cancers and HIV infection. Curr HIV/AIDS Rep; 2005 Aug;2(3):146-53
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-defining cancers and HIV infection.
  • With fewer patients now succumbing to infectious complications of AIDS, other HIV-related morbidities, such as malignancies, have become increasingly important.
  • Apart from Kaposi's sarcoma, non-Hodgkin's lymphoma, and cervical cancer, which are considered as AIDS-defining, several additional cancers, referred to as non-AIDS-defining cancers, are also statistically increased in HIV-infected persons.
  • These include Hodgkin's disease, anal carcinoma, lung cancer, nonmelanomatous skin cancer, and testicular germ cell tumors, among others.
  • However, the types of cancer observed at an increased frequency and the relative risks reported vary widely among studies.
  • Although immunosuppression is consistently associated with an increased risk of AIDS-related malignancies, the role of immunosuppression in the pathogenesis of non-AIDS- defining cancers is controversial.
  • Although data regarding the optimal management of these cancers are lacking, current studies suggest that patients with HIV-associated malignancies should be treated with similar approaches to those of their counterparts in the general population.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Eur J Epidemiol. 1995 Dec;11(6):609-14 [8861842.001]
  • [Cites] Ann Thorac Surg. 2003 Feb;75(2):367-71 [12607641.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):444-50 [11035615.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Apr;5(2):343-56 [2022598.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 5;89(21):1602-8 [9362158.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] AIDS Care. 1996 Feb;8(1):5-14 [8664369.001]
  • [Cites] Ann Oncol. 1993 Sep;4(8):635-41 [8240994.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2540-6 [7595705.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1276-87 [11423259.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2705-11 [7595728.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2739-45 [11753946.001]
  • [Cites] Int J STD AIDS. 2001 Feb;12(2):100-2 [11236097.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2157-64 [11684935.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):432-6 [1617592.001]
  • [Cites] Cancer. 1990 May 15;65(10):2248-54 [2346909.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Ann Oncol. 1999 Feb;10(2):189-95 [10093688.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):563-9 [10649248.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1562-9 [14504059.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1391-7 [7538557.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1348-9; author reply 1349-50 [15051794.001]
  • [Cites] Clin Infect Dis. 2003 Jul 15;37(2):292-8 [12856222.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):480-8 [10950375.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Oct;10(5):997-1010 [8880192.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] Chest. 1993 Feb;103(2):410-3 [8432128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Sep;11(9):1587-93 [3928544.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2319-26 [10090942.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12667-71 [11058153.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] Chest. 1998 Jan;113(1):154-61 [9440583.001]
  • [Cites] Mutat Res. 1999 Oct 19;429(2):249-59 [10526209.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):754-8 [10762748.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1922-7 [12743144.001]
  • [Cites] Fundam Appl Toxicol. 1996 Aug;32(2):148-58 [8921318.001]
  • [Cites] Mutagenesis. 2000 Sep;15(5):405-10 [10970446.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):753-7 [11745473.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:201-5 [1710920.001]
  • [Cites] Lung Cancer. 2002 Apr;36(1):9-14 [11891027.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):457-9 [12888811.001]
  • [Cites] Am J Surg Pathol. 1996 Dec;20(12):1520-4 [8944046.001]
  • [Cites] Chest. 1992 Dec;102(6):1704-8 [1446476.001]
  • (PMID = 16091262.001).
  • [ISSN] 1548-3568
  • [Journal-full-title] Current HIV/AIDS reports
  • [ISO-abbreviation] Curr HIV/AIDS Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 64
  •  go-up   go-down


25. Hoffmann C, Horst HA, Weichenthal M, Hauschild A: Malignant melanoma and HIV infection -- aggressive course despite immune reconstitution. Onkologie; 2005 Jan;28(1):35-7
HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma and HIV infection -- aggressive course despite immune reconstitution.
  • BACKGROUND: Highly active antiretroviral therapy (HAART) has altered the course of most AIDS-related malignancies.


26. Llibre JM, Falco V, Tural C, Negredo E, Pineda JA, Muñoz J, Ortega E, Videla S, Sirera G, Martinez E, Miralles C, Iribarren J, Galindo MJ, Domingo P, d'Arminio-Monforte A, Miro JM, Clotet B: The changing face of HIV/AIDS in treated patients. Curr HIV Res; 2009 Jul;7(4):365-77
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The changing face of HIV/AIDS in treated patients.
  • Typical AIDS-defining illnesses have been substituted by new comorbid conditions that threaten even those patients who maintain virologic suppression.
  • Proper management of cardiovascular risk, and early diagnosis of AIDS-related and, particularly, non-AIDS-related malignancies (including papilomavirus-related neoplasms) must be introduced into the routine of care.
  • Hot areas of investigation include HIV-associated neurocognitive disorders, hepatitis B and C coinfection, non-alcoholic fatty liver disease, progressive multifocal leukoencephalopathy and tuberculosis.
  • [MeSH-minor] AIDS-Related Complex / epidemiology. AIDS-Related Complex / therapy. AIDS-Related Opportunistic Infections / epidemiology. AIDS-Related Opportunistic Infections / therapy. Cardiovascular Diseases / epidemiology. Cardiovascular Diseases / therapy. HIV-Associated Lipodystrophy Syndrome / epidemiology. HIV-Associated Lipodystrophy Syndrome / therapy. Humans. Immune Reconstitution Inflammatory Syndrome / therapy. Lymphoma, AIDS-Related / epidemiology. Lymphoma, AIDS-Related / therapy. Neoplasms / epidemiology. Neoplasms / therapy


27. Orem J, Otieno MW, Banura C, Katongole-Mbidde E, Johnson JL, Ayers L, Ghannoum M, Fu P, Feigal EG, Black J, Whalen C, Lederman M, Remick SC: Capacity building for the clinical investigation of AIDS malignancy in East Africa. Cancer Detect Prev; 2005;29(2):133-45
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capacity building for the clinical investigation of AIDS malignancy in East Africa.
  • PURPOSE: To build capacity in the resource-poor setting to support the clinical investigation and treatment of AIDS-related malignancies in a region of the world hardest hit by the AIDS pandemic.
  • METHODS: An initial MEDLINE database search for international collaborative partnerships dedicated to AIDS malignancies in developing countries failed to identify any leads.
  • Building on the formal Uganda-Case Western Reserve University (Case) Research Collaboration dating back to 1987, established NIH-supported centers of research excellence at Case, and expanding activities in Kenya, scientific and training initiatives, research capital amongst our institutions are emerging to sustain a international research enterprise focused on AIDS and other viral-related malignancies.
  • An oral chemotherapy feasibility trial in AIDS lymphoma is near completion; a second lymphoma trial of byrostatin and vincristine is anticipated and a feasibility trial of indinavir for endemic Kaposi's sarcoma is planned.
  • CONCLUSIONS: In the absence of published reports of evolving international partnerships dedicated to AIDS malignancy in resource constrained settings, we feel it important for such progress on similar or related international collaborative pursuits to be published.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15829373.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Rao D, Debb S, Blitz D, Choi SW, Cella D: Racial/Ethnic differences in the health-related quality of life of cancer patients. J Pain Symptom Manage; 2008 Nov;36(5):488-96

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racial/Ethnic differences in the health-related quality of life of cancer patients.
  • Previous research has suggested that, when compared to European Americans (EAs), African Americans (AAs) are at higher risk of metastatic disease at time of cancer diagnosis, and a higher risk of shorter survival.
  • Although AA patients have reported worse physical health than EA patients, studies have rarely addressed whether racial/ethnic disparities exist on the social, emotional, and functional aspects of health-related quality of life.
  • Five hundred and two AA and 396 EA patients with AIDS-related malignancies or breast, colon, head/neck, and lung cancers seeking treatment within the contiguous United States and Puerto Rico participated in the present study.
  • Responses on the Functional Assessment of Cancer Therapy-General were analyzed for possible racial/ethnic disparities using multivariable regression models and item response theory modeling to detect differential item functioning.
  • Differential item functioning was found in six items of the Functional Assessment of Cancer Therapy-General, indicating that AA and EA participants had different probabilities of responding to these items.
  • Compared to EAs at the same level of health-related quality of life, AAs reported more severe symptomatology on items that reflected malaise and ability to work, and less severe symptomatology on items that reflected fatigue, treatment side effects, and outlook on life.
  • Some items appear to be responded to differently by AAs and EAs, suggesting it is important to consider race/ethnicity when evaluating responses to questions about health-related quality of life.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Health Serv Res. 2000 Feb;34(6):1273-302 [10654830.001]
  • [Cites] Med Care. 2008 Apr;46(4):423-31 [18362823.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 7;93(3):219-25 [11158191.001]
  • [Cites] J Natl Cancer Inst. 2001 Mar 7;93(5):388-95 [11238701.001]
  • [Cites] Cancer. 2001 May 1;91(9):1834-43 [11335911.001]
  • [Cites] J Urol. 2001 Dec;166(6):2281-5 [11696752.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1451-9 [11745222.001]
  • [Cites] Cultur Divers Ethnic Minor Psychol. 2002 Nov;8(4):366-77 [12416322.001]
  • [Cites] Cancer. 2003 Jan 1;97(1 Suppl):311-7 [12491494.001]
  • [Cites] Arch Phys Med Rehabil. 2003 Apr;84(4 Suppl 2):S35-42 [12692770.001]
  • [Cites] Pain Med. 2003 Sep;4(3):277-94 [12974827.001]
  • [Cites] Psychooncology. 2004 Jun;13(6):408-28 [15188447.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):570-9 [8445433.001]
  • [Cites] JAMA. 1995 Jan 4;273(1):59-65 [7996652.001]
  • [Cites] J Health Soc Behav. 1995 Mar;36(1):1-10 [7738325.001]
  • [Cites] Int J Health Serv. 1996;26(3):483-505 [8840198.001]
  • [Cites] Cancer. 1997 Oct 1;80(7):1261-6 [9317177.001]
  • [Cites] Med Care. 1998 Sep;36(9):1407-18 [9749663.001]
  • [Cites] Urology. 2005 Jan;65(1):101-8 [15667873.001]
  • [Cites] J Health Care Poor Underserved. 2005 May;16(2):375-90 [15937399.001]
  • [Cites] Urology. 2006 May;67(5):1022-7 [16698362.001]
  • [Cites] Med Care. 2006 Nov;44(11 Suppl 3):S3-4 [17060831.001]
  • [Cites] Cultur Divers Ethnic Minor Psychol. 2007 Jan;13(1):64-71 [17227178.001]
  • [Cites] Cancer. 2000 Mar 1;88(5 Suppl):1217-23 [10705358.001]
  • (PMID = 18504096.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01-CA61679; United States / NIAMS NIH HHS / AR / U01 AR052177; United States / NIAMS NIH HHS / AR / AR052177-04; United States / NIAMS NIH HHS / AR / U01 AR052177-04; United States / NCI NIH HHS / CA / R01 CA061679
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS78122; NLM/ PMC2596636
  •  go-up   go-down


29. Laurido M, Urueña A, Vizzotti C, Bugarin G, Cassetti I: [Incidence variation in malignancies associated or not with AIDS at an outpatient care center, 1997-2005]. Medicina (B Aires); 2007;67(3):243-6
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidence variation in malignancies associated or not with AIDS at an outpatient care center, 1997-2005].
  • In Argentina there are no published data on the incidence of AIDS (ARM) and non-AIDS related malignancies (non-ARM) in the HIV positive population.
  • Our aim was to establish the incidence of these malignancies at an ambulatory care center between 1997 and 2005.
  • We describe 103 cases of malignancies, 73 out of them were ARM and 30 were non-ARM.
  • Among those patients with ARM, simultaneous diagnosis of malignancy and HIV infection was more frequently seen (p <0.001) and the proportion of patients with AIDS was higher (p = 0.015).
  • Among those patients with non-ARM the mean duration of HIV infection and HAART was higher (p = 0.038 and 0.002 respectively); also was higher the mean CD4 count nadir (p = 0.009), and CD4 count at the time of malignancy diagnosis (p <0.001).
  • [MeSH-minor] AIDS-Related Opportunistic Infections / complications. AIDS-Related Opportunistic Infections / drug therapy. AIDS-Related Opportunistic Infections / mortality. Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / drug therapy. Acquired Immunodeficiency Syndrome / mortality. Adult. Antiretroviral Therapy, Highly Active. Argentina / epidemiology. Female. Humans. Immunocompromised Host. Incidence. Male. Retrospective Studies

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17628911.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


30. Belloso WH, Orellana LC, Grinsztejn B, Madero JS, La Rosa A, Veloso VG, Sanchez J, Ismerio Moreira R, Crabtree-Ramirez B, Garcia Messina O, Lasala MB, Peinado J, Losso MH: Analysis of serious non-AIDS events among HIV-infected adults at Latin American sites. HIV Med; 2010 Oct 1;11(9):554-64
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of serious non-AIDS events among HIV-infected adults at Latin American sites.
  • OBJECTIVE: Acquired immune deficiency appears to be associated with serious non-AIDS (SNA)-defining conditions such as cardiovascular disease, liver and renal insufficiency and non-AIDS-related malignancies.
  • We analysed the incidence of, and factors associated with, several SNA events in the LATINA retrospective cohort.
  • Conditional logistic models were fitted to estimate the effect of traditional risk factors as well as HIV-associated factors on non-AIDS-defining conditions.
  • RESULTS: Among 6007 patients in follow-up, 130 had an SNA event (0.86 events/100 person-years of follow-up) and were defined as cases (40 with cardiovascular events, 54 with serious liver failure, 35 with non-AIDS-defining malignancies and two with renal insufficiency).
  • CD4 cell count at index date was significantly associated with the outcome after adjusting for risk factors.


31. Mwanda WO, Orem J, Fu P, Banura C, Kakembo J, Onyango CA, Ness A, Reynolds S, Johnson JL, Subbiah V, Bako J, Wabinga H, Abdallah FK, Meyerson HJ, Whalen CC, Lederman MM, Black J, Ayers LW, Katongole-Mbidde E, Remick SC: Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa. J Clin Oncol; 2009 Jul 20;27(21):3480-8
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa.
  • PURPOSE Africa is burdened by the AIDS epidemic and attendant increase in HIV/AIDS-related malignancies.
  • Dose-modified oral chemotherapy for AIDS-related non-Hodgkin's lymphoma is one such approach.
  • Four febrile neutropenia episodes and three treatment-related deaths (6% mortality rate) occurred.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV-1 / physiology. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Med Pediatr Oncol. 2003 Dec;41(6):532-40 [14595710.001]
  • [Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]
  • [Cites] Am J Med. 1986 Jan;80(1):119-22 [3942143.001]
  • [Cites] Ann Intern Med. 1989 Jun 1;110(11):937-40 [2719427.001]
  • [Cites] Rev Infect Dis. 1989 Nov-Dec;11(6):954-63 [2690289.001]
  • [Cites] J Acquir Immune Defic Syndr. 1990;3(4):430-7 [2313564.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):26-36 [8478145.001]
  • [Cites] Blood. 1993 May 15;81(10):2810-5 [8490187.001]
  • [Cites] Drugs. 1999;58 Suppl 3:99-107 [10711848.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]
  • [Cites] Ann N Y Acad Sci. 2000 Nov;918:362-6 [11131726.001]
  • [Cites] Am J Hematol. 2001 Mar;66(3):178-88 [11279624.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2171-8 [11304769.001]
  • [Cites] Biometrics. 1999 Jun;55(2):625-9 [11318225.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):687-91 [11340573.001]
  • [Cites] J Am Coll Nutr. 2001 Dec;20(6):609-15 [11771676.001]
  • [Cites] J Natl Cancer Inst. 2002 May 15;94(10):718-32 [12011222.001]
  • [Cites] Lancet Oncol. 2003 Jan;4(1):22-9 [12517536.001]
  • [Cites] Curr Opin Oncol. 2004 Sep;16(5):468-76 [15314517.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1691-702 [8355036.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Leuk Lymphoma. 1994 Jul;14(3-4):263-71 [7950915.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):3026-35 [8918501.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] AIDS. 1998;12 Suppl 1:S3-14 [9677185.001]
  • [Cites] Haematologica. 1998 Jun;83(6):508-13 [9676023.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3601-6 [9817281.001]
  • [Cites] Pediatr Blood Cancer. 2005 Mar;44(3):245-50 [15547922.001]
  • [Cites] Cancer Detect Prev. 2005;29(2):133-45 [15829373.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):985-90 [16106415.001]
  • [Cites] East Afr Med J. 2005 Sep;82(9 Suppl):S155-60 [16619692.001]
  • [Cites] Blood. 2006 May 15;107(10):3832-40 [16410446.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):479-86 [16894296.001]
  • [Cites] N Engl J Med. 2006 Sep 14;355(11):1141-53 [16971720.001]
  • [Cites] Lancet Oncol. 2008 Apr;9(4):319 [18380064.001]
  • [Cites] Nat Rev Cancer. 2008 May;8(5):398-403 [18385682.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):673-96, v [12852650.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • (PMID = 19470940.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / FIC NIH HHS / TW / TW00011; United States / NCI NIH HHS / CA / R01 CA083528; United States / NIAID NIH HHS / AI / AI36219; United States / NCI NIH HHS / CA / CA83528; United States / NCI NIH HHS / CA / U01 CA070081; United States / NCI NIH HHS / CA / P30 CA043703; United States / NCI NIH HHS / CA / CA066531; United States / NCI NIH HHS / CA / CA43703; United States / FIC NIH HHS / TW / D43 TW000011; United States / NCI NIH HHS / CA / CA70081; United States / NCI NIH HHS / CA / U01 CA066531; United States / NIAID NIH HHS / AI / P30 AI036219
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ PMC2717754
  •  go-up   go-down


32. Reekie J, Kosa C, Engsig F, Monforte Ad, Wiercinska-Drapalo A, Domingo P, Antunes F, Clumeck N, Kirk O, Lundgren JD, Mocroft A, EuroSIDA Study Group: Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer; 2010 Nov 15;116(22):5306-15
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies.
  • BACKGROUND: In the combined antiretroviral therapy (cART) era, non-acquired immunodeficiency syndrome (AIDS)-defining malignancies account for more morbidity and mortality in human immunodeficiency virus-infected patients than AIDS-defining malignancies.
  • However, conflicting data have been reported on the relationship between immunodeficiency and the development of some non-AIDS-defining malignancies.
  • Malignancies were classified as virus-related, non-virus-related epithelial, and other.
  • The incidence of non-AIDS-defining malignancies was calculated stratified by current CD4 count.
  • Poisson regression was used to investigate factors associated with the development of non-AIDS-defining malignancies.
  • RESULTS: A total of 356 non-AIDS-defining malignancies occurred, with an incidence rate of 4.3 per 1000 person years of follow-up (95% confidence interval [CI], 3.8-4.7); 172 (48.3%) were virus-related, 135 (37.9%) were non-virus-related epithelial, and 49 (13.7%) were classified as other.
  • Anal (69 cases), lung (31 cases), and melanoma (13 cases), respectively, were the most common non-AIDS-defining malignancies within each group.
  • After adjustment, current CD4 was associated with virus-related non-AIDS-defining malignancies (incidence rate ratio [IRR], 0.81 per doubling; 95% CI, 0.75-0.88; P < .0001) and non-virus-related epithelial non-AIDS-defining malignancies (IRR, 0.84; 95% CI, 0.75-0.95; P = .004), but not with other non-AIDS-defining malignancies (IRR, 1.04; 95% CI, 0.83-1.31; P = .73).
  • Current CD4 count was also associated with anal cancer (IRR, 0.86; 95% CI, 0.75-0.99; P = .03), Hodgkin lymphoma (n = 52; IRR, 0.83; 95% CI, 0.73-0.95; P = .005), and lung cancer (IRR, 0.76; 95% CI, 0.64-0.90; P = .0002).
  • CONCLUSIONS: A low current CD4 count was associated with an increased incidence of certain non-AIDS-defining malignancies.
  • Starting cART earlier to reduce the proportion of patients with a low CD4 count may decrease the rate of developing many common non-AIDS-related malignancies.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • (PMID = 20661911.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Losso M; Elias C; Vetter N; Zangerle R; Karpov I; Vassilenko A; Mitsura VM; Suetnov O; Clumeck N; De Wit S; Delforge M; Colebunders R; Vanderkerckhove L; Hadziosmanovic V; Kostov K; Begovac J; Machala L; Rozsypal H; Sedlacek D; Nielsen J; Kronborg G; Benfield T; Larsen M; Gerstoft J; Katzenstein T; Hansen A-; Skinhoj P; Pedersen C; Larsen OD; Oestergaard L; Zilmer K; Smidt J; Ristola M; Katlama C; Viard J-; Girard P-; Livrozet JM; Vanhems P; Pradier C; Dabis F; Neau D; Rockstroh J; Schmidt R; van Lunzen J; Degen O; Stellbrink HJ; Staszewski S; Bogner J; Fatkenheuer G; Kosmidis J; Gargalianos P; Xylomenos G; Perdios J; Panos G; Filandras A; Karabatsaki E; Sambatakou H; Banhegyi D; Mulcahy F; Yust I; Turner D; Burke M; Pollack S; Hassoun G; Mayyan S; Vella S; Esposito R; Mazeau I; Mussini C; Arici C; Pristera R; Mazzotta F; Gabbuti A; Vullo V; Lichtner M; Chirianni A; Montesarchio E; Gargiulo M; Antonucci G; Iacomi F; Narciso P; Vlassi C; Zacarelli M; Lazzarin A; Finazzi R; Galli M; Ridolfo A; d'Arminio Monforte A; Rozental B; Zeltina I; Chaplinskas S; Hemmer R; Staub T; Reiss P; Ormaasen V; Maeland A; Bruun J; Knysz B; Gasiorowski J; Horban A; Bakowska E; Grzeszczuk A; Flisiak R; Boron-Kaczmarska A; Pynka M; Parczewski M; Beniowski M; Mularska E; Trocha H; Jablonowska E; Malolepsza E; Wojcik K; Antunes F; Valadas E; Mansinho K; Maltez F; Duiculescu D; Rakhmanova A; Vinogradova E; Buzunova S; Jevtovic D; Mokras M; Stanekova D; Tomazic J; Gonzalez-Lahoz J; Soriano V; Labarga P; Medrano J; Moreno S; Clotet B; Jou A; Paredes R; Tural C; Puig J; Bravo I; Gatell JM; Miro JM; Domingo P; Gutierrez M; Mateo G; Sambeat MA; Karlsson A; Flamholc L; Ledergerber B; Weber R; Francioli P; Cavassini M; Hirschel B; Boffi E; Furrer H; Battegay M; Elzi L; Kravchenko E; Chentsova N; Kutsyna G; Servitskiy S; Antoniak S; Krasnov M; Barton S; Johnson AM; Mercey D; Phillips A; Johnson MA; Mocroft A; Murphy M; Weber J; Scullard G; Fisher M; Leen C
  •  go-up   go-down


33. Krentz HB, Kliewer G, Gill MJ: Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med; 2005 Mar;6(2):99-106
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIDS deaths were reconciled with Public Health Reports.
  • In the pre-HAART era, 90% of all deaths were AIDS related whereas only 67% were AIDS related in the current HAART era.
  • The leading causes of AIDS deaths were AIDS multiple causes (31%), Mycobacterium avium complex (18%), Pneumocystis pneumonia (10%) and non-Hodgkin's lymphoma (7%).
  • The proportion of non-AIDS related deaths increased from 7% pre-HAART to 32% in the current HAART era.
  • Accidental deaths, including drug overdose (29%), suicide (7%) and violence (3%), hepatic disease (19%), non-AIDS related malignancies (19%), and cardiovascular disease (16%) accounted for the majority of non-AIDS related deaths.
  • A total of 14% of patients dying from AIDS were ARV-naive in contrast to 35% dying from non-HIV related conditions.
  • Of all those dying from AIDS, 23% died<3 months after their initial diagnosis, reflecting late presentation.
  • In the current HAART era, 87% of patients who died from AIDS were extensively treated, reflecting HAART treatment failures due mostly to multiclass drug resistance (42%), inexorable disease progression despite ARV (32%), lack of ability or interest to be maintained on a lifelong HAART programme (21%) and, rarely, drug intolerance (<1%).
  • CONCLUSIONS: Deaths from AIDS-related causes have decreased significantly, but deaths from non-AIDS related conditions have increased, both as an absolute number of deaths and as a proportion of all deaths in HIV-infected patients.


34. Chaturvedi AK, Mbulaiteye SM, Engels EA: Underestimation of relative risks by standardized incidence ratios for AIDS-related cancers. Ann Epidemiol; 2008 Mar;18(3):230-4
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Underestimation of relative risks by standardized incidence ratios for AIDS-related cancers.
  • PURPOSE: Registry-based studies provide valuable data regarding cancer risk among people with HIV/AIDS (PWHA).
  • However, SIR may underestimate RR when HIV/AIDS prevalence in the general population or RR is high.
  • We quantified the extent of this underestimation for 3 AIDS-related cancers: Kaposi sarcoma (KS), central nervous system non-Hodgkin lymphoma (CNS NHL) and cervical cancer.
  • METHODS: We used data on cancer risk among PWHA from the U.S.
  • HIV/AIDS Cancer Match Study.
  • (1) SIRs calculated using pre-AIDS era (1973-1979) cancer incidence rates (SIRpre-AIDS) and (2) SIRs calculated after subtraction of cancers known to be among PWHA from general population rates (SIRexclusion).
  • RESULTS: For KS and CNS NHL, SIRs (117.8 and 133.9, respectively) calculated using overall general population rates substantially underestimated both SIRpre-AIDS (19,778 and 3,612, respectively) and SIRexclusion (657.7 and 536.4, respectively).
  • In contrast, the extent of underestimation was negligible for cervical cancer (SIR = 4.9 vs. SIRexclusion = 5.1).
  • However, SIRpre-AIDS and SIRexclusion estimates were more similar, indicating that SIR differences artifactually reflect differences in HIV/AIDS prevalence between males and females.
  • For KS and CNS NHL, trends across calendar time were weaker in SIRs than in SIRpre-AIDS and SIRexclusion.
  • SIRs must be interpreted cautiously when HIV/AIDS prevalence is high or varies across groups of interest.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. HIV Infections / complications. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Sarcoma, Kaposi / epidemiology. Uterine Cervical Neoplasms / epidemiology


35. Shackelford J, Pagano JS: Role of the ubiquitin system and tumor viruses in AIDS-related cancer. BMC Biochem; 2007;8 Suppl 1:S8
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of the ubiquitin system and tumor viruses in AIDS-related cancer.
  • Tumor viruses are linked to approximately 20% of human malignancies worldwide.
  • This review focuses on examples of human oncogenic viruses that manipulate the ubiquitin system in a subset of viral malignancies; those associated with AIDS.
  • The viruses include Kaposi's sarcoma herpesvirus, Epstein-Barr virus and human papilloma virus, which are causally linked to Kaposi's sarcoma, certain B-cell lymphomas and cervical cancer, respectively.
  • We discuss the molecular mechanisms by which these viruses subvert the ubiquitin system and potential viral targets for anti-cancer therapy from the perspective of this system.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr HIV Res. 2004 Oct;2(4):343-9 [15544455.001]
  • [Cites] Cell Cycle. 2004 Nov;3(11):1345-7 [15492505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13057-62 [11087859.001]
  • [Cites] Acta Virol. 2000 Jun-Aug;44(3):211-26 [11155368.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1218-23 [11158620.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1227-35 [11423255.001]
  • [Cites] J Virol. 2001 Aug;75(16):7583-91 [11462030.001]
  • [Cites] Oncogene. 2001 Aug 2;20(34):4740-9 [11498796.001]
  • [Cites] Chem Biol. 2001 Aug;8(8):739-58 [11514224.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):637-46 [11710679.001]
  • [Cites] J Cell Biol. 2001 Dec 24;155(7):1265-73 [11756476.001]
  • [Cites] J Biol Chem. 2002 Feb 22;277(8):6124-30 [11751860.001]
  • [Cites] Nat Med. 2002 Apr;8(4):338-40 [11927937.001]
  • [Cites] EMBO J. 2002 May 15;21(10):2418-29 [12006494.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5):657-65; discussion 665, 668-70 [12108891.001]
  • [Cites] Oral Dis. 2002;8 Suppl 2:161-8 [12164651.001]
  • [Cites] Curr Top Microbiol Immunol. 2002;269:23-36 [12224511.001]
  • [Cites] Cancer Lett. 2002 Dec 15;188(1-2):15-24 [12406543.001]
  • [Cites] Virus Res. 2002 Nov;89(2):213-28 [12445661.001]
  • [Cites] Semin Cancer Biol. 2002 Dec;12(6):431-41 [12450729.001]
  • [Cites] Semin Cancer Biol. 2003 Feb;13(1):59-67 [12507557.001]
  • [Cites] Semin Cancer Biol. 2003 Feb;13(1):69-76 [12507558.001]
  • [Cites] J Pathol. 2003 Feb;199(2):140-5 [12533825.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):159-69 [12584163.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):307-12 [12619117.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] Med Sci (Paris). 2003 Jan;19(1):100-6 [12836198.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):697-702, v-vi [12852651.001]
  • [Cites] Virology. 2004 Jun 20;324(1):17-27 [15183049.001]
  • [Cites] Isr Med Assoc J. 2004 Jul;6(7):420-4 [15274534.001]
  • [Cites] Trends Immunol. 2004 Aug;25(8):422-6 [15275641.001]
  • [Cites] Cancer Chemother Biol Response Modif. 2003;21:717-46 [15338771.001]
  • [Cites] Semin Cancer Biol. 2004 Dec;14(6):453-71 [15489139.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Science. 1989 Feb 17;243(4893):934-7 [2537532.001]
  • [Cites] EMBO J. 1989 Dec 20;8(13):4099-105 [2556261.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):630-9 [15659509.001]
  • [Cites] Annu Rev Med. 2005;56:29-44 [15660500.001]
  • [Cites] Immunity. 2005 Jan;22(1):59-70 [15664159.001]
  • [Cites] Viral Immunol. 2004;17(4):473-80 [15671745.001]
  • [Cites] Cleve Clin J Med. 2005 Jan;72(1):73-8 [15691060.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Mar;53(3):253-65 [15718150.001]
  • [Cites] Curr Med Chem. 2005;12(3):357-74 [15723624.001]
  • [Cites] Expert Opin Emerg Drugs. 2005 Feb;10(1):5-19 [15757400.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2005;45:465-76 [15822185.001]
  • [Cites] J Virol. 2005 May;79(9):5705-12 [15827185.001]
  • [Cites] Am J Clin Pathol. 2005 Feb;123(2):222-8 [15842046.001]
  • [Cites] Anticancer Drugs. 2005 Jun;16(5):475-81 [15846112.001]
  • [Cites] Cell Cycle. 2005 Feb;4(2):290-6 [15655370.001]
  • [Cites] Mem Inst Oswaldo Cruz. 2005 Feb;100(1):1-12 [15867955.001]
  • [Cites] AIDS Rev. 2005 Jan-Mar;7(1):56-61 [15875661.001]
  • [Cites] Oncologist. 2005 Jun-Jul;10(6):412-26 [15967835.001]
  • [Cites] Science. 2005 Jul 1;309(5731):127-30 [15994556.001]
  • [Cites] J Antimicrob Chemother. 2005 Aug;56(2):277-81 [16006448.001]
  • [Cites] EMBO J. 2006 Apr 19;25(8):1635-45 [16601694.001]
  • [Cites] Adv Dent Res. 2006;19(1):99-105 [16672559.001]
  • [Cites] Lancet. 2006 May 6;367(9521):1495-502 [16679162.001]
  • [Cites] Curr Mol Med. 2006 May;6(3):291-308 [16712476.001]
  • [Cites] Front Biosci. 2006;11:2672-713 [16720343.001]
  • [Cites] Cancer Treat Rev. 2006 Oct;32(6):445-55 [16860939.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9870-7 [17047048.001]
  • [Cites] Mol Cell Biol. 2007 Apr;27(8):2910-8 [17296724.001]
  • [Cites] Adv Cancer Res. 2000;78:1-29 [10547667.001]
  • [Cites] Oncogene. 1999 Dec 13;18(53):7690-700 [10618709.001]
  • [Cites] Virology. 2000 Mar 1;268(1):178-91 [10683340.001]
  • [Cites] Semin Cancer Biol. 1999 Dec;9(6):387-95 [10712885.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):717-45 [12852653.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3A):2133-8 [12894587.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5108-21 [12910248.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5122-30 [12910249.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6639-45 [14528289.001]
  • [Cites] Ann Med. 2003;35(6):404-12 [14572164.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15572-6 [14663138.001]
  • [Cites] AIDS Rev. 2003 Oct-Dec;5(4):222-9 [15012001.001]
  • [Cites] Oncogene. 2004 Mar 15;23(11):2107-15 [15021898.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):349-60 [15122206.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5089-93 [15169876.001]
  • [Cites] Curr Protein Pept Sci. 2004 Jun;5(3):153-61 [15180520.001]
  • [Cites] Oncologist. 2005 Aug;10(7):528-38 [16079320.001]
  • [Cites] Curr HIV/AIDS Rep. 2004 Apr;1(1):5-11 [16091217.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Oct;56(1):155-67 [15979320.001]
  • [Cites] Antivir Ther. 2005;10(6):745-51 [16218174.001]
  • [Cites] Essays Biochem. 2005;41:139-56 [16250903.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18431-6 [16344472.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18562-6 [16352731.001]
  • [Cites] Curr Opin Infect Dis. 2006 Feb;19(1):14-9 [16374212.001]
  • [Cites] Ann Pharm Fr. 2005 Sep;63(5):343-9 [16385784.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1056:328-43 [16387699.001]
  • [Cites] Annu Rev Med. 2006;57:33-47 [16409135.001]
  • [Cites] Expert Opin Investig Drugs. 2006 Feb;15(2):117-30 [16433592.001]
  • [Cites] Yonsei Med J. 2006 Feb 28;47(1):1-14 [16502480.001]
  • [Cites] Cancer Gene Ther. 2006 May;13(5):445-50 [16341140.001]
  • [Cites] Curr Med Chem. 2006;13(7):745-54 [16611064.001]
  • [Cites] Nihon Rinsho. 2006 Mar;64 Suppl 3:635-8 [16615550.001]
  • [Cites] Int J Oncol. 2000 May;16(5):853-70 [10762621.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):690-8 [10793105.001]
  • [Cites] Bioessays. 2000 May;22(5):442-51 [10797484.001]
  • [Cites] Clin Lab Med. 2000 Jun;20(2):383-406 [10863646.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8051-6 [10859362.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Adv Pharmacol. 2000;49:479-514 [11013772.001]
  • [Cites] Mol Cell Biol. 2000 Nov;20(22):8526-35 [11046148.001]
  • [Cites] Cell. 1990 Dec 21;63(6):1129-36 [2175676.001]
  • [Cites] Hum Cell. 1992 Mar;5(1):25-41 [1329931.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Princess Takamatsu Symp. 1991;22:239-48 [1668886.001]
  • [Cites] Int J Cancer. 1993 Sep 9;55(2):208-12 [8370617.001]
  • [Cites] Hosp Pract (1995). 1996 Sep 15;31(9):41-8, 53-5, 59-60 [8814120.001]
  • [Cites] Mol Med Today. 1997 Jun;3(6):246-53 [9211415.001]
  • [Cites] Semin Cancer Biol. 1996 Dec;7(6):317-26 [9284524.001]
  • [Cites] J Biol Chem. 1997 Nov 28;272(48):30135-40 [9374493.001]
  • [Cites] FEBS Lett. 1997 Dec 22;420(1):25-7 [9450543.001]
  • [Cites] J Biol Chem. 1998 Mar 13;273(11):6439-45 [9497376.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Nature. 1998 Aug 6;394(6693):588-92 [9707121.001]
  • [Cites] Trends Microbiol. 1998 Jul;6(7):276-82 [9717216.001]
  • [Cites] Oncogene. 1998 Dec 10;17(23):2943-54 [9881696.001]
  • [Cites] Front Biosci. 1999 May 15;4:D468-75 [10331991.001]
  • (PMID = 18047745.001).
  • [ISSN] 1471-2091
  • [Journal-full-title] BMC biochemistry
  • [ISO-abbreviation] BMC Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ubiquitin
  • [Number-of-references] 119
  • [Other-IDs] NLM/ PMC2106372
  •  go-up   go-down


36. Tirado-Ramos A, Saltz J, Lechowicz MJ: HIV-K: an integrative knowledge base for semantic integration of AIDS-related malignancy data and treatment outcomes. Stud Health Technol Inform; 2010;159:239-43
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-K: an integrative knowledge base for semantic integration of AIDS-related malignancy data and treatment outcomes.
  • Technological innovations such as web services and collaborative Grid platforms like caGrid can create opportunities to converge the worlds of health care and clinical research, by facilitating access and integration of HIV-related malignancy clinical and outcomes data at more sophisticated, semantic levels.
  • At the same time, large numbers of randomized clinical trial and outcomes data on AIDS-defining malignancies (ADM) and non-AIDS-defining malignancies (nADM) have been produced during the last few years.
  • This is a white paper on work in progress from Emory University's HIV/AIDS related malignancy data integrative knowledge base project (HIV-K).
  • We are working to increase the understanding of available clinical trial data and outcomes of ADM such as lymphoma, as well as nADM such as anal cancer, Hodgkin lymphoma, or liver cancer.
  • Our hypothesis is that, by creating prototypes of tools for semantics-enabled integrative knowledge bases for HIV/AIDS-related malignancy data, we will facilitate the identification of patterns and potential new overall evidence, as well as the linking of integrated data and results to registries of interest.
  • [MeSH-major] Databases, Factual. HIV-1. Lymphoma, AIDS-Related / therapy. Semantics

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • HIV InSite. treatment guidelines - How to Tell Patients .
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2008 Dec 1;112(12):4384-99 [19029456.001]
  • [Cites] PLoS One. 2009;4(3):e4724 [19266092.001]
  • [Cites] J Clin Exp Neuropsychol. 2010 Apr;32(4):398-407 [19763997.001]
  • [Cites] Int J STD AIDS. 1999 Dec;10(12):795-802 [10639060.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Stat Med. 1988 Nov;7(11):1121-37 [3201038.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Am J Public Health. 2005;95 Suppl 1:S144-50 [16030331.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] Oncology (Williston Park). 2005 Nov;19(12):1634-8; discussion 1638-40, 1645 passim [16396154.001]
  • [Cites] Bioinformatics. 2006 Aug 1;22(15):1910-6 [16766552.001]
  • [Cites] Antiviral Res. 2006 Sep;71(2-3):335-42 [16782210.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 1;85(17):1382-97 [8350362.001]
  • (PMID = 20543443.001).
  • [ISSN] 0926-9630
  • [Journal-full-title] Studies in health technology and informatics
  • [ISO-abbreviation] Stud Health Technol Inform
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI050409; United States / NIAID NIH HHS / AI / P30 AI050409; United States / NIAID NIH HHS / AI / P30 AI050409-11; United States / NCRR NIH HHS / RR / UL1 RR025008; United States / NCRR NIH HHS / RR / UL1 RR025008-04; United States / NCATS NIH HHS / TR / UL1 TR000454
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS315000; NLM/ PMC3157699
  •  go-up   go-down


37. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA, HIV/AIDS Cancer Match Study: AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst; 2007 Jun 20;99(12):962-72
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related cancer and severity of immunosuppression in persons with AIDS.
  • BACKGROUND: The incidence of Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer has been declining among persons with AIDS.
  • We investigated the association between cancer risk and CD4 cell count among such persons.
  • METHODS: Data from US AIDS registries were linked to local cancer registry data.
  • Cancer incidence per 100,000 person-years was determined for the 4-27 months from the onset of AIDS from January 1, 1990, through December 31, 1995--before highly active antiretroviral therapy (HAART) became available--and from January 1, 1996, through December 31, 2002.
  • The relationships between CD4 count at AIDS onset and cancer incidence were assessed by proportional hazards models.
  • RESULTS: Among 325,516 adults with AIDS, the incidence of Kaposi sarcoma was lower in 1996-2002 (334.6 cases per 100,000 person-years) than in 1990-1995 (1838.9 cases per 100,000 person-years), and the incidence of non-Hodgkin lymphoma followed a similar pattern (i.e., 390.1 cases per 100,000 person-years in 1996-2002 and 1066.2 cases per 100,000 person-years in 1990-1995).
  • Cervical cancer incidence was higher in 1996-2002 (86.5 per 100,000 person-years) than in 1990-1995 (64.2 per 100,000 person-years), although not statistically significantly so (relative risk [RR] = 1.41, 95% CI = 0.81 to 2.46).
  • Similar relationships of these cancers to CD4 count were observed for 1990-1995.
  • CONCLUSIONS: Both before and after HAART was available, CD4 count was strongly associated with risks for Kaposi sarcoma and non-Hodgkin lymphoma but not for cervical cancer and Burkitt lymphoma.
  • The decreasing incidences of most AIDS-associated cancers in persons with AIDS during the 1990s are consistent with improving CD4 counts after HAART introduction in 1996.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / immunology. Lymphoma, AIDS-Related / immunology. Lymphoma, Non-Hodgkin / immunology. Sarcoma, Kaposi / immunology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17565153.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


38. Lou J, Ruggeri T, Tebaldi C: Modeling cancer in hiv-1 infected individuals: equilibria, cycles and chaotic behavior. Math Biosci Eng; 2006 Apr;3(2):313-24

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modeling cancer in hiv-1 infected individuals: equilibria, cycles and chaotic behavior.
  • For HIV-infected individuals, cancer remains a significant burden.
  • Gaining insight into the epidemiology and mechanisms that underlie AIDS- related cancers can provide us with a better understanding of cancer immunity and viral oncogenesis.
  • In this paper, an HIV-1 dynamical model incorporat- ing the AIDS-related cancer cells was studied.
  • The model consists of three components, cancer cells, healthy CD4+ T lymphocytes and infected CD4+ T lymphocytes, and can have six steady states.
  • We discuss the existence, the stability properties and the biological meanings of these steady states, in par- ticular for the positive one: cancer-HIV-healthy cells steady state.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20361826.001).
  • [ISSN] 1547-1063
  • [Journal-full-title] Mathematical biosciences and engineering : MBE
  • [ISO-abbreviation] Math Biosci Eng
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Schlichemeyer R, Chambers C, Gill MJ: The oncology impact of highly active antiretroviral therapy. J Oncol Pharm Pract; 2007 Mar;13(1):17-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To examine the impact of using highly active antiretroviral therapy (HAART) in a human immunodeficiency virus (HIV) infected population on the chemotherapy related costs of treating acquired immunodeficiency (AIDS)-related cancers.
  • METHODS: We used the Southern Alberta Clinic (SAC) database to define the incidence and prevalence of AIDS-related cancers in a geographically defined HIV population in both the pre- HAART and HAART eras, and subsequently, the Alberta Cancer Board Pharmacy database to determine the chemotherapy associated costs of the cancer treatment.
  • RESULTS: During both eras, 60% of AIDS-related cancer patients received chemotherapy.
  • The absolute number of patients treated in the pre-HAART era was 70, but during the HAART era, due to the decreased incidence of these cancers, only 13 patients received chemotherapy.
  • The number of distinct regimens used for AIDS cancer treatment standardised, and decreased from 29 to six between eras.
  • CONCLUSION: The introduction of HAART has dramatically reduced the amount spent on chemotherapy due to a decreased incidence of AIDSrelated cancers, even though the individual patient treatments have become more effective and expensive.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17621563.001).
  • [ISSN] 1078-1552
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


40. Akanmu AS: AIDS-associated malignancies. Afr J Med Med Sci; 2006 Dec;35 Suppl:57-70
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-associated malignancies.
  • A number of immunodeficiency states--both inherited (such as agammaglobulinaemia, Bloom's syndrome, hereditary telangiectasia) and acquired (e.g. immunosuppressive therapy) have been associated with varieties of cancers.
  • HIV induces more profound immunodeficiency state and it should not be difficult to imaging why cancer diagnosis is made in over 40% of HIV infected patients.
  • Impairment of normal function of natural killer cells as a result of lack of helper signals from CD4+ T-lymphocytes may be a major mechanism of increased susceptibility to cancer development in HIV infected patients.
  • Although many neoplastic diseases could occur at a frequency not higher than would be expected by chance alone, the biological behaviour of such malignancies tend to be more aggressive.
  • Three neoplastic diseases are associated so commonly with HIV infection that each of them has become recognized as an AIDS defining illness.
  • Both KS and NHL were recognized as AIDS associated cancers from the onset of the epidemic in 1981 but carcinoma of the cervix became AIDS defining in 1993.
  • [MeSH-major] HIV. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Sarcoma, Kaposi / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18050776.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Nigeria
  • [Number-of-references] 114
  •  go-up   go-down


41. Wood C, Harrington W Jr: AIDS and associated malignancies. Cell Res; 2005 Nov-Dec;15(11-12):947-52
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS and associated malignancies.
  • AIDS associated malignancies (ARL) is a major complication associated with AIDS patients upon immunosuppression.
  • In the era of potent antiretrovirals therapy (ARV), the malignant complications due to HIV-1 infection have decreased in developed nations where ARV is administered, but still poses a major problem in developing countries where HIV-1 incidence is high and ARV is still not yet widely available.
  • Even in ARV treated individuals there is a concern that the prolonged survival of many HIV-1 carriers is likely to eventually result in an increased number of malignancies diagnosed.
  • Malignancies that were found to have high incidence in HIV-infected individuals are Kaposi's sarcoma (KS), Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).
  • The incidence of NHL has increased nearly 200 fold in HIV-positive patients, and accounts for a greater percentage of AIDS defining illness in the US and Europe since the advent of HAART therapy.
  • These AIDS related lymphomas are distinct from their counterparts seen in HIV-1 seronegative patients.
  • For example nearly half of all cases of ARL are associated with the presence of a gamma herpesvirus, Epstein Barr virus (EBV) or human herpesvirus-8 (HHV-8)/ Kaposi's sarcoma associated herpesvirus (KSHV).

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16354573.001).
  • [ISSN] 1001-0602
  • [Journal-full-title] Cell research
  • [ISO-abbreviation] Cell Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA082274; United States / NCI NIH HHS / CA / CA76958; United States / NICHD NIH HHS / HD / HD39620; United States / NCRR NIH HHS / RR / RR15635
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] China
  • [Number-of-references] 60
  •  go-up   go-down


42. Tserenpuntsag B, Kołacińska A, Jabłonowska E: [AIDS associated cancers in the era of highly active antiretroviral therapy (HAART)]. Przegl Epidemiol; 2007;61(3):529-34
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [AIDS associated cancers in the era of highly active antiretroviral therapy (HAART)].
  • [Transliterated title] Nowotwory zwiazane z AIDS w erze skojarzonego leczenia antyretrowirusowego (HAART).
  • HIV infected subjects are at increased risk of developing cancer and the risk seems to be directly associated with the level of immunodeficiency.
  • Kaposi's sarcoma, Non-Hodgkin's lymphoma (ARL) and invasive cervical cancer are the most common AIDS-defining malignancies.
  • It significantly reduced the incidence of AIDS associated events and deaths and even changed treatment regimens ofAIDS associated cancers.
  • With the immune restoration afforded by HAART, patients better responded to cancer treatment.
  • HAART allows the use of standard-dose chemotherapies for NON-Hodgkin lymphoma in HIV infected pacients and same treatment regimen for invasive cervical cancer in infected patients as non-infected patients.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / virology. Lymphoma, Non-Hodgkin / virology. Sarcoma, Kaposi / virology. Uterine Cervical Neoplasms / virology


43. Deeken JF, Pantanowitz L, Dezube BJ: Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Curr Opin Oncol; 2009 Sep;21(5):445-54
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook.
  • PURPOSE OF REVIEW: Highly active antiretroviral therapy has led to a dramatic improvement in the prognosis of patients diagnosed with HIV and AIDS.
  • This includes a significant decline in the rates of AIDS-related cancers, including Kaposi's sarcoma and non-Hodgkin's lymphoma.
  • Unfortunately, rates of non-AIDS-defining cancers are on the rise, and now exceed the rates of AIDS-related cancers in patients with HIV.
  • Treating non-AIDS-defining cancers in patients who are on highly active antiretroviral therapy is an open and complicated clinical question.
  • RECENT FINDINGS: Newer targeted therapies are now available to treat cancers which were historically refractory to traditional cytotoxic chemotherapy.
  • We conclude with considerations on how to use these new agents to treat non-AIDS-defining cancers, and discuss a future research agenda to better understand and predict potential highly active antiretroviral therapy-targeted therapy interactions.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Clin Pharmacol. 2008 Jan;64(1):31-41 [18000659.001]
  • [Cites] J Clin Pharmacol. 2008 Feb;48(2):209-14 [18077730.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):626-32 [18235122.001]
  • [Cites] Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:27-37 [18333863.001]
  • [Cites] Br J Cancer. 2008 Jun 3;98(11):1797-802 [18458675.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Lancet. 2008 Aug 9;372(9637):449-56 [18653228.001]
  • [Cites] Drug Metab Dispos. 2008 Sep;36(9):1828-39 [18556438.001]
  • [Cites] J Clin Pharmacol. 2008 Sep;48(9):1032-40 [18728241.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2008 Jun;30(5):383-408 [18806898.001]
  • [Cites] Top HIV Med. 2008 Oct-Nov;16(4):117-21 [18838745.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Sep;6 Suppl 5:S1-20; quiz S21-2 [18926092.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2008 Sep;30(7):543-88 [18985183.001]
  • [Cites] Clin Ther. 2008 Nov;30(11):1956-75 [19108785.001]
  • [Cites] Clin Genitourin Cancer. 2009 Jan;7(1):24-7 [19213664.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] Eur J Cancer. 2009 Mar;45(4):579-87 [19101137.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2008 Dec;30(10):761-82 [19271026.001]
  • [Cites] Br J Clin Pharmacol. 2009 Apr;67(4):421-6 [19371315.001]
  • [Cites] Clin Pharmacokinet. 2009;48(3):199-209 [19385713.001]
  • [Cites] Drug Metab Dispos. 2009 Jun;37(6):1242-50 [19282395.001]
  • [Cites] Drug Metab Dispos. 1999 Dec;27(12):1488-95 [10570031.001]
  • [Cites] Drug Metab Dispos. 2001 Feb;29(2):100-2 [11159797.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2009 Mar;31(2):107-46 [19455266.001]
  • [Cites] Clin Pharmacol Ther. 1990 May;47(5):647-54 [2111751.001]
  • [Cites] Drug Metab Dispos. 1990 May-Jun;18(3):369-72 [1974201.001]
  • [Cites] AIDS. 1992 Dec;6(12):1471-5 [1283519.001]
  • [Cites] J Pharmacol Exp Ther. 1996 Apr;277(1):423-31 [8613951.001]
  • [Cites] Drug Metab Dispos. 1997 Feb;25(2):256-66 [9029057.001]
  • [Cites] J Clin Pharmacol. 1998 Feb;38(2):106-11 [9549640.001]
  • [Cites] Drug Metab Dispos. 1998 Jun;26(6):552-61 [9616191.001]
  • [Cites] J Pharm Sci. 1998 Jul;87(7):803-7 [9649346.001]
  • [Cites] Drug Metab Dispos. 1998 Jul;26(7):609-16 [9660842.001]
  • [Cites] Drug Metab Dispos. 1999 Jan;27(1):86-91 [9884314.001]
  • [Cites] Drug Metab Dispos. 1999 Aug;27(8):902-8 [10421617.001]
  • [Cites] J Med Chem. 2004 Dec 30;47(27):6658-61 [15615512.001]
  • [Cites] Clin Pharmacokinet. 2005;44(2):111-45 [15656694.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] Clin Pharmacokinet. 2005;44(9):879-94 [16122278.001]
  • [Cites] Clin Colorectal Cancer. 2005 Sep;5(3):188-96 [16197622.001]
  • [Cites] Drug Metab Dispos. 2005 Nov;33(11):1723-8 [16103134.001]
  • [Cites] Drug Metab Dispos. 2005 Nov;33(11):1729-39 [16118329.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):144-51 [16397036.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85 [16433896.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 May;57(5):685-92 [16133532.001]
  • [Cites] Drug Metab Dispos. 2006 Mar;34(3):420-6 [16381666.001]
  • [Cites] Drug Metab Dispos. 2006 Apr;34(4):702-8 [16443666.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2531-41 [16775234.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] JAMA. 2006 Aug 16;296(7):827-43 [16905788.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4867-74 [17001068.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Nov;50(11):3801-8 [16940065.001]
  • [Cites] Neuro Endocrinol Lett. 2006 Dec;27 Suppl 2:27-30 [17159773.001]
  • [Cites] N Engl J Med. 2006 Dec 28;355(26):2733-43 [17192538.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Eur J Cancer. 2007 Jan;43(1):55-63 [17095207.001]
  • [Cites] Drug Metab Dispos. 2007 Apr;35(4):602-6 [17267620.001]
  • [Cites] Clin Pharmacol Ther. 2002 Jul;72(1):1-9 [12151999.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1965-71 [12200353.001]
  • [Cites] Curr Pharm Des. 2002;8(25):2255-7 [12369853.001]
  • [Cites] Chem Biol Interact. 2002 Nov 10;142(1-2):135-54 [12399160.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):327-37 [12538485.001]
  • [Cites] N Engl J Med. 2003 Mar 13;348(11):994-1004 [12637609.001]
  • [Cites] Mol Cancer Ther. 2003 May;2(5):471-8 [12748309.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4009-16 [12873999.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Br J Cancer. 2003 Nov 17;89(10):1855-9 [14612892.001]
  • [Cites] Int J Clin Pharmacol Ther. 2003 Dec;41(12):618-9 [14692719.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1034-40 [15247556.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Oct;54(4):290-4 [15138710.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3207-13 [17185463.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2684-91 [17473200.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Pharmacotherapy. 2007 Jun;27(6):888-909 [17542771.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3731-7 [17575239.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4849-57 [17699864.001]
  • [Cites] Drug Metab Dispos. 2007 Sep;35(9):1554-63 [17540708.001]
  • [Cites] Drug Metab Dispos. 2007 Sep;35(9):1657-63 [17591678.001]
  • [Cites] J Clin Pharmacol. 2007 Nov;47(11):1430-9 [17913896.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3540-6 [17715389.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7394-400 [18094422.001]
  • (PMID = 19606034.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA121947
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Number-of-references] 118
  • [Other-IDs] NLM/ NIHMS382143; NLM/ PMC3377583
  •  go-up   go-down


44. Nunnari G, Smith JA, Daniel R: HIV-1 Tat and AIDS-associated cancer: targeting the cellular anti-cancer barrier? J Exp Clin Cancer Res; 2008 May 15;27:3
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-1 Tat and AIDS-associated cancer: targeting the cellular anti-cancer barrier?
  • The acquired immunodeficiency syndrome (AIDS) is accompanied by a significant increase in the incidence of neoplasms.
  • Cancer in general is closely linked to genomic instability and DNA repair mechanisms.
  • The latter maintains genomic stability and serves as a cellular anti-cancer barrier.
  • Defects in DNA repair pathway are associated with carcinogenesis.
  • We propose that the Tat-induced DNA repair deficiencies may play a significant role in the development of AIDS-associated cancer.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2005 Apr 22;308(5721):551-4 [15790808.001]
  • [Cites] Cell Cycle. 2005 Mar;4(3):359-62 [15684609.001]
  • [Cites] EMBO J. 2005 Jul 20;24(14):2634-45 [16001085.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13182-7 [16141325.001]
  • [Cites] Front Biosci. 2006;11:1958-76 [16368571.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):37-45 [16327781.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):91-9 [16341205.001]
  • [Cites] J Exp Med. 2006 Feb 20;203(2):297-303 [16461339.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):842-50 [16751065.001]
  • [Cites] Mol Cell. 2006 Dec 28;24(6):827-39 [17189186.001]
  • [Cites] Oncogene. 2007 Feb 15;26(7):993-1002 [16909103.001]
  • [Cites] Curr HIV Res. 2007 Jul;5(4):403-9 [17627503.001]
  • [Cites] Nature. 2007 Aug 30;448(7157):1063-7 [17728759.001]
  • [Cites] Nature. 1990 May 3;345(6270):84-6 [2184372.001]
  • [Cites] J Virol. 1993 Jan;67(1):277-87 [8416373.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5613-7 [8516308.001]
  • [Cites] Am J Gastroenterol. 1994 Feb;89(2):254-6 [8304313.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6904-8 [8041718.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Science. 1995 Apr 28;268(5210):582-3 [7725108.001]
  • [Cites] Nature. 1995 Jun 8;375(6531):497-500 [7539892.001]
  • [Cites] Nat Med. 1995 Jul;1(7):707-8 [7585156.001]
  • [Cites] Virology. 1996 Feb 15;216(2):357-66 [8607265.001]
  • [Cites] Cell. 1996 Aug 9;86(3):379-89 [8756720.001]
  • [Cites] J Virol. 1996 Nov;70(11):8151-4 [8892944.001]
  • [Cites] Mol Cell Biol. 1997 Mar;17(3):1425-33 [9032269.001]
  • [Cites] J Infect Dis. 1997 Jul;176(1):84-93 [9207353.001]
  • [Cites] Nature. 1997 Jul 31;388(6641):492-5 [9242410.001]
  • [Cites] Curr Biol. 1997 Aug 1;7(8):588-98 [9259561.001]
  • [Cites] J Biol Chem. 1998 Jan 16;273(3):1623-8 [9430704.001]
  • [Cites] J Biol Chem. 1998 Mar 6;273(10):5858-68 [9488723.001]
  • [Cites] Mol Cell. 1998 Jun;1(7):969-79 [9651580.001]
  • [Cites] EMBO J. 1998 Sep 15;17(18):5497-508 [9736627.001]
  • [Cites] EMBO J. 1998 Nov 2;17(21):6412-25 [9799249.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3299-304 [10866324.001]
  • [Cites] Curr Biol. 2000 Jul 27-Aug 10;10(15):886-95 [10959836.001]
  • [Cites] Cell. 2000 Aug 18;102(4):463-73 [10966108.001]
  • [Cites] Adv Pharmacol. 2000;48:209-27 [10987092.001]
  • [Cites] Science. 1999 Nov 5;286(5442):1162-6 [10550055.001]
  • [Cites] Mutat Res. 1973 Oct;20(1):45-51 [4586554.001]
  • [Cites] Cancer. 1988 Aug 1;62(3):616-9 [3390798.001]
  • [Cites] Am J Clin Pathol. 1989 Apr;91(4):458-61 [2929501.001]
  • [Cites] Int J STD AIDS. 1999 Dec;10(12):795-802 [10639060.001]
  • [Cites] EMBO J. 2000 Apr 3;19(7):1703-10 [10747037.001]
  • [Cites] Nature. 2000 Apr 6;404(6778):613-7 [10766245.001]
  • [Cites] Nature. 2000 Apr 20;404(6780):897-900 [10786799.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):677-9 [10793096.001]
  • [Cites] Nat Genet. 2000 May;25(1):115-9 [10802669.001]
  • [Cites] Mol Cell Biol. 2000 Jun;20(11):3772-80 [10805721.001]
  • [Cites] Nature. 2000 May 25;405(6785):473-7 [10839544.001]
  • [Cites] Nature. 2000 May 25;405(6785):477-82 [10839545.001]
  • [Cites] Adv Pharmacol. 2000;48:229-50 [10987093.001]
  • [Cites] Nature. 2000 Nov 23;408(6811):433-9 [11100718.001]
  • [Cites] Genes Dev. 2000 Dec 1;14(23):2989-3002 [11114888.001]
  • [Cites] Curr Opin Genet Dev. 2001 Feb;11(1):71-7 [11163154.001]
  • [Cites] AIDS. 2001 Mar 9;15(4):433-40 [11242139.001]
  • [Cites] Am J Epidemiol. 2001 Sep 15;154(6):544-56 [11549560.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):42462-7 [11571274.001]
  • [Cites] Science. 2001 Nov 23;294(5547):1713-6 [11721054.001]
  • [Cites] J Biol Chem. 2001 Dec 21;276(51):47759-62 [11673449.001]
  • [Cites] Mol Pathol. 2002 Feb;55(1):19-24 [11836442.001]
  • [Cites] EMBO J. 2002 Apr 2;21(7):1704-12 [11927554.001]
  • [Cites] Nat Cell Biol. 2002 Dec;4(12):993-7 [12447390.001]
  • [Cites] Nature. 2003 Jan 30;421(6922):499-506 [12556884.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):497-501 [12640452.001]
  • [Cites] Curr Drug Targets Infect Disord. 2003 Jun;3(2):115-28 [12769789.001]
  • [Cites] Science. 2003 Jun 6;300(5625):1542-8 [12791985.001]
  • [Cites] Angiogenesis. 2002;5(3):141-51 [12831055.001]
  • [Cites] Cell. 2003 Aug 8;114(3):371-83 [12914701.001]
  • [Cites] Am Surg. 2003 Nov;69(11):981-7 [14627261.001]
  • [Cites] Acta Biochim Pol. 2003;50(4):891-908 [14739985.001]
  • [Cites] Nature. 2004 Mar 25;428(6981):431-7 [15042092.001]
  • [Cites] Oncogene. 2004 Apr 8;23(15):2664-71 [14755242.001]
  • [Cites] Mol Biol Cell. 2004 May;15(5):2347-60 [15020715.001]
  • [Cites] Curr Opin Genet Dev. 2004 Feb;14(1):11-6 [15108799.001]
  • [Cites] Curr Opin Genet Dev. 2004 Apr;14(2):147-54 [15196461.001]
  • [Cites] J Virol. 2004 Sep;78(17):9336-42 [15308728.001]
  • [Cites] Cancer Biol Ther. 2004 Jun;3(6):509-14 [15254414.001]
  • [Cites] Radiat Res. 1998 Nov;150(5 Suppl):S42-51 [9806608.001]
  • [Cites] Cell. 1998 Nov 25;95(5):583-6 [9845359.001]
  • [Cites] Cell. 1998 Nov 25;95(5):705-16 [9845372.001]
  • [Cites] Genes Cells. 1998 Dec;3(12):789-800 [10096020.001]
  • [Cites] Genes Dev. 1999 May 15;13(10):1276-88 [10346816.001]
  • [Cites] Biochemistry. 1999 Jul 6;38(27):8826-30 [10393559.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8324-6 [10411869.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 1;91(17):1453-8 [10469745.001]
  • [Cites] J Cell Biol. 1999 Sep 6;146(5):905-16 [10477747.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4375-82 [10485486.001]
  • [Cites] Curr HIV Res. 2004 Oct;2(4):343-9 [15544455.001]
  • [Cites] Mol Cell. 2004 Dec 3;16(5):715-24 [15574327.001]
  • [Cites] Mutat Res. 2005 Jan 6;569(1-2):123-32 [15603757.001]
  • [Cites] Science. 2004 Dec 17;306(5704):2084-7 [15528408.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):949-61 [15592499.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1877-82 [15671175.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2433; author reply 2433-4 [15800341.001]
  • [Cites] Nature. 2005 Mar 31;434(7033):605-11 [15758953.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):864-70 [15829956.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):907-13 [15829965.001]
  • (PMID = 18577246.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K01 CA098090; United States / NCI NIH HHS / CA / R01 CA125272; United States / NCI NIH HHS / CA / CA125272; United States / NCI NIH HHS / CA / CA98090
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / tat Gene Products, Human Immunodeficiency Virus
  • [Number-of-references] 99
  • [Other-IDs] NLM/ PMC2438332
  •  go-up   go-down


45. Monforte Ad, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD, Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group: HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS; 2008 Oct 18;22(16):2143-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.
  • OBJECTIVE: To evaluate deaths from AIDS-defining malignancies (ADM) and non-AIDS-defining malignancies (nADM) in the D:A:D Study and to investigate the relationship between these deaths and immunodeficiency.
  • We used Poisson regression models to identify factors independently associated with deaths from ADM and nADM.
  • Analyses of factors associated with mortality due to nADM were repeated after excluding nADM known to be associated with a specific risk factor.
  • RESULTS: Three hundred five patients died due to a malignancy, 298 prior to the cutoff for this analysis (ADM: n = 110; nADM: n = 188).
  • In multivariable regression analyses, a two-fold higher latest CD4 cell count was associated with a halving of the risk of ADM mortality.
  • Other predictors of an increased risk of ADM mortality were homosexual risk group, older age, a previous (non-malignancy) AIDS diagnosis and earlier calendar years.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutagenesis. 2005 Mar;20(2):139-46 [15784690.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Clin Infect Dis. 2005 Sep 15;41(6):855-63 [16107986.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1505-11 [16104038.001]
  • [Cites] AIDS. 2006 Jan 2;20(1):49-57 [16327319.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Arch Intern Med. 2006 Aug 14-28;166(15):1632-41 [16908797.001]
  • [Cites] Ann Intern Med. 2006 Sep 19;145(6):397-406 [16983127.001]
  • [Cites] Environ Mol Mutagen. 2007 Apr-May;48(3-4):239-47 [17358029.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Blood. 2000 May 1;95(9):2860-8 [10779432.001]
  • [Cites] AIDS. 2000 May 5;14(7):771-80 [10839584.001]
  • [Cites] Lancet. 2000 Oct 21;356(9239):1423-30 [11052597.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] AIDS. 2002 Aug 16;16(12):1663-71 [12172088.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2002 Jul 26;51(29):642-5 [12186222.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):505-7 [12888821.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):1993-2003 [14627784.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] Int J Epidemiol. 2005 Feb;34(1):121-30 [15561752.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):407-9 [15769998.001]
  • [Cites] J Hepatol. 2005 Jun;42(6):799-805 [15973779.001]
  • (PMID = 18832878.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / 5U01AI046362-03; United States / NIAID NIH HHS / AI / U01 AI069907-02; United States / NIAID NIH HHS / AI / U01 AI046362; United States / NIAID NIH HHS / AI / 5U01AI042170-10; United States / NIAID NIH HHS / AI / U01 AI069907; United States / NIAID NIH HHS / AI / U01 AI042170
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Other-IDs] NLM/ NIHMS113887; NLM/ PMC2715844
  • [Investigator] Collins S; Loeliger E; Tressler R; Weller I; Friis-Møller N; Worm SW; Sabin CA; Sjøl A; Lundgren JD; Sawitz A; Rickenbach M; Pezzotti P; Krum E; Gras L; Balestre E; Sundström A; Poll B; Fontas E; Torres F; Petoumenos K; Kjaer J; de Wolf F; Zaheri S; Gras L; Bronsveld W; Hillebrand-Haverkort ME; Prins JM; Bos JC; Schattenkerk JK; Geerlings SE; Godfried MH; Lange JM; van Leth FC; Lowe SH; van der Meer JT; Nellen FJ; Pogány K; van der Poll T; Reiss P; Ruys TA; Sankatsing SR; van Twillert G; van der Valk M; van Vonderen MG; Vrouenraets SM; van Vugt M; Wit FW; van Eeden A; ten Veen JH; van Dam PS; Roos JC; Brinkman K; Frissen PH; Weigel HM; Mulder JW; van Gorp EC; Meenhorst PL; Mairuhu AT; Veenstra J; Danner SA; Van Agtmael MA; Claessen FA; Perenboom RM; Rijkeboer A; van Vonderen M; Richter C; van der Berg J; van Leusen R; Vriesendorp R; Jeurissen FJ; Kauffmann RH; Koger EL; Bravenboer B; ten Napel CH; Kootstra GJ; Sprenger HG; Miesen WM; Doedens R; Scholvinck EH; ten Kate RW; van Houte DP; Polee M; Kroon FP; van den Broek; van Dissel JT; Schippers EF; Schreij G; van de Geest S; Verbon A; Koopmans PP; Keuter M; Post F; van der Ven AJ; van der Ende ME; Gyssens IC; van der Feltz M; den Hollander JG; de Marie S; Nouwen JL; Rijnders BJ; de Vries TE; Juttmann JR; van de Heul C; van Kasteren ME; St Elisabeth SM; Bonten MJ; Borleffs JC; Ellerbroek PM; Hoepelman IM; Jaspers CA; Schouten I; Schurink CA; Blok WL; Tanis AA; Groeneveld PH; Salamon R; Beylot J; Dupon M; Le Bras M; Pellegrin JL; Ragnaud JM; Dabis F; Chêne G; Jacqmin-Gadda H; Thiébaut R; Lawson-Ayayi S; Lavignolle V; Balestre E; Blaizeau MJ; Decoin M; Formaggio AM; Delveaux S; Labarerre S; Uwamaliya B; Vimard E; Merchadou L; Palmer G; Touchard D; Dutoit D; Pereira F; Boulant B; Beylot J; Morlat P; Bernard N; Bonarek M; Bonnet F; Coadou B; Gelie P; Jaubert D; Nouts C; Lacoste D; Dupon M; Dutronc H; Cipriano G; Lafarie S; Chossat I; Lacut JY; Leng B; Pellegrin JL; Mercié P; Viallard JF; Faure I; Rispal P; Cipriano C; Tchamgoué S; Le Bras M; Djossou F; Malvy D; Pivetaud JP; Ragnaud JM; Chambon D; De La Taille C; Galperine T; Lafarie S; Neau D; Ochoa A; Beylot C; Doutre MS; Bezian JH; Moreau JF; Taupin JL; Conri C; Constans J; Couzigou P; Castera L; Fleury H; Lafon ME; Masquelier B; Pellegrin I; Trimoulet P; Moreau F; Mestre C; Series C; Taytard A; Law M; Glenday K; Petoumenos K; Anderson J; Cortissos P; Mijch A; Watson K; Roth N; Nicolson J; Bloch M; Agrawal S; Franic T; Baker D; Vale R; Carr A; Cooper D; Lacey M; Hesse K; Chuah J; Lester D; Fankhauser W; Mallal S; Forsdyke C; Bulgannawar S; Calvo G; Torres F; Mateu S; Domingo P; Sambeat MA; Gatell J; Del Cacho E; Cadafalch J; Fuster M; Codina C; Sirera G; Vaqué A; Clumeck N; De Wit S; Gerard M; Kabeya K; Konopnicki D; Libois A; Payen MC; Poll B; Van Laethem Y; Neaton J; Bartsch G; El-Sadr WM; Krum E; Thompson G; Wentworth D; Luskin-Hawk R; Telzak E; El-Sadr WM; Abrams DI; Cohn D; Markowitz N; Arduino R; Mushatt D; Friedland G; Perez G; Tedaldi E; Fisher E; Gordin F; Crane RL; Sampson J; Baxter J; Kirk O; Olsen CH; Mocroft A; Phillips AN; Lundgren JD; Vetter N; Karpov I; Vassilenko A; Clumeck N; De Wit S; Poll B; Colebunders R; Machala L; Rozsypal H; Sedlacek D; Nielsen J; Benfield T; Gerstoft J; Katzenstein T; Hansen AB; Skinhøj P; Pedersen C; Zilmer K; Katlama C; Viard JP; Girard PM; Saint-Marc T; Vanhems P; Pradier C; Dabis F; Dietrich M; Manegold C; van Lunzen J; Stellbrink HJ; Staszewski S; Bieckel M; Goebel FD; Fätkenheuer C; Rockstroh J; Schmidt RE; Kosmidis J; Gargalianos P; Sambatakou H; Perdios J; Panos G; Filandras A; Banhegyi D; Mulcahy F; Yust I; Burke M; Turner D; Pollack S; Hassoun J; Sthoeger Z; Maayan S; Vella S; Chiesi A; Arici C; Pristerá R; Mazzotta F; Gabbuti A; Esposito R; Bedini A; Chirianni A; Montesarchio E; Vullo V; Santopadre P; Narciso P; Antinori A; Franci P; Zaccarelli M; Lazzarin A; Castagna A; Monforte Ad; Viksna L; Chaplinskas S; Hemmer R; Staub T; Reiss P; Bruun J; Maeland A; Ormaasen V; Knysz B; Gasiorowski J; Horban A; Prokopowicz D; Wiercinska-Drapalo A; Boron-Kaczmarska A; Pynka M; Beniowski M; Mularska E; Trocha H; Antunes F; Mansinho K; Maltez F; Duiculescu D; Babes V; Streinu-Cercel A; Vinogradova E; Rakhmanova A; Jevtovic D; Mokrás M; Staneková D; González-Lahoz J; Sanchez-Conde M; García-Benayas T; Martin-Carbonero L; Soriano V; Clotet B; Jou A; Conejero J; Ruiz L; Tural C; Gatell JM; Miró JM; Zamora L; Blaxhult A; Karlsson A; Pehrson P; Ledergerber B; Weber R; Francioli P; Telenti A; Hirschel B; Soravia-Dunand V; Furrer H; Kravchenko E; Chentsova N; Fisher M; Brettle R; Barton S; Johnson AM; Mercey D; Murphy M; Johnson MA; Weber J; Scullard G; Morfeldt L; Thulin G; Sundström A; Akerlund B; Koppel K; Karlsson A; Flamholc L; Håkangård C; Monforte Ad; Ammassari A; Antinori A; Maggiolo F; Balotta C; Bonfanti P; Capobianchi M; Castagna A; Ceccherini-Silberstein F; Cozzi-Lepri A; Monforte Ad; De Luca A; Gervasoni C; Girardi E; Lo Caputo S; Murri R; Mussini C; Puoti M; Torti C; Moroni M; Carosi G; Cauda R; Chiodo F; Monforte Ad; Di Perri G; Galli M; Iardino R; Ippolito G; Lazzarin A; Mazzotta F; Panebianco R; Pastore G; Perno CF; Montroni M; Scalise G; Costantini A; Riva A; Tirelli U; Martellotta F; Pastore G; Ladisa N; Suter F; Maggiolo F; Chiodo F; Colangeli V; Fiorini C; Carosi G; Cristini G; Torti C; Minardi C; Bertelli D; Quirino T; Manconi PE; Piano P; Pizzigallo E; D'Alessandro M; Carnevale G; Zoncada A; Ghinelli F; Sighinolfi L; Leoncini F; Mazzotta F; Pozzi M; Lo Caputo S; Grisorio B; Ferrara S; Pagano G; Cassola G; Alessandrini A; Piscopo R; Soscia F; Tacconi L; Orani A; Perini P; Tommasi D; Congedo P; Chiodera F; Castelli P; Moroni M; Lazzarin A; Rizzardini G; Caggese L; Monforte Ad; Galli A; Merli S; Pastecchia C; Moioli MC; Esposito R; Mussini C; Gori A; Cagni S; Abrescia N; Chirianni A; Izzo CM; De Marco M; Viglietti R; Manzillo E; Ferrari C; Pizzaferri P; Filice G; Bruno R; Magnani G; Ursitti MA; Arlotti M; Ortolani P; Cauda R; Andreoni M; Antinori A; Antonucci G; Narciso P; Tozzi V; Vullo V; De Luca A; Zaccarelli M; Acinapura R; De Longis P; Trotta MP; Lichtner M; Carletti F; Mura MC; Mannazzu M; Caramello P; Di Perri G; Orofino GC; Sciandra M; Raise E; Ebo F; Pellizzer G; Buonfrate D; Pradier C; Fontas E; Caissotti C; Dellamonica P; Bentz L; Bernard E; De Salvador-Guillouet F; Durant J; Mondain-Miton V; Perbost I; Prouvost-Keller B; Pugliese P; Rahelinirina V; Roger PM; Vandenbos F; Battegay M; Bernasconi E; Böni J; Bucher H; Bürgisser P; Cattacin S; Cavassini M; Dubs R; Egger M; Elzi L; Erb P; Fischer M; Flepp M; Fontana A; Francioli P; Furrer HJ; Gorgievski M; Günthard H; Hirschel B; Kaiser L; Kind C; Klimkait T; Lauper U; Ledergerber B; Opravil M; Paccaud F; Pantaleo G; Perrin L; Piffaretti JC; Rickenbach M; Schmid CR; Schüpbach J; Speck R; Telenti A; Trkola A; Vernazza P; Weber R; Yerly S
  •  go-up   go-down


46. Silverberg MJ, Abrams DI: AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol; 2007 Sep;19(5):446-51
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era.
  • Recent literature is reviewed with respect to the incidence and risk factors for cancer in HIV patients.
  • RECENT FINDINGS: Previous studies have demonstrated substantial declines in AIDS-defining malignancies in the era of antiretroviral therapy, with clear links to better immune function.
  • Increases in non-AIDS-defining malignancies such as Hodgkin's disease, skin, lung, anal, and kidney cancers have been noted by some but not all authors.
  • Certain non-AIDS-defining malignancies may be related to immunodeficiency, although data are conflicting.
  • Recent studies have indicated that confounding by traditional risk factors, including cigarette use, may account for some of the increased risk of lung and other cancers in HIV patients.
  • SUMMARY: Non-AIDS-defining malignancies account for more morbidity and mortality than AIDS-defining malignancies in the antiretroviral therapy era.
  • Traditional risk factors play a significant role in the increased risk of non-AIDS-defining malignancies for HIV-infected individuals, but do not entirely explain the excess cancer risk.
  • Unanswered questions remain including the relationship of immunodeficiency and the risk of site-specific non-AIDS-defining malignancies, and the effect of antiretroviral therapy duration and drug class on cancer risk.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762569.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 67
  •  go-up   go-down


47. Ayers LW, Silver S, McGrath MS, Orenstein JM: The AIDS and Cancer Specimen Resource: role in HIV/AIDS scientific discovery. Infect Agent Cancer; 2007;2:7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The AIDS and Cancer Specimen Resource: role in HIV/AIDS scientific discovery.
  • The AIDS Cancer and Specimen Resource (ACSR) supports scientific discovery in the area of HIV/AIDS-associated malignancies.
  • The ACSR was established as a cooperative agreement between the NCI (Office of the Director, Division of Cancer Treatment and Diagnosis) and regional consortia, University of California, San Francisco (West Coast), George Washington University (East Coast) and Ohio State University (Mid-Region) to collect, preserve and disperse HIV-related tissues and biologic fluids and controls along with clinical data to qualified investigators.
  • ACSR also provides tissue microarrays of, e.g., Kaposi's sarcoma and non-Hodgkin's lymphoma, for biomarker assays and has developed collaborations with other groups that provide access to additional AIDS-related malignancy specimens.
  • The ACSR promotes the scientific exploration of the relationship between HIV/AIDS and malignancy by participation at national and international scientific meetings, contact with investigators who have productive research in this area and identifying, collecting, preserving, enhancing, and dispersing HIV/AIDS-related malignancy specimens to funded, approved researchers at no fee.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cardiovasc Res. 2003 Oct 15;60(1):108-18 [14522412.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2004;50 Online Pub:OL581-9 [15555424.001]
  • [Cites] Pediatr Infect Dis J. 2005 Mar;24(3):237-42 [15750460.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] BMC Med Inform Decis Mak. 2005;5:12 [15871741.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 Oct;289(4):H1373-80 [15923317.001]
  • [Cites] Science. 2005 Jun 10;308(5728):1582-3 [15947174.001]
  • [Cites] BMC Med Inform Decis Mak. 2005;5:25 [16086837.001]
  • [Cites] J Virol. 2005 Sep;79(17):11343-52 [16103186.001]
  • [Cites] Int J Hematol. 2006 Jul;84(1):3-11 [16867895.001]
  • [Cites] J Clin Microbiol. 2000 Feb;38(2):696-701 [10655369.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1599-601 [10942415.001]
  • [Cites] Nat Med. 2001 Jan;7(1):73-9 [11135619.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5536-42 [12359765.001]
  • [Cites] Am J Clin Pathol. 2002 Nov;118(5):733-41 [12428794.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1961-71 [12466110.001]
  • [Cites] BMC Med Inform Decis Mak. 2003 May 23;3:5 [12769826.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):308-20 [12843741.001]
  • [Cites] Blood. 1996 Dec 15;88(12):4620-9 [8977254.001]
  • [Cites] AIDS Res Hum Retroviruses. 1997 Jan 20;13(2):135-49 [9007199.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):687-93 [15220918.001]
  • (PMID = 17335575.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA066531
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1851770
  •  go-up   go-down


48. Ponte CM, Gurgel MH, Montenegro RM Jr: [Gonadotrophic axis dysfunction in men with HIV-infection/aids]. Arq Bras Endocrinol Metabol; 2009 Nov;53(8):983-8
Hazardous Substances Data Bank. TESTOSTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gonadotrophic axis dysfunction in men with HIV-infection/aids].
  • [Transliterated title] Disfunção do eixo gonadotrófico em homens com infecção pelo HIV/Aids.
  • The pathogenesis is multifactorial and related to duration of HIV infection, direct cytopathic effects of viruses, use of drugs, opportunistic infections, malignancies, and malnutrition, among other factors.
  • In men, reduced levels of testosterone is associated with loss of muscle mass and strength, decreased bone mineral density, lipodystrophy, depression, asthenia, fatigue and sexual dysfunction.
  • Thus, this review aimed to present a brief update of epidemiologic data, pathophysiology aspects and treatment strategies for the major abnormalities of male gonadotrophic axis associated with HIV infection and its treatment.
  • [MeSH-minor] Androgens / therapeutic use. Gynecomastia / etiology. HIV-Associated Lipodystrophy Syndrome / complications. Humans. Hyperprolactinemia / etiology. Hypogonadism / drug therapy. Hypogonadism / etiology. Male. Testosterone / therapeutic use

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20126851.001).
  • [ISSN] 1677-9487
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Androgens; 3XMK78S47O / Testosterone
  • [Number-of-references] 58
  •  go-up   go-down


49. Stebbing J, Powles T, Mandalia S, Nelson M, Gazzard B, Bower M: Use of antidepressants and risk of cancer in individuals infected with HIV. J Clin Oncol; 2008 May 10;26(14):2305-10
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of antidepressants and risk of cancer in individuals infected with HIV.
  • PURPOSE: Preclinical and cohort studies suggest that certain antidepressants are associated with a predisposition to cancer whereas others decrease the risk.
  • We aimed to assess whether different classes of antidepressants were associated with changes in cancer incidence in a population of HIV-1 infected individuals, based on duration of exposure.
  • METHODS: Antidepressant exposure was measured from date of first prescription of the antidepressant until the date of last follow-up or cancer diagnosis.
  • Univariate and multivariate analyses were performed to establish the risk of AIDS-related cancers and non-AIDS-related cancers according to whether patients were receiving selective serotonin reuptake inhibitors, tricyclic antidepressants, or other medicines for depression.
  • A total of 1,607 (15%) individuals were diagnosed with cancer.
  • There were no significant associations between any class of antidepressant and any type of cancer (P = .19), in either the pre-HAART or HAART era (P = .23), and use of serotonin reuptake inhibitors did not alter the risk of Burkitt lymphoma.
  • CONCLUSION: Antidepressants, irrespective of their class, do not affect cancer risk in HIV-infected individuals.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Antidepressants.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18467722.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Antidepressive Agents, Tricyclic; 0 / Serotonin Uptake Inhibitors
  •  go-up   go-down


50. Phatak UA, Joshi R, Badakh DK, Gosavi VS, Phatak JU, Jagdale RV: AIDS-associated cancers: an emerging challenge. J Assoc Physicians India; 2010 Mar;58:159-62
HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-associated cancers: an emerging challenge.
  • OBJECTIVES: To study the incidence and effects of anti-retroviral therapy along with cancer chemotherapy on outcome of AIDS associated Cancers in Indian patients.
  • METHOD: 3832 cancers patients were investigated over a period of 5 years.
  • 46 AIDS-associated cancers were identified.
  • Patients were treated with different modalities of cancer management and anti-retroviral therapy was discussed with the patient and relatives.
  • RESULTS: Incidence of AIDS-associated cancers was 1.2 percent.
  • AIDS-Defining Cancers (ADC) were seen in 26 (54.35%) while non-AIDS-Defining Cancers (NADC) were observed in 21 (45.65%).
  • Non Hodgkin Lymphoma was the commonest form of AIDS-defining cancers in 21 (84%) patients, cervical cancers in 4 (16%) women while there was not a single case of Kaposi's Sarcoma.
  • AIDS associated cancers were common in males.
  • Only 33.5% patients received treatment for HIV and cancers.
  • CONCLUSIONS: AIDS-associated cancers are seen in advanced stage of HIV infection.
  • Cervical cancers and non-AIDS-defining cancers do not show predictable response to anti-retroviral therapy.
  • Mortality in non-AIDS related cancers was significantly higher than AIDS related cancers.


51. Maggiorella L, Wen B, Frascogna V, Opolon P, Bourhis J, Deutsch E: Combined radiation sensitizing and anti-angiogenic effects of ionizing radiation and the protease inhibitor ritonavir in a head and neck carcinoma model. Anticancer Res; 2005 Nov-Dec;25(6B):4357-62
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reports of dramatic improvement of AIDS-related cancers, such as primary central system lymphoma after radiation therapy as well as Kaposi's sarcoma, led to the recent discovery of the "non viral" antitumor activity of HIV protease inhibitors.
  • Thus, the antitumor effect of the latter combination is associated with the enhancement of radiation-induced apoptosis and inhibition of angiogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309240.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; O3J8G9O825 / Ritonavir
  •  go-up   go-down


52. Biggar RJ, Engels EA, Ly S, Kahn A, Schymura MJ, Sackoff J, Virgo P, Pfeiffer RM: Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr; 2005 Jul 1;39(3):293-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after cancer diagnosis in persons with AIDS.
  • The survival of persons with AIDS (PWA) has recently improved because of better antiretroviral therapies.
  • Similarly, the prognosis of cancer has also improved.
  • To determine if survival in PWA with cancer has also improved, we compared cancer survival in adults with and without AIDS using data from New York City from 1980 through 2000.
  • Analyses were made for AIDS-related cancers (Kaposi sarcoma, non-Hodgkin lymphoma [NHL], and cervical cancer) and for 8 non-AIDS-related cancers (lung, larynx, colorectum, anus, Hodgkin lymphoma, breast, prostate, and testis).
  • Death hazard ratios compared survival in PWA with cancer with that in cancer patients without AIDS, adjusted for age, sex, race, and calendar-time of cancer occurrence.
  • The 24-month survival rate of PWA with cancer (9015 AIDS cancers and 929 non-AIDS-related cancers of 8 types) improved significantly for most cancer types.
  • By 1996 through 2000, the 24-month survival rate in PWA was 58% for Kaposi sarcoma, 41% for peripheral NHL, 29% for central nervous system NHL, and 64% for cervical cancer.
  • For non-AIDS-related cancers, survival of PWA was lowest for lung cancer (10%) but was >50% for most other cancer types.
  • In 1996 through 2000, significant differences in survival between cancer patients with and without AIDS still remained for Hodgkin lymphoma and lung, larynx, and prostate cancers.
  • We conclude that recent improvements in AIDS and cancer care have greatly narrowed the gap in survival between cancer patients with and without AIDS.
  • Clinicians should be encouraged by the improving prognosis and be diligent about detecting and treating cancer in PWA.
  • [MeSH-minor] Antiretroviral Therapy, Highly Active. Female. Humans. Lymphoma, AIDS-Related / mortality. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / mortality. Male. New York City / epidemiology. Prognosis. Registries. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / mortality. Survival Rate

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15980688.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Chadburn A, Chiu A, Lee JY, Chen X, Hyjek E, Banham AH, Noy A, Kaplan LD, Sparano JA, Bhatia K, Cesarman E: Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol; 2009 Oct 20;27(30):5039-48
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034.
  • PATIENTS AND METHODS: We examined 81 DLBCLs from patients with AIDS in AMC010 (cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP] v CHOP-rituximab) and AMC034 (etoposide, doxorubicin, vincristine, prednisone, and dose-adjusted cyclophosphamide plus rituximab concurrent v sequential) clinical trials and compared the immunophenotype with survival data, Epstein-Barr virus (EBV) positivity, and CD4 counts.
  • RESULTS: The GC and non-GC subtypes of DLBCL did not differ significantly with respect to overall survival or CD4 count at cancer presentation.
  • Expression of FOXP1, Blimp-1/PRDM1, or BCL-2 was not correlated with the outcome in patients with AIDS-related DLBCL.
  • The only predictive immunohistochemical marker was found to be Ki-67, where a higher proliferation index was associated with better survival, suggesting a better response to therapy in patients whose tumors had higher proliferation rates.
  • [MeSH-major] Immunophenotyping. Ki-67 Antigen. Lymphoma, AIDS-Related / immunology. Lymphoma, Large B-Cell, Diffuse / immunology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Oncology (Williston Park). 2002 Apr;16(4):441-51, 456, 459 [12017534.001]
  • [Cites] Lancet Oncol. 2003 Jan;4(1):22-9 [12517536.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2363-7 [12424193.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):464-70 [15087665.001]
  • [Cites] Ann Hematol. 2004 Jul;83(7):414-9 [15085385.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2933-5 [15238418.001]
  • [Cites] Blood. 1988 Apr;71(4):1157-60 [3281723.001]
  • [Cites] Lancet. 1991 Feb 9;337(8737):320-2 [1671232.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1460-6 [8123837.001]
  • [Cites] Ann Oncol. 1994;5 Suppl 1:113-6 [8172807.001]
  • [Cites] Blood. 1997 Jan 15;89(2):601-9 [9002964.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1931-9 [9586912.001]
  • [Cites] Leuk Lymphoma. 1998 Aug;30(5-6):515-24 [9711914.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1065-72 [15709173.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1851-61 [15550490.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1762-9 [15905193.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9067-72 [16172462.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):438-46 [16444194.001]
  • [Cites] Haematologica. 2006 Apr;91(4):467-74 [16585013.001]
  • [Cites] Microbes Infect. 2006 Apr;8(5):1301-7 [16697236.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 May;6(6):455-7 [16796775.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4135-42 [16943530.001]
  • [Cites] Ann Oncol. 2007 May;18(5):931-9 [17395602.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4930-5 [17299093.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Histopathology. 2007 Jul;51(1):70-9 [17593082.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):458-63 [17762571.001]
  • [Cites] Eur J Haematol. 2007 Dec;79(6):501-7 [17986209.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2816-24 [18077790.001]
  • [Cites] Annu Rev Immunol. 2008;26:133-69 [18370921.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2717-24 [18378569.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5 [18765795.001]
  • [Cites] Nat Rev Immunol. 2007 Dec;7(12):923-7 [17965637.001]
  • [Cites] Nat Rev Immunol. 2002 Dec;2(12):920-32 [12461565.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [CommentIn] J Clin Oncol. 2010 Jun 1;28(16):e260; author reply e261-2 [20421532.001]
  • (PMID = 19752343.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / CA-121947
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  • [Other-IDs] NLM/ PMC2799056
  •  go-up   go-down


54. Dhir AA, Sawant SP: Malignancies in HIV: the Indian scenario. Curr Opin Oncol; 2008 Sep;20(5):517-21
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancies in HIV: the Indian scenario.
  • PURPOSE OF REVIEW: India has the second largest number of HIV/AIDS patients in the world; however, studies done in the area of HIV-related malignancies are few.
  • With the availability of highly active antiretroviral therapy and treatment and prevention of opportunistic infections, an increase in life expectancy of HIV-infected individuals and an increase in HIV-related malignancies is expected.
  • The purpose of this review is to put forth the Indian scenario of HIV-related malignancies.
  • RECENT FINDINGS: About 2.5 million Indians have HIV/AIDS.
  • Non-Hodgkin's lymphoma and cervical cancer were found to occur in a higher proportion among the HIV-infected individuals in India as compared with non-HIV-infected individuals.
  • The incidence of AIDS-related primary central nervous system lymphoma is low in India.
  • Amongst the non-AIDS defining cancers anal cancer, testicular cancer, Hodgkin's disease, colon cancer and certain head and neck cancer sites in men and vaginal cancers among women were found to occur more frequently.
  • As India is a large country and geographically and culturally diverse, large-scale studies need to be done linking the regional cancer centres with the AIDS centres across the country to evaluate the exact burden of HIV-related malignancies.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / etiology. Neoplasms / etiology

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106653.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


55. Neuman HB, Charlson ME, Temple LK: Is there a role for decision aids in cancer-related decisions? Crit Rev Oncol Hematol; 2007 Jun;62(3):240-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a role for decision aids in cancer-related decisions?
  • Cancer-related decisions are challenging, requiring patients to evaluate associated medical and psychological outcomes within the context of their personal values.
  • Clinical decision aids are decisional support tools designed to facilitate patient-driven decision-making by providing relevant information on the options while eliciting and incorporating patient preferences; they have been designed to support decision-making in the prevention, screening, and treatment of cancer.
  • In randomized controlled trials, cancer-related decision aids have been shown to increase patients' knowledge regarding their disease, and may facilitate patients playing a more active role in decision-making.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317206.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Number-of-references] 93
  •  go-up   go-down


56. Bonnet F, Chêne G: Evolving epidemiology of malignancies in HIV. Curr Opin Oncol; 2008 Sep;20(5):534-40
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolving epidemiology of malignancies in HIV.
  • PURPOSE OF REVIEW: Morbidity and mortality related to malignancy are increasing in HIV-infected patients.
  • We aim at reviewing the literature on recent changes in the incidence of AIDS-defining and non-AIDS-defining malignancies and the specific characteristics of the main cancers emerging in HIV-infected patients.
  • RECENT FINDINGS: Currently, malignancies are the most frequent underlying cause of death (around one-third) of HIV-infected patients.
  • Since the introduction of combination antiretroviral therapy, the incidence of Kaposi's sarcoma and cerebral lymphoma (among AIDS-defining cancers) decreased in parallel with AIDS-defining infections, whereas the incidence of systemic non-Hodgkin's lymphoma and cervical cancer decreased less than others and remains higher in HIV-infected patients than in the general population.
  • The most recent and large studies have also shown a 1.7-3-fold higher risk of developing non-AIDS malignancies in HIV-infected patients as compared with the general population without a significant impact of combination antiretroviral therapy on these trends.
  • These malignancies include Hodgkin's disease, lung, anal, head and neck cancers, hemopathies, and conjunctival cancers.
  • In addition, the poorer prognosis reported in HIV-infected patients affected by malignancies might be interpreted as a consequence of late screening or immunosuppression.

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106656.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 75
  •  go-up   go-down


57. Epstein JB: Oral malignancies associated with HIV. J Can Dent Assoc; 2007 Dec;73(10):953-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral malignancies associated with HIV.
  • HIV is associated with an increased risk of malignant disease that is related to immunosuppression and the activity of the HIV transactivator of transcription protein, coviral infection and exposure to carcinogens.
  • The presence of oral malignancies varies with the route of the transmission of HIV and varies geographically, based on behaviour, viral cofactors, HIV therapy and genetic variation.
  • [MeSH-minor] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / etiology. Humans. Immunosuppression / adverse effects. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / etiology. Sarcoma, Kaposi / diagnosis. Sarcoma, Kaposi / etiology. rev Gene Products, Human Immunodeficiency Virus / physiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18275699.001).
  • [ISSN] 1488-2159
  • [Journal-full-title] Journal (Canadian Dental Association)
  • [ISO-abbreviation] J Can Dent Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / rev Gene Products, Human Immunodeficiency Virus
  •  go-up   go-down


58. Bottler T, Kuttenberger J, Hardt N, Oehen HP, Baltensperger M: Non-HIV-associated Kaposi's sarcoma of the tongue. Case report and review of the literature. Int J Oral Maxillofac Surg; 2007 Dec;36(12):1218-20
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-HIV-associated Kaposi's sarcoma of the tongue. Case report and review of the literature.
  • Kaposi's sarcoma is a frequently seen AIDS-related malignant neoplasm in the head and neck region, especially in the oral cavity, but is rarely described in the HIV-negative and non-immunosuppressed individual.

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17614259.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 20
  •  go-up   go-down


59. Blanes M, Belinchón I, Merino E, Portilla J, Sánchez-Payá J, Betlloch I: [Current prevalence and characteristics of dermatoses associated with human immunodeficiency virus infection]. Actas Dermosifiliogr; 2010 Oct;101(8):702-9
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current prevalence and characteristics of dermatoses associated with human immunodeficiency virus infection].
  • The frequency of opportunistic infections and AIDS-related cancers has fallen, though new health problems have developed.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20965013.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


60. Bernstein WB, Little RF, Wilson WH, Yarchoan R: Acquired immunodeficiency syndrome-related malignancies in the era of highly active antiretroviral therapy. Int J Hematol; 2006 Jul;84(1):3-11
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired immunodeficiency syndrome-related malignancies in the era of highly active antiretroviral therapy.
  • Since the beginning of the acquired immunodeficiency syndrome (AIDS) epidemic, malignancies have been an important feature of this disease.
  • Several cancers, including Kaposi sarcoma (KS), certain aggressive B-cell lymphomas, and cervical cancer, are considered AIDS-defining when they occur in patients infected with human immunodeficiency virus.
  • Most AIDS-defining tumors are associated with one of 3 DNA viruses: KS-associated herpesvirus, Epstein-Barr virus, or human papillomavirus.
  • With the introduction of highly active antiretroviral therapy (HAART), the incidence of KS and certain lymphomas has decreased, whereas that of other tumors, such as cervical cancer, has undergone little change.
  • Several new drugs and therapies have been developed for KS and AIDS-related lymphomas, and these treatments, plus the development of HAART, have contributed to improvements in morbidity and mortality.
  • At the same time, the improved overall survival of patients with HAART has contributed to an increase in the number of patients living with AIDS in developed countries such as the United States.
  • With the development of HAART and improved prevention and treatment of opportunistic infections, an increasing percentage of the deaths in AIDS patients have been from malignancies.
  • [MeSH-major] Acquired Immunodeficiency Syndrome. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related. Sarcoma, Kaposi
  • [MeSH-minor] AIDS-Related Opportunistic Infections / etiology. AIDS-Related Opportunistic Infections / mortality. AIDS-Related Opportunistic Infections / prevention & control. AIDS-Related Opportunistic Infections / virology. Humans

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1997 Jan;71(1):715-9 [8985403.001]
  • [Cites] JAMA. 2002 Jan 9;287(2):221-5 [11779265.001]
  • [Cites] Leuk Lymphoma. 1994 Feb;12(5-6):413-9 [8180604.001]
  • [Cites] Lancet Oncol. 2003 Jan;4(1):22-9 [12517536.001]
  • [Cites] Annu Rev Microbiol. 2003;57:609-39 [14527293.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1433-43 [9626048.001]
  • [Cites] N Engl J Med. 1999 Apr 8;340(14):1063-70 [10194235.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1369-77 [11070101.001]
  • [Cites] Lancet. 1981 Sep 19;2(8247):598-600 [6116083.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] AIDS. 2002 Sep 6;16(13):1799-802 [12218392.001]
  • [Cites] J Infect Dis. 2003 Jan 1;187(1):149-53 [12508160.001]
  • [Cites] Curr Opin Oncol. 2000 Mar;12(2):174-80 [10750730.001]
  • [Cites] JAMA. 2000 Feb 23;283(8):1031-7 [10697063.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Exp Med. 1998 Jul 20;188(2):405-8 [9670053.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):149-53 [16394845.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] AIDS. 1995 Nov;9(11):1255-62 [8561979.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Semin Hematol. 2003 Apr;40(2):143-53 [12704591.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):399-402 [14752065.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Mar;53(3):253-65 [15718150.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2157-64 [11684935.001]
  • [Cites] Am J Pathol. 1993 Oct;143(4):1072-85 [8214003.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2593-602 [10893291.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):153-9 [11773164.001]
  • [Cites] Am J Med. 1991 Apr;90(4):427-33 [1707230.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):317-24 [15241829.001]
  • [Cites] AIDS. 2004 Aug 20;18(12):1737-40 [15280789.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] AIDS. 2003 Jul 25;17(11):F17-22 [12853764.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] Histopathology. 1994 Jul;25(1):77-82 [7959648.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):86-9 [9422510.001]
  • [Cites] Leukemia. 1999 Jul;13(7):1093-9 [10400426.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):24-5 [9422503.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2876-82 [12885804.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] J Natl Cancer Inst. 1999 Feb 3;91(3):226-36 [10037100.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):683-91 [9469358.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1181-5 [7700310.001]
  • [Cites] Radiother Oncol. 1998 Jan;46(1):19-22 [9488122.001]
  • [Cites] Int J STD AIDS. 1998 Dec;9(12):751-5 [9874123.001]
  • [Cites] Blood. 2004 Aug 1;104(3):810-4 [15073028.001]
  • [Cites] JAMA. 2005 Mar 23;293(12):1471-6 [15784870.001]
  • [Cites] Science. 1997 Oct 10;278(5336):290-4 [9323208.001]
  • [Cites] N Engl J Med. 1983 May 5;308(18):1071-6 [6835320.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1982 Jun 4;31(21):277-9 [6808345.001]
  • [Cites] Nat Med. 2002 Mar;8(3):225-32 [11875492.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 19;87(8):581-6 [7538593.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1876-83 [10561228.001]
  • [Cites] Lancet. 1982 Sep 18;2(8299):631-3 [6125777.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):1027-38 [10749966.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4650-7 [16507779.001]
  • [Cites] Blood. 1996 May 1;87(9):3877-82 [8611715.001]
  • [Cites] Lancet. 1995 Jul 1;346(8966):26-8 [7603142.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2353-64 [8708728.001]
  • [Cites] J Virol. 2003 Jun;77(12):6761-8 [12767996.001]
  • [Cites] J Infect Dis. 2001 Feb 1;183(3):383-91 [11133369.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S42-8 [10430218.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2173-6 [11264189.001]
  • [Cites] Curr Opin Oncol. 2002 Sep;14(5):528-32 [12192272.001]
  • (PMID = 16867895.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] Japan
  • [Number-of-references] 97
  •  go-up   go-down


61. Crum-Cianflone N, Hullsiek KH, Satter E, Marconi V, Weintrob A, Ganesan A, Barthel RV, Fraser S, Agan BK: Cutaneous malignancies among HIV-infected persons. Arch Intern Med; 2009 Jun 22;169(12):1130-8
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous malignancies among HIV-infected persons.
  • BACKGROUND: As the life expectancy of persons infected with human immunodeficiency virus (HIV) increases, cancers have become an important cause of morbidity and mortality.
  • Although cutaneous cancers are the most common malignant neoplasms in the general population, little data exist among HIV-positive persons, especially regarding the impact of HIV-specific factors.
  • METHODS: We evaluated the incidence rates and factors associated with the development of cutaneous malignancies among HIV-infected persons by examining data that were prospectively collected from a large HIV study that included 4490 participants (1986-2006).
  • RESULTS: Six percent of HIV-infected persons (n = 254) developed a cutaneous malignancy during 33 760 person-years of follow-up (mean, 7.5 years).
  • Since the advent of highly active antiretroviral therapy (HAART), the incidence rates of cutaneous non-AIDS-defining cancers (NADCs), in particular basal cell carcinoma, have exceeded the rates of cutaneous AIDS-defining cancers such as Kaposi sarcoma.
  • Factors associated with the development of cutaneous NADCs in the multivariate models included increasing age (hazard ratio [HR], 2.1; 95% confidence interval [CI], 1.7-2.6) and race.
  • CONCLUSIONS: At present, the most common cutaneous malignancies among HIV-infected persons are NADCs.
  • Cutaneous NADCs do not appear to be significantly associated with immune function or HAART but rather are related to traditional factors such as aging and skin color.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J STD AIDS. 1999 Dec;10(12):795-802 [10639060.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] AIDS. 2001 Mar 30;15(5):629-33 [11317001.001]
  • [Cites] Clin Microbiol Rev. 2002 Apr;15(2):310-26 [11932235.001]
  • [Cites] Br J Dermatol. 2002 Apr;146 Suppl 61:1-6 [11966724.001]
  • [Cites] Arch Dermatol. 2002 Jun;138(6):758-63 [12056956.001]
  • [Cites] Arch Dermatol. 2002 Jun;138(6):765-70 [12056957.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20 [12077575.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] J R Soc Med. 2003 May;96(5):238-9 [12724438.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):595-7 [15061841.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1981 Jul 3;30(25):305-8 [6789108.001]
  • [Cites] N Engl J Med. 1986 Jan 9;314(2):131-2 [2934633.001]
  • [Cites] J Am Acad Dermatol. 1989 Apr;20(4):587-91 [2715405.001]
  • [Cites] Arch Dermatol. 1992 May;128(5):623-7 [1575523.001]
  • [Cites] J Am Acad Dermatol. 1993 Sep;29(3):400-6 [8349856.001]
  • [Cites] J Am Acad Dermatol. 1993 Oct;29(4):539-44 [7691905.001]
  • [Cites] Mayo Clin Proc. 1995 Aug;70(8):766-72 [7630215.001]
  • [Cites] Arch Dermatol. 1997 May;133(5):577-83 [9158410.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Transplant Proc. 1998 Sep;30(6):2859-60 [9745599.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S34-41 [10430217.001]
  • [Cites] J Clin Pathol. 1999 Apr;52(4):249-53 [10474513.001]
  • [Cites] Drugs Today (Barc). 2005 Jan;41(1):37-53 [15753968.001]
  • [Cites] JAMA. 2005 Aug 10;294(6):681-90 [16091570.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1505-11 [16104038.001]
  • [Cites] JAMA. 2005 Sep 28;294(12):1476-80 [16189357.001]
  • [Cites] J Am Acad Dermatol. 2005 Dec;53(6):1067-71 [16310071.001]
  • [Cites] J Am Acad Dermatol. 2006 Feb;54(2):189-206; quiz 207-10 [16443048.001]
  • [Cites] Br J Dermatol. 2006 Mar;154(3):498-504 [16445782.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 15;98(6):389-95 [16537831.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Dermatol Clin. 2006 Oct;24(4):521-30, vii [17010780.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1079-80 [17034550.001]
  • [Cites] Ann Intern Med. 2007 Jan 16;146(2):87-95 [17227932.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] J Infect Dis. 2007 Sep 15;196(6):876-83 [17703418.001]
  • [Cites] AIDS. 2007 Sep 12;21(14):1957-63 [17721103.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • (PMID = 19546414.001).
  • [ISSN] 1538-3679
  • [Journal-full-title] Archives of internal medicine
  • [ISO-abbreviation] Arch. Intern. Med.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / HU0001-05-2-0011; United States / PHS HHS / / HU0001-05-2-0011
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ NIHMS127594; NLM/ PMC2761839
  •  go-up   go-down


62. Aboulafia DM, Ratner L, Miles SA, Harrington WJ Jr, AIDS Associated Malignancies Clinical Trials Consortium: Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. Clin Lymphoma Myeloma; 2006 Mar;6(5):399-402
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019.
  • PURPOSE: A consistent association with Epstein-Barr Virus (EBV) distinguishes acquired immunodeficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL) from that which occurs in the general population.
  • Recent descriptions of long-term remissions in patients with posttransplantation EBV-associated PCNSL who received EBV-specific therapy suggest some antitumor effect is anti-EBV mediated.
  • PATIENTS AND METHODS: We enrolled 4 patients with AIDS-related PCNSL into a novel antiviral and immunomodulatory protocol.
  • All 6 patients had advanced-stage AIDS as reflected by a CD4+ T-lymphocyte cell count of < 50/microL and a detectable human immunodeficiency virus (HIV)-1 viral RNA load (median copies, 135,000/mL; range, 2170-360,000/mL).
  • CONCLUSION: We conclude that for patients with AIDS and PCNSL, treatments with dual efficacy against HIV and EBV merit further investigation.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / methods. Brain Neoplasms / drug therapy. Brain Neoplasms / mortality. Interleukins / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / mortality
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Positron-Emission Tomography. Prospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome


63. Kristinsson SY, Goldin LR, Björkholm M, Koshiol J, Turesson I, Landgren O: Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Haematologica; 2009 Nov;94(11):1581-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies.
  • There are data to support a role for genetic and immune-related factors in the pathogenesis of lymphomas and plasma cell diseases.
  • We discuss the overlap in risk factors between related malignancies and explore the underlying mechanisms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Clin Pract Rheumatol. 2007 Oct;3(10):561-9 [17906611.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3326-33 [17687107.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):717-23 [18021086.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):762-71 [18021089.001]
  • [Cites] Mayo Clin Proc. 2007 Dec;82(12):1468-73 [18053453.001]
  • [Cites] Arthritis Rheum. 2008 Mar;58(3):657-66 [18311836.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3388-94 [18239085.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] J Natl Cancer Inst. 1993 Feb 17;85(4):307-11 [8426374.001]
  • [Cites] Cancer Causes Control. 1993 Jul;4(4):361-8 [8347786.001]
  • [Cites] Leukemia. 1993 Sep;7(9):1363-9 [8371587.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2378-85 [8162584.001]
  • [Cites] Scand J Immunol. 1994 Aug;40(2):195-200 [8047841.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 2;86(21):1600-8 [7932824.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1943-9 [8656264.001]
  • [Cites] J Rheumatol. 1996 Jun;23(6):1095-7 [8782146.001]
  • [Cites] Eur J Cancer. 1996 Sep;32A(10):1753-7 [8983286.001]
  • [Cites] Haematologica. 2005 Jan;90(1):66-71 [15642671.001]
  • [Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]
  • [Cites] Blood. 2005 Jul 15;106(2):668-72 [15811955.001]
  • [Cites] J Med Genet. 2005 Jul;42(7):595-601 [15994882.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2402-6 [16214923.001]
  • [Cites] Arch Intern Med. 2005 Nov 14;165(20):2337-44 [16287762.001]
  • [Cites] Am J Epidemiol. 2005 Dec 15;162(12):1153-61 [16251389.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):51-60 [16391371.001]
  • [Cites] Blood. 2006 Feb 1;107(3):904-6 [16210333.001]
  • [Cites] N Engl J Med. 2008 Jul 10;359(2):152-7 [18614782.001]
  • [Cites] Lupus. 2008 Jul;17(7):613-4 [18625632.001]
  • [Cites] Arch Intern Med. 2008 Sep 22;168(17):1903-9 [18809818.001]
  • [Cites] Nat Genet. 2008 Oct;40(10):1204-10 [18758461.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3052-6 [18703425.001]
  • [Cites] N Engl J Med. 2008 Oct 16;359(16):1734-5; author reply 1735 [18923179.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):659-67 [19213679.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):904-10 [19114699.001]
  • [Cites] Am J Med. 1985 Jan 21;78(1A):29-32 [3970037.001]
  • [Cites] Br J Haematol. 1985 Jul;60(3):551-4 [3925983.001]
  • [Cites] J Natl Cancer Inst. 1986 Aug;77(2):371-8 [3461199.001]
  • [Cites] Br J Cancer. 1987 Jan;55(1):85-90 [3814482.001]
  • [Cites] Cancer Res. 1987 Jun 1;47(11):2978-81 [3567914.001]
  • [Cites] Leuk Res. 1988;12(1):81-8 [3357350.001]
  • [Cites] Am J Pathol. 1988 Oct;133(1):173-92 [2845789.001]
  • [Cites] Nouv Rev Fr Hematol. 1988;30(5-6):353-7 [3222144.001]
  • [Cites] Am J Epidemiol. 1991 Jul 1;134(1):22-8 [1853857.001]
  • [Cites] Cancer Causes Control. 1992 Jan;3(1):63-7 [1536915.001]
  • [Cites] Haematologica. 2009 May;94(5):647-53 [19286886.001]
  • [Cites] Int J Cancer. 2009 Jul 15;125(2):398-405 [19365835.001]
  • [Cites] Br J Haematol. 2009 Jun;146(1):91-4 [19438470.001]
  • [Cites] Blood. 2009 Jul 23;114(4):785-90 [19179466.001]
  • [Cites] Blood. 2009 Jul 23;114(4):791-5 [19182202.001]
  • [Cites] Haematologica. 2009 Aug;94(8):1179-81 [19546435.001]
  • [Cites] Int J Cancer. 2009 Nov 1;125(9):2147-50 [19582882.001]
  • [Cites] Hum Genet. 2000 May;106(5):553-6 [10914686.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):497-502 [11054684.001]
  • [Cites] Nat Immunol. 2001 Sep;2(9):793-5 [11526388.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1979-81 [11535538.001]
  • [Cites] APMIS. 2001 Nov;109(11):797-800 [11900061.001]
  • [Cites] Blood. 2002 Jun 1;99(11):3909-15 [12010788.001]
  • [Cites] Arthritis Rheum. 2003 Apr;48(4):963-70 [12687538.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3759-64 [12881316.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):76-80 [15185346.001]
  • [Cites] Curr Opin Pharmacol. 2004 Aug;4(4):347-54 [15251127.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1850-4 [15161669.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1415-21 [15342441.001]
  • [Cites] Blood. 1966 Apr;27(4):435-48 [5327005.001]
  • [Cites] Nature. 1970 Dec 12;228(5276):1056-8 [4320657.001]
  • [Cites] N Engl J Med. 1977 Feb 3;296(5):248-50 [831107.001]
  • [Cites] Scand J Haematol. 1977 Oct;19(4):396-404 [562530.001]
  • [Cites] Cancer. 1977 Nov;40(5):2094-101 [336182.001]
  • [Cites] Acta Med Scand. 1982 May;211(3):237-9 [6805257.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] Cancer Causes Control. 1992 Sep;3(5):449-56 [1525326.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):488-94 [16357024.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3095-8 [16395700.001]
  • [Cites] Blood. 2006 Jul 1;108(1):292-6 [16527887.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Semin Immunol. 2006 Oct;18(5):305-17 [16916610.001]
  • [Cites] Am J Hum Genet. 2006 Oct;79(4):695-701 [16960805.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1321-30 [16985251.001]
  • [Cites] Haematologica. 2006 Dec;91(12):1697-700 [17145609.001]
  • [Cites] Arthritis Rheum. 2006 Dec;54(12):3774-81 [17133544.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1099-102 [17131330.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2198-201 [17082317.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):401-4 [17337646.001]
  • [Cites] Int J Cancer. 2007;120 Suppl 12:40-61 [17405120.001]
  • [Cites] Int J Cancer. 2007;120 Suppl 12:1-39 [17405121.001]
  • [Cites] JAMA. 2007 May 9;297(18):2010-7 [17488966.001]
  • [Cites] Cell. 2007 Jul 13;130(1):25-35 [17632054.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1260-7 [17426058.001]
  • [Cites] Expert Opin Pharmacother. 2007 Sep;8(13):2089-107 [17714062.001]
  • (PMID = 19586941.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Number-of-references] 93
  • [Other-IDs] NLM/ PMC2770969
  •  go-up   go-down


64. Stebbing J, Duru O, Bower M: Non-AIDS-defining cancers. Curr Opin Infect Dis; 2009 Feb;22(1):7-10
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-defining cancers.
  • PURPOSE OF REVIEW: Individuals with HIV infection are at higher risk for the development of a wide variety of non-AIDS-defining cancers (NADCs).
  • Although all three AIDS-defining malignancies and many NADCs are associated with viral etiopathogenesis, some, such as lung cancer, are not related to any known viral oncogenes and the reason for their increased incidence in immunosuppressed individuals remains unclear.
  • RECENT FINDINGS: The majority of the excess risk of NADC is accounted for by a limited number of specific cancers, which repeatedly occur with increased incidence in published series.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19532075.001).
  • [ISSN] 1473-6527
  • [Journal-full-title] Current opinion in infectious diseases
  • [ISO-abbreviation] Curr. Opin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


65. Wang X, Wang X, Liang D, Lan K, Guo W, Ren G: Classic Kaposi's sarcoma in Han Chinese and useful tools for differential diagnosis. Oral Oncol; 2010 Sep;46(9):654-6
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma (KS) is a common AIDS-related malignant neoplasm in the head and neck region, especially in the oral cavity, but is rarely described in the HIV-negative and non-immunosuppressed individual.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20656545.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


66. Villafañe MF, Trione N, Corti M, Mendez N, Gancedo E, Zamora N, Levin M: Primary liver AIDS-related lympoma. Rev Inst Med Trop Sao Paulo; 2006 Jul-Aug;48(4):229-31
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary liver AIDS-related lympoma.
  • Non-Hodgkin's lymphomas (NHL) are the second most frequent malignancies in AIDS patients.
  • The majority of NHL associated with AIDS involves extranodal sites, especially the digestive tract and the central nervous system.
  • Primary liver lymphoma (PLL) is an uncommon neoplasm among these patients.
  • We report a case of PLL as the initial manifestation of AIDS in a patient without any previous infection by hepatitis C or B virus, presented as multiple and large hepatic masses.
  • [MeSH-major] Liver Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17119682.001).
  • [ISSN] 0036-4665
  • [Journal-full-title] Revista do Instituto de Medicina Tropical de São Paulo
  • [ISO-abbreviation] Rev. Inst. Med. Trop. Sao Paulo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


67. Gichuhi S, Irlam JJ: Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals. Cochrane Database Syst Rev; 2007;(2):CD005643
HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This pattern is related to the co-existence of the HIV/AIDS pandemic, high HPV exposure, and solar radiation in the region.
  • SEARCH STRATEGY: Using a sensitive search strategy, we attempted to identify all relevant trials, regardless of language or publication status, from the following electronic databases; Medline/PubMed, CENTRAL, AIDSearch, EMBASE, LILACS, African Healthline, Cochrane HIV/AIDS Specialised Register, and the Cochrane Cancer Network Specialised Register.
  • We searched the clinical trial register of the US National Institutes of Health, searched the international conference proceedings of AIDS and AIDS-related cancers, and contacted individual researchers, research organisations, and pharmaceutical companies that manufacture the drugs used as interventions.
  • HIV/AIDS research has not focused on treatment of this tumour.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2013;2:CD005643 [23450564.001]
  • (PMID = 17443606.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 64
  •  go-up   go-down


68. Kasamon YL, Ambinder RF: AIDS-related primary central nervous system lymphoma. Hematol Oncol Clin North Am; 2005 Aug;19(4):665-87, vi-vii
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related primary central nervous system lymphoma.
  • The clinical features, diagnosis, and management of AIDS-related PCNSL are reviewed.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma, AIDS-Related / pathology

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16083829.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA96888; United States / NCI NIH HHS / CA / UO1 CA70062
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 100
  •  go-up   go-down


69. Dhir AA, Sawant S, Dikshit RP, Parikh P, Srivastava S, Badwe R, Rajadhyaksha S, Dinshaw KA: Spectrum of HIV/AIDS related cancers in India. Cancer Causes Control; 2008 Mar;19(2):147-53
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of HIV/AIDS related cancers in India.
  • OBJECTIVE: To study the cancer pattern among HIV positive cancer cases.
  • METHOD: The study group included patients registered in the HIV Cancer clinic at the Tata Memorial Hospital (TMH), Mumbai, which is the largest tertiary referral cancer center in India.
  • We used the gender and age-specific proportions of each cancer site of the year 2002 that was recorded in the Hospital Cancer Registry to estimate an expected number of various cancer sites among HIV positive cancer patients during the period 2001-2005.
  • The observed number of site-specific cancer cases was divided by the expected number to obtain proportional incidence ratio (PIR).
  • In males, PIR was increased for anal cancer (PIR = 10.3, 95%CI 4.30-24.83), Hodgkin's disease, testicular cancer, colon cancer, and few head and neck cancer sites.
  • Among females, the PIRs for cervical cancer (PIR = 4.1, 95%CI 2.90-5.75), vaginal cancer (PIR = 7.7, 95%CI 2.48-23.85), and anal cancer (PIR = 6.5, 95%CI 0.91-45.88) were increased.
  • CONCLUSIONS: The absence of Kaposi's sarcoma and increased PIRs for certain non-AIDS defining cancers among HIV infected cancer cases indicates a different spectrum of HIV associated malignancies in this region.
  • The raised PIR for cervical cancer emphasizes the urgent need for screening programs for cervical cancer among HIV infected individuals in India.


70. Whitman AG, Bryan BA, Dyson OF, Patel DK, Ramasamy D, Anantharaman S, Reber AJ, Akula SM: AIDS related viruses, their association with leukemia, and Raf signaling. Curr HIV Res; 2005 Oct;3(4):319-27
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS related viruses, their association with leukemia, and Raf signaling.
  • In this review, we present an update on the role of AIDS related viruses as an etiology for leukemia.
  • Human immunodeficiency virus-1 and -2 (HIV-1; -2) are the cause for the development of acquired immune deficiency syndrome (AIDS).
  • Epstein-Barr virus (EBV), human cytomegalovirus (HCMV), Human papillomavirus (HPV), and Kaposi's sarcoma-associated herpesvirus (KSHV) are specifically implicated in AIDS associated malignancies.
  • However, there are other viruses that are associated to a lesser extent with the AIDS condition and they are Human T-cell leukemia virus-1 (HTLV-1), hepatitis B virus (HBV), hepatitis C virus (HCV), and human herpesvirus-6 (HHV-6).
  • Of these viruses, HTLV-1 has been etiologically associated with leukemia.
  • Raf signaling has been shown to aid in the infection and pathogenesis of many of these viruses, making Raf pathway components good potential targets for the treatment of leukemia induced by AIDS related viruses.


71. Sivakumaran H, van der Horst A, Fulcher AJ, Apolloni A, Lin MH, Jans DA, Harrich D: Arginine methylation increases the stability of human immunodeficiency virus type 1 Tat. J Virol; 2009 Nov;83(22):11694-703
Hazardous Substances Data Bank. (L)-ARGININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The stabilizing action of PRMT6 could allow Tat to persist within the cell and the extracellular environment and thereby enable functions implicated in AIDS-related cancer, neurodegeneration, and T-cell death.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2006 Jan 27;124(2):381-92 [16439211.001]
  • [Cites] Retrovirology. 2009;6:1 [19128510.001]
  • [Cites] Mol Cell. 2006 Apr 7;22(1):51-62 [16600869.001]
  • [Cites] Microbes Infect. 2006 Apr;8(5):1347-57 [16697675.001]
  • [Cites] Retrovirology. 2006;3:48 [16893449.001]
  • [Cites] J Cell Biol. 2006 Nov 6;175(3):401-13 [17088425.001]
  • [Cites] Mol Cell Biol. 2007 Jan;27(1):120-34 [17043108.001]
  • [Cites] Nature. 2007 Jan 11;445(7124):214-8 [17215844.001]
  • [Cites] Retrovirology. 2006;3:93 [17176473.001]
  • [Cites] Mol Cell. 2007 Feb 9;25(3):369-83 [17289585.001]
  • [Cites] J Virol. 2007 Apr;81(8):4226-34 [17267505.001]
  • [Cites] AIDS. 2007 Apr 23;21(7):795-805 [17415034.001]
  • [Cites] Mol Cell. 2007 Jun 22;26(6):831-42 [17588518.001]
  • [Cites] Mol Cell. 2007 Jun 22;26(6):843-52 [17588519.001]
  • [Cites] Curr HIV Res. 2007 Sep;5(5):473-83 [17896967.001]
  • [Cites] Nature. 2007 Oct 18;449(7164):933-7 [17898714.001]
  • [Cites] EMBO J. 1999 Nov 1;18(21):6106-18 [10545121.001]
  • [Cites] Mol Ther. 2000 Oct;2(4):404-14 [11020357.001]
  • [Cites] J Biol Chem. 2001 Jul 27;276(30):28179-84 [11384967.001]
  • [Cites] Mol Cell Biol. 2001 Dec;21(23):7956-70 [11689688.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3537-43 [11724789.001]
  • [Cites] EMBO J. 2002 Jul 1;21(13):3516-25 [12093752.001]
  • [Cites] J Cell Physiol. 2002 Aug;192(2):209-15 [12115727.001]
  • [Cites] Nat Biotechnol. 2003 Aug;21(8):921-6 [12872131.001]
  • [Cites] Nat Cell Biol. 2003 Aug;5(8):754-61 [12883554.001]
  • [Cites] Gene. 2004 Feb 4;326:1-11 [14729258.001]
  • [Cites] Eur J Clin Invest. 2004 Jan;34(1):57-66 [14984439.001]
  • [Cites] Cell. 2004 Jun 11;117(6):690-1 [15186770.001]
  • [Cites] Mol Cell. 2004 Aug 27;15(4):559-71 [15327772.001]
  • [Cites] J Mol Biol. 1971 Dec 28;62(3):465-77 [5136579.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Nature. 1990 May 3;345(6270):84-6 [2184372.001]
  • [Cites] Biotechniques. 1991 Dec;11(6):739-40, 742-3 [1809326.001]
  • [Cites] J Biol Chem. 1993 May 15;268(14):10501-9 [7683681.001]
  • [Cites] Arch Virol. 1994;137(1-2):149-55 [7979988.001]
  • [Cites] J Biol Chem. 1996 Mar 29;271(13):7844-50 [8631829.001]
  • [Cites] J Immunol. 1996 Aug 1;157(3):974-7 [8757599.001]
  • [Cites] J Biol Chem. 1997 Mar 28;272(13):8145-8 [9079628.001]
  • [Cites] EMBO J. 1997 Mar 17;16(6):1224-35 [9135139.001]
  • [Cites] Cell. 1998 Feb 20;92(4):451-62 [9491887.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 17;244(2):384-9 [9514931.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1998;61:65-131 [9752719.001]
  • [Cites] Virology. 1998 Dec 5;252(1):126-36 [9875323.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):353-60 [15525938.001]
  • [Cites] J Virol. 2005 Jan;79(1):124-31 [15596808.001]
  • [Cites] PLoS Biol. 2005 Feb;3(2):e41 [15719057.001]
  • [Cites] Endocr Rev. 2005 Apr;26(2):147-70 [15479858.001]
  • [Cites] Mol Cell. 2005 Apr 29;18(3):263-72 [15866169.001]
  • [Cites] J Exp Med. 2005 Aug 1;202(3):371-7 [16061726.001]
  • [Cites] J Immunol. 2005 Nov 15;175(10):6402-11 [16272292.001]
  • [Cites] Microbes Infect. 2005 Oct;7(13):1364-9 [16046164.001]
  • [Cites] Science. 2007 Oct 19;318(5849):444-7 [17947579.001]
  • [Cites] Genes Dev. 2007 Dec 15;21(24):3369-80 [18079182.001]
  • [Cites] Retrovirology. 2008;5:40 [18498648.001]
  • [Cites] Cell Cycle. 2008 May 15;7(10):1433-9 [18418067.001]
  • [Cites] Biochim Biophys Acta. 2008 Sep;1780(9):1062-9 [18573314.001]
  • [Cites] Retrovirology. 2008;5:63 [18620576.001]
  • [Cites] J Biol Chem. 2006 Feb 17;281(7):3764-72 [16293633.001]
  • (PMID = 19726520.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / tat Gene Products, Human Immunodeficiency Virus; 94ZLA3W45F / Arginine; EC 2.1.1.- / PRMT6 protein, human; EC 2.1.1.- / Protein-Arginine N-Methyltransferases
  • [Other-IDs] NLM/ PMC2772670
  •  go-up   go-down


72. Ho-Yen C, Chang F, van der Walt J, Lucas S: Gastrointestinal malignancies in HIV-infected or immunosuppressed patients: pathologic features and review of the literature. Adv Anat Pathol; 2007 Nov;14(6):431-43
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal malignancies in HIV-infected or immunosuppressed patients: pathologic features and review of the literature.
  • The gastrointestinal (GI) tract is a common internal organ to be involved by human immunodeficiency virus (HIV)-related malignancies.
  • It is the second most common site for Kaposi sarcoma after skin, and the commonest visceral site, for Kaposi sarcoma in AIDS patients.
  • GI lymphomas have been documented in approximately 25% of AIDS patients with systemic lymphomas.
  • Moreover, GI involvement of AIDS-lymphoma has been associated with poor prognosis and short survival.
  • Several other malignancies that occur in the GI tract are also closely related to HIV-infected or immunosuppressed individuals; these include posttransplant lymphoproliferative disorder, Epstein-Barr virus-associated smooth muscle tumors, anal precancerous lesions, and squamous cell carcinoma.
  • As a result of active antiretroviral therapy, patients infected with HIV are living longer and are consequently at increased risk for development of cancer.
  • Therefore, it is possible that the number of AIDS-associated malignancies will rise and the pattern of tumors may change in the future.
  • In this paper, the clinicopathologic features of GI malignancies associated with AIDS patients are reviewed and the differential diagnosis with other mimic lesions is discussed.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / pathology. Gastrointestinal Neoplasms / pathology. Immunocompromised Host. Immunosuppression. Lymphoma, AIDS-Related / pathology. Sarcoma, Kaposi / pathology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18049132.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 103
  •  go-up   go-down


73. Epstein JB, Cabay RJ, Glick M: Oral malignancies in HIV disease: changes in disease presentation, increasing understanding of molecular pathogenesis, and current management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Nov;100(5):571-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral malignancies in HIV disease: changes in disease presentation, increasing understanding of molecular pathogenesis, and current management.
  • Infection with human immunodeficiency virus (HIV) and progression to acquired immune deficiency syndrome (AIDS) are associated with a vide variety of morbidities.
  • Local and systemic diseases can develop in association with HIV infection and may manifest themselves as malignancies of the oropharynx.
  • Advances in HIV management, fueled by increasing understanding of molecular pathogenesis, have resulted in marked changes in the prevalence of oral malignant disease.
  • This paper discusses recent trends in the presentation and treatment of malignancies related to HIV and AIDS with an emphasis on malignancies seen in the oral cavity.
  • [MeSH-minor] Animals. Antiretroviral Therapy, Highly Active. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / therapy. Carcinoma, Squamous Cell / virology. DNA, Viral / analysis. Developed Countries. Herpesvirus 4, Human / isolation & purification. Humans. Lymphoma, AIDS-Related / complications. Lymphoma, AIDS-Related / epidemiology. Lymphoma, AIDS-Related / therapy. Prevalence. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / therapy. United States / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16243242.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Number-of-references] 82
  •  go-up   go-down


74. Rochford R, Feuer G, Orem J, Banura C, Katongole-Mbidde E, Mwanda WO, Moormann A, Harrington WJ, Remick SC: Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma. East Afr Med J; 2005 Sep;82(9 Suppl):S155-60
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma.
  • BACKGROUND: Strategies to circumvent or lessen the myelotoxicity associated with combination chemotherapy may improve the overall outcome of the management of patients particularly in resource poor settings.
  • OBJECTIVES: To develop effective non-myelotoxic therapies for Burkitt's Lymphoma (BL) and AIDS-related non-Hodgkin's lymphoma.
  • CONCLUSION: Myelotoxic death rates using multi-agent induction chemotherapy approach 25% for endemic Burkitt's lymphoma and range between 20% to 60% for AIDS-related malignancy.
  • This is mostly explained by the paucity of supportive care compounded by wasting and inanition attributable to advanced cancer and HIV infection making patients more susceptible to myelosuppressive side effects of cytotoxic chemotherapy.
  • Investigations and alternative approaches that lessen or circumvent myelotoxicity of traditional cytotoxic chemotherapy for the management of Burkitt's lymphoma and AIDS-related non-Hodgkin's lymphoma in the resource-constrained setting are warranted.
  • This can be achieved by developing targeted anti-viral and other strategies, such as the use of bryostatin 1 and vincristine, and by developing a preclinical mouse model to frame the clinical rationale for a pilot trial of metronomic therapy for the treatment of Burkitt's and AIDS-related lymphoma.
  • Implementation of these investigational approaches must be encouraged as viable anti-cancer therapeutic strategies particularly in the resource-constrained settings.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy. Macrolides / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619692.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Kenya
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bryostatins; 0 / Macrolides; 37O2X55Y9E / bryostatin 1; 5J49Q6B70F / Vincristine
  • [Number-of-references] 38
  •  go-up   go-down


75. Kanmogne GD: Noninfectious pulmonary complications of HIV/AIDS. Curr Opin Pulm Med; 2005 May;11(3):208-12
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninfectious pulmonary complications of HIV/AIDS.
  • PURPOSE OF REVIEW: This article reviews recent findings on noninfectious pulmonary complications of HIV/AIDS, with a focus on HIV/AIDS-related lung malignancies and pulmonary hypertension, and discusses their incidence in the highly active antiretroviral therapy (HAART) era.
  • RECENT FINDINGS: Noninfectious pulmonary complications of HIV/AIDS are now recognized as important contributors to morbidity and mortality in HIV-infected patients.
  • This is especially the case for HIV-related lung cancer and other non-AIDS-defining malignancies, which are now being diagnosed with increased frequency in HIV-infected patients.
  • The incidence of Kaposi sarcoma and AIDS-related lymphoma has decreased in the HAART era, but compared with the general population, the risk of these malignancies and pulmonary hypertension is still very high in HIV-infected patients.
  • Concurrent use of HAART and chemotherapy improves prognosis and survival of patients with AIDS-related lymphoma.
  • For patients with HIV-related pulmonary hypertension, some studies show no beneficial effect of HAART whereas other reports show that HAART improves patient survival and response to antihypertensive treatment.
  • SUMMARY: The beneficial effect of HAART and improved immune response on the treatment of Kaposi sarcoma and AIDS-related lymphoma suggests that HIV or viral-induced immunosuppression plays an important role in the development of these malignancies.
  • Evidence from current studies suggests that HAART does not protect against HIV-related lung cancer.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / epidemiology. Hypertension, Pulmonary / epidemiology. Lung Neoplasms / epidemiology. Lymphoma, AIDS-Related / epidemiology. Sarcoma, Kaposi / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15818181.001).
  • [ISSN] 1070-5287
  • [Journal-full-title] Current opinion in pulmonary medicine
  • [ISO-abbreviation] Curr Opin Pulm Med
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / 1KO1MH068214-1
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


76. Yasuoka A: [Opportunistic infections in HIV/AIDS]. Nihon Rinsho; 2010 Mar;68(3):486-90
HIV InSite. treatment guidelines - Pneumocystosis and HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Opportunistic infections in HIV/AIDS].
  • The number of diagnosed AIDS and HIV infection is still increasing year by year in Japan.
  • Increment of malignancies such as malignant lymphoma and Kaposi's sarcoma is remarkable in recent years.
  • Although diagnosis and treatment of OIs are almost established, some novel diagnostic tests and treatment option have developed and imploved the clinical outcome of HIV-related OIs.
  • [MeSH-major] AIDS-Related Opportunistic Infections

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20229795.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 2
  •  go-up   go-down


77. Ramírez-Olivencia G, Valencia-Ortega ME, Martin-Carbonero L, Moreno-Celda V, González-Lahoz J: [Malignancies in HIV infected patients: study of 139 cases]. Med Clin (Barc); 2009 Nov 21;133(19):729-35
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignancies in HIV infected patients: study of 139 cases].
  • The purpose of this study was to describe the types of tumor, clinical features and prognosis of HIV infected patients with malignant diseases.
  • Information was collected on age, sex, risk factors for HIV, HBV/HCV coinfection, malignancies, diagnosis of AIDS, viral load and CD4 cell counts at diagnosis, antiretroviral therapy and mortality.
  • A total of 139 HIV-infected patients were identified who had at least one malignancy.
  • RESULTS: Types of malignancy were Kaposi's Sarcoma (n=43, 30.9%); non-Hodgkin lymphoma (n=42, 30.2%); gynecologic malignancy (n=16, 11.5%); Hodgkin's disease (n=15, 10.8%); hepatocellular carcinoma (n=7, 5%) and others (n=16, 11.5%).
  • There were 77 (55.4%) patients on HAART when cancer was diagnosed.
  • CONCLUSIONS: Increased survival of HIV-infected patients receiving HAART makes it possible the development of secondary tumors and AIDS- unrelated malignancies, sometimes related to another virus.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19880148.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


78. Lebovitch S, Mydlo JH: HIV-AIDS: urologic considerations. Urol Clin North Am; 2008 Feb;35(1):59-68; vi
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-AIDS: urologic considerations.
  • This article reviews conditions such as HIV-related urinary tract infections, urolithiasis, voiding dysfunction, fertility, sexual dysfunction, HIV-related nephropathy, malignancies, and occupational exposure and prophylaxis.
  • [MeSH-major] AIDS-Associated Nephropathy. HIV Infections / complications. Urologic Diseases / complications. Urologic Diseases / therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18061024.001).
  • [ISSN] 0094-0143
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 80
  •  go-up   go-down


79. Kiely B, O'Flaherty J, Surah S, Kieran J, O'Donnell D, Bergin C, Mulcahy F: HIV-related malignancies pre- and post-highly active antiretroviral therapy: experiences in an inner city tertiary referral centre. Int J STD AIDS; 2010 May;21(5):332-6
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-related malignancies pre- and post-highly active antiretroviral therapy: experiences in an inner city tertiary referral centre.
  • With highly active antiretroviral therapy (HAART), AIDS-defining malignancies are becoming less common.
  • The aim of this study was to review the demographics and outcomes of patients with cancer in the post-HAART era and to assess the impact of changing demographics and HAART through comparing them with previously published pre-HAART data from the same centre.
  • A retrospective chart review of 42 patients diagnosed with malignancy from 2000 to 2007 was performed and compared with pre-HAART (1987-1994) data.
  • The incidence of malignancies has decreased from 5.2% to 2.4%.
  • Non-AIDS-defining malignancies have increased and were associated with longer duration of HIV infection.
  • The change in patient demographics did not have an impact on the type of malignancies diagnosed.
  • Overall the incidence of malignancy has decreased; however, the increase in non-AIDS-defining malignancies highlights the importance of early diagnosis, use of HAART and prospective surveillance.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20498102.001).
  • [ISSN] 0956-4624
  • [Journal-full-title] International journal of STD & AIDS
  • [ISO-abbreviation] Int J STD AIDS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


80. Sunil M, Reid E, Lechowicz MJ: Update on HHV-8-Associated Malignancies. Curr Infect Dis Rep; 2010 Mar;12(2):147-54

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on HHV-8-Associated Malignancies.
  • The human herpesvirus 8 (HHV-8) is the oncogenic virus associated with Kaposi's sarcoma (KS) and lymphoproliferative disorders, namely, primary effusion lymphoma and multicentric Castleman's disease.
  • KS is among the most common malignancies seen in HIV-infected patients despite the decreased incidence of KS in the era of highly active antiretroviral therapy.
  • This review summarizes the recent developments in the fields of virus transmission, molecular biology, and treatment of HHV-8-related neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2008 Feb;82(3):1518-25 [18032494.001]
  • [Cites] Nature. 2007 Dec 13;450(7172):1096-9 [18075594.001]
  • [Cites] Ann Intern Med. 2007 Dec 18;147(12):836-9 [18087054.001]
  • [Cites] Blood. 2008 May 1;111(9):4731-40 [18199825.001]
  • [Cites] Cancer Lett. 2008 May 18;263(2):182-8 [18234418.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1236-7 [18525275.001]
  • [Cites] Clin Infect Dis. 2008 Sep 1;47(5):684-8 [18652555.001]
  • [Cites] Transplantation. 2008 Sep 15;86(5):738-44 [18791457.001]
  • [Cites] Clin Infect Dis. 2008 Nov 1;47(9):1209-15 [18808357.001]
  • [Cites] J Clin Virol. 2009 Jan;44(1):81-3 [18835212.001]
  • [Cites] J Virol. 1999 May;73(5):4156-70 [10196312.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3279-81 [11050015.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]
  • [Cites] N Engl J Med. 2005 Mar 31;352(13):1317-23 [15800227.001]
  • [Cites] J Infect Dis. 2006 Apr 15;193(8):1054-62 [16544245.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1389-94 [16549833.001]
  • [Cites] Lancet. 2006 May 6;367(9521):1495-502 [16679162.001]
  • [Cites] Nat Genet. 2006 Jun;38 Suppl:S25-30 [16736021.001]
  • [Cites] Mol Immunol. 2007 Feb;44(6):1352-60 [16828498.001]
  • [Cites] Cancer Cell. 2006 Aug;10(2):133-43 [16904612.001]
  • [Cites] Pathol Int. 2006 Oct;56(10):617-24 [16984619.001]
  • [Cites] J Infect Dis. 2006 Oct 15;194(8):1078-88 [16991082.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1550-8 [17047149.001]
  • [Cites] PLoS Pathog. 2006 Oct;2(10):e116 [17069461.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1129-35 [17154170.001]
  • [Cites] Science. 2007 Apr 27;316(5824):604-8 [17463289.001]
  • [Cites] N Engl J Med. 2008 Jan 31;358(5):535-6; author reply 536 [18234764.001]
  • [Cites] Am J Hematol. 2008 Jun;83(6):498-503 [18260115.001]
  • [Cites] Am J Transplant. 2008 Mar;8(3):707-10 [18261181.001]
  • [Cites] Am J Transplant. 2008 Apr;8(4):906-7 [18294348.001]
  • [Cites] J Virol. 2008 May;82(9):4235-49 [18305042.001]
  • [Cites] Virology. 2008 May 25;375(1):94-102 [18321555.001]
  • [Cites] Br J Haematol. 2008 May;141(4):559-61 [18341641.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 May;14(5):601-2 [18410904.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] AIDS. 2008 May 11;22(8):937-45 [18453853.001]
  • [Cites] Am J Surg Pathol. 2008 Jul;32(7):1006-12 [18469709.001]
  • [Cites] J Infect Dis. 2008 Jul 1;198(1):23-30 [18491970.001]
  • [Cites] Am J Epidemiol. 2008 Aug 1;168(3):311-20 [18515794.001]
  • [Cites] AIDS. 2008 May 31;22(9):1019-28 [18520345.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1232-4 [18525273.001]
  • [Cites] Curr Opin Infect Dis. 2007 Apr;20(2):152-6 [17496573.001]
  • [Cites] PLoS Pathog. 2007 May 11;3(5):e65 [17500590.001]
  • [Cites] Cancer. 2007 Aug 25;111(4):224-33 [17554754.001]
  • [Cites] J Infect Dis. 2007 Jul 15;196(2):199-207 [17570106.001]
  • [Cites] AIDS. 2007 Jul 31;21(12):1541-5 [17630548.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5297-9 [18854561.001]
  • [Cites] Semin Cancer Biol. 2008 Dec;18(6):423-36 [18948197.001]
  • [Cites] Int Urol Nephrol. 2009;41(3):679-85 [19009366.001]
  • [Cites] J Med Virol. 2008 Dec;80(12):2153-60 [19040293.001]
  • [Cites] Transplantation. 2009 Jan 27;87(2):157-63 [19155967.001]
  • [Cites] Mod Pathol. 2009 May;22(5):618-26 [19287457.001]
  • [Cites] J Infect Dis. 2009 Aug 1;200(3):430-8 [19534596.001]
  • [Cites] Leukemia. 2009 Oct;23(10):1867-74 [19554030.001]
  • [Cites] Lancet. 1990 Jan 20;335(8682):123-8 [1967430.001]
  • [Cites] Br J Haematol. 2009 Nov;147(3):405-8 [19681885.001]
  • [Cites] J Korean Med Sci. 2009 Oct;24(5):970-4 [19795003.001]
  • [Cites] Lancet. 1981 Sep 19;2(8247):598-600 [6116083.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3350-6 [17664482.001]
  • [Cites] Mol Cancer Ther. 2007 Aug;6(8):2360-70 [17699731.001]
  • [Cites] Am J Surg Pathol. 2007 Sep;31(9):1439-45 [17721201.001]
  • [Cites] J Virol. 2007 Dec;81(23):12836-45 [17881434.001]
  • [Cites] N Engl J Med. 2007 Sep 27;357(13):1352-3 [17898112.001]
  • [Cites] PLoS Pathog. 2007 Sep 7;3(9):1348-60 [17907806.001]
  • [Cites] Br J Haematol. 2008 Jan;140(1):13-24 [17991301.001]
  • (PMID = 20461118.001).
  • [ISSN] 1534-3146
  • [Journal-full-title] Current infectious disease reports
  • [ISO-abbreviation] Curr Infect Dis Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Pancharoen C, Nuchprayoon I, Thisyakorn U, Chokephaibulkit K, Veerakul G, Punpanich W, Kanjanapongkul S, Mekmullica J, Wongsawat J, Bowonkiratikachorn P, Hongsiriwon S, Thanarattanakorn P, Kosalaraksa P, Wiangnon S, Saerejittima A, Kochavate S: Hospital-based epidemiologic survey of malignancies in children infected with human immunodeficiency virus in Thailand. Pediatr Infect Dis J; 2005 Oct;24(10):923-4
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hospital-based epidemiologic survey of malignancies in children infected with human immunodeficiency virus in Thailand.
  • To determine the incidence and spectrum of malignancies in human immunodeficiency virus-infected children, we surveyed 48 hospitals in Thailand between 1996 and 2000.
  • There were 23 children (14 boys and 9 girls; average age at diagnosis of malignancy, 4.2 years), and the incidence rate was 0.6 per 1000 person-years.
  • The most common malignancy was lymphoma (87.0%).
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. HIV Infections / complications. HIV Infections / epidemiology. Hospitals. Lymphoma, AIDS-Related / epidemiology. Neoplasms / epidemiology


82. Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, Rosenthal E, Jougla E, Cacoub P, Salmon D, Chêne G, Morlat P, Agence Nationale de Recherches sur le Sida et les Hépatites Virales EN19 Mortalité Study Group, Mortavic Study Group: Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Clin Infect Dis; 2009 Mar 1;48(5):633-9
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey.
  • BACKGROUND: The goal of the current study was to describe the distribution and characteristics of malignancy related deaths among human immunodeficiency virus (HIV)-infected patients with use of data obtained from a national survey conducted in France in 2005 and to compare with results obtained from a similar survey conducted in 2000.
  • RESULTS: Among the 1042 deaths reported in 2005 (964 were reported in 2000), 344 were cancer related (34%), which represented a significant increase from 2000 (29% of deaths were cancer related) (P=.02); 134 of the cancer-related deaths were AIDS related and 210 were not AIDS related.
  • Among the cancer-related causes of death, the proportion of hepatitis-related cancers (6% in 2000 vs. 11% in 2005) and non-AIDS/hepatitis-related cancers (38% in 2000 vs 50% in 2005) significantly increased from 2000 to 2005 (P=.03 and P=.01, respectively), compared with the proportion of cancer that was AIDS related and adjusting for age and sex.
  • Among cases involving AIDS, the proportion of non-Hodgkin lymphoma-associated deaths did not change statistically significantly between 2000 and 2005 (11% and 10% of deaths, respectively).
  • CONCLUSIONS: In this study, an increasing proportion of lethal non-AIDS-related cancers was demonstrated from 2000 to 2005; meanwhile, the proportion of lethal AIDS-related cancers remained stable among HIV-infected patients.
  • Thus, cancer prophylaxis, early diagnosis, and improved management should be included in the routine long-term follow-up of HIV-infected patients.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Infect Dis. 2009 Aug 1;49(3):481-2 [19586399.001]
  • [CommentIn] Clin Infect Dis. 2009 Mar 1;48(5):640-1 [19202628.001]
  • (PMID = 19202627.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Chêne G; Costagliola D; Jougla E; May T; Morlat P; Salmon D; Cacoub P; Rosenthal E; Bonnet F; Burty C; Lewden C; François M; Boileau J; Zouari H; Tourteau F; Bursacchi P; Delfraissy JF; Semaille C; Redecker S; Imbert Y; Rispal P; Allegre T; Riou J; Marquant M; Undreiner P; Abino J; Barel P; Greziller; Gosse; Lagier A; Bastide D; Schmit J; Decaux N; Chennebault J; Fialaire P; Abgueguen P; Loison J; Gaillat J; Legrand E; Dor J; Quinsat D; Lerousseau L; Chavaillon; Toquet-Maillet E; Sutton L; Genet P; Salord J; Raison G; Dubois D; Lierman Y; Bervar J; Castan B; Malbec D; Delassus J; Bakir R; Lepeu G; Pichancourt G; Theodourou-Touchais A; De La Blanchardiere OA; Evon P; Aubry Y; Giffo B; Bonnal F; Labarrere S; Amanieu M; Valet D; Faller J; Eglinger P; Duchene F; Humbert P; Dupond J; Estavoyer J; Hoen B; Roche C; Chirouze C; Faucher J; Oziol E; Saad A; Cabrol M; Gateau P; Seiberras S; Vidal C; Mazari A; Bentata M; Honore P; Bouchaud O; Bessin C; Jeantils V; Tassi S; Fain O; Dupon M; Morlat P; Beylot J; Lacoste D; Bonarek M; Bernard N; Bonnet F; Ragnaud J; Longy-Boursier M; Mercie P; Series C; Portal B; Terrier F; Rouveix E; Olivier C; Vaillant J; Moulias S; Hanslik T; Granier P; Colucci T; Mornet M; Aaron L; Guimard Y; Agbodjan J; Julien J; Fabre M; Garre M; Gouerou; Savary O; Nousbaum J; Granier H; Brousse P; Verdon R; Feret P; Guivarch; Sire S; Simonet P; Tempesta S; Vialatte B; Prudhomme L; Djossou F; Bichat S; Nacher M; Couppie P; Dellinger; Picard J; Sabbagh; Rogeaux O; Penalba C; Aubert C; Alba C; Galanaud P; Delavalle A; Boue F; Defuentes G; Pik J; Laurichesse H; Beytout J; Cormerais L; Fantin B; Uludag A; Mantz J; Cohen J; Kohser F; Plaisance N; Blaison G; Martinot M; Minozzi C; Ferreira C; Zeng F; Domart Y; Merrien D; Zylberait D; Devidas A; Turpauld I; Chevojon P; Bardet M; Jacquemard P; Sobel A; Jung C; Dumont C; Chousterman M; Housset B; Bassinet L; Schortgen F; Loste P; Antoniotti O; Nehme E; Granet P; Brunello; Portier H; Grappin M; Buisson M; Duong M; Braconnier C; Waldner-Combernoux A; Laine J; Brousse A; Cardon G; Visticot F; Vella M; Bonnevie F; Vanrenterghem; Soupison T; Gruat N; Roche J; Sicot; Saraux J; Lepretre A; El Hajj L; Frossard; Brung M; Lefebvre; Beguinot I; Schuhmacher H; Hirsch J; Reumont G; Saad; Galan; Estebe; Cabie A; Abel S; Quist D; Counillon E; Armero R; Del Giudice P; Gamblin V; Bouchard I; De Truchis P; Berthe H; Leclercq P; Brambilla C; Gineste E; Sarrot-Reynauld F; Jenny; Class J; Raynaud-Simon A; Alvarez F; Perre P; Aubry O; Suaud I; Courbes I; Batejat B; Dupont A; Lagarde P; David-Ouaknine F; Le Moigne E; Caumont B; Robin M; Hoel J; Doll J; Colardelle P; Roussin-Bretagne S; Greder A; Belan; Bedos J; Bruneel F; Thibous F; Lemeunier; Delfraissy J; Goujard C; Rannou M; Wind P; Monange B; Lamblin C; Cochonat K; Balquet M; De Ribes DC; Force G; Ceccaldi J; Marcos J; Hammou Y; Codaccioni X; Weinbreck P; Genet C; Debette-Gratien M; Geffray L; Le Mercier Y; Follet; Duvert B; Lacroix; Arnaud A; Selles Y; Levasseur F; Touraine J; Jeanblanc F; Trepo C; Benmakhlouf N; Lebouche B; Peyramond D; Boibieux A; Chidiac C; Delorme C; Carbonnel E; Baty V; Kisterman J; Roubert X; Granier F; Tremolières F; Billy C; Perronne V; Testaud J; Gastaut J; Drogoul M; Fabre G; Moreau J; Vandergheynst E; Bourliere M; Ruiz J; Philibert P; Gamby T; Petit N; Simon F; Fontaneau; Meissonnier P; Bayada J; Christian B; Armand A; Galzin M; Dumas D; De Witte S; Jobard J; Poncet A; Caillet B; Reynes J; De Boever CM; Siffert M; Bourgeois A; Villadoro A; Tramoni C; Faucherre V; Larrey D; Jonquet O; Landreau; Andre M; Winter C; Roge C; Beck-Wirth G; Drenou B; Benomar M; Ruel M; Chemlal K; Raffi F; Morineau-Le Houssine P; Le Bavec CG; Lemesre F; Masson B; Loison F; Razafimahery M; De Lacour JL; Dellamonica P; Mondain-Miton V; Cua E; Oran N; Valerio L; Rosenthal E; Fuzibet J; Tran A; Brocker P; Barrelier P; Vincent D; Mauboussin J; Barbuat C; Rouanet I; Jourdan N; Sotto A; Del Bucchia F; Jourdan J; Lapine M; Capdevielle P; Lacassin-Beller F; Droetto F; Diab G; Grihon F; Arsac P; Hocqueloux L; Levasseur M; Fourdilis M; Jarno P; Derouineau J; Morel P; Timsit F; Compagnucci A; Oksenhendler E; Gerard L; Delgado J; Sereni D; Lascoux-Combe C; Viard J; Dupont B; Maignan A; Bergmann J; Sellier P; Magnier J; Pialoux G; Godard V; Goetschel A; Lebrette M; Weiss L; Tisne-Dessus D; Leport C; Ecobichon J; Colasante U; Guillevin L; Salmon-Ceron D; Pietri M; Brunet A; Silbermann B; Blanche P; Schoen H; Valantin M; Hausfater P; Martinez V; Herson S; Simon A; Brancon C; Girard P; Begle A; Raguin G; Lupin C; Molina J; Ponscarme D; Garrait V; Cabotin P; Janier M; Spindler E; Yeni P; Gerbe J; Cabane J; Ziza J; Aerts J; Carlet J; Gilquin J; Auperin I; Misset B; Crof A; Piette J; Cacoub P; Turpin G; Varet B; Dupin N; Le Jeunne C; Aslangul E; Pol S; Poynard T; Lebray P; Carbonell N; Benlian P; Goujon M; Dhainaut J; Charpentier J; Andrieu J; Brunel M; Landgraf N; Bary M; Pouyanne; Meraud J; Riviere C; Aumaître H; Saada M; Cros H; Pellegrin J; Adjeoda R; Durieu I; Rousset H; Vital-Durand D; Lamaury I; Sow M; Hillion D; Masson H; Becq-Giraudon B; Le Moal G; Silvain C; Danne O; Blum L; Larzul J; Perfezou P; Rouger C; Novella J; Michelet C; Tattevin P; Arvieux C; Souala F; Delmont-Hanry M; Guyader D; Gandemer V; Camus C; Taverson; Lutz M; Climas M; Wemeau J; Gueit I; Suel P; Caron F; Mechali D; Khuong-Josses M; Etienne Y; Lucht F; Fresard A; Ronat V; Vergnon; Garcier; Deluca J; Randrianjohany A; Monnot H; Poubeau P; Andre H; Beuscart C; Aubry M; Hurbin E; Debord T; Rapp C; Bissuel F; Walter V; Ferret J; Bonnefoy M; Riche A; Marot J; Michau C; Bonnin E; Pasdeloup T; Chaby G; Grilliat E; Wurtz E; Loth F; Kitschke B; Line D; Gaud C; Sautron C; Cathebras P; Welker Y; Sandron D; Lang J; Fischer P; Pasquali J; Lalanne H; Chartier C; Berlin C; Andres E; Christmann D; Hansmann Y; Fraisse P; Bletry O; Zucman D; Majerholc C; Stern M; Couderc L; Petitou J; Truchetet F; Pouaha J; Romand P; Lafeuillade A; Lambry V; Bernard P; Adoue D; Duffaut M; Marchou B; Garipuy D; Cuzin L; Marchou B; Garipuy D; Cuzin L; Uzan M; Vinel J; Metivier S; Didier A; Rouquet R; Mouton Y; Yazdanpanah Y; Marysse F; Guery B; Faure K; Besnier J; Le Bret P; Nau P; Sigogneau H; Bressieux J; Libbrecht E; Rezzouk L; Collignon A; Ponceau B; Kyndt X; Vermersch-Langlin A; May T; Burty C; Lederlin P; Poinsignon Y; Creusat C; Richard C; Merle C; Essayan A; Vittecoq D; Bolliot C; Quignard; Patey O; Dellion S; Chossat I
  •  go-up   go-down


83. Makombe SD, Harries AD, Yu JK, Hochgesang M, Mhango E, Weigel R, Pasulani O, Fitzgerald M, Schouten EJ, Libamba E: Outcomes of patients with Kaposi's sarcoma who start antiretroviral therapy under routine programme conditions in Malawi. Trop Doct; 2008 Jan;38(1):5-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIDS-associated Kaposi's sarcoma (KS) is the most common AIDS-related malignancy in sub-Saharan Africa, with a generally unfavourable prognosis.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18302849.001).
  • [ISSN] 0049-4755
  • [Journal-full-title] Tropical doctor
  • [ISO-abbreviation] Trop Doct
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  •  go-up   go-down


84. Hull MW, Phillips P, Montaner JS: Changing global epidemiology of pulmonary manifestations of HIV/AIDS. Chest; 2008 Dec;134(6):1287-98
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing global epidemiology of pulmonary manifestations of HIV/AIDS.
  • Tremendous advances have occurred in the care of patients with HIV/AIDS resulting from the advent of highly active antiretroviral therapy (HAART).
  • This has led to differences in the presentations of HIV-related pulmonary disease.
  • Noninfectious pulmonary conditions such as chronic obstructive lung disease and pulmonary malignancies are gaining prominence as patients are accessing antiretroviral care and enjoying significantly extended survival.
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. Antiretroviral Therapy, Highly Active / utilization. Developed Countries. Developing Countries. Global Health. Lung Diseases / epidemiology


85. Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, Gatell J, Rakhmanova A, Johnson M, Kirk O, Lundgren J, EuroSIDA Study Group: Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr; 2010 Oct;55(2):262-70
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serious fatal and nonfatal non-AIDS-defining illnesses in Europe.
  • BACKGROUND: Little is known about the incidence and risk factors for serious non-AIDS-defining events.
  • METHODS: The incidence of non-AIDS events (malignancies, end-stage renal disease, liver failure, pancreatitis, cardiovascular disease), and AIDS after January 1, 2001, was calculated; Poisson regression was used to investigate factors associated with non-AIDS and AIDS.
  • RESULTS: Among 12,844 patients, 1058 were diagnosed with a non-AIDS event [incidence 1.77 per 100 person-years of follow-up; 95% confidence interval (CI): 1.66 to 1.87]; 462 patients (43.7%) died.
  • The incidence of AIDS (1025 diagnoses; 339 deaths, 33.1%) was 1.72 per 100 person-years of follow-up (1.61 to 1.83).
  • After adjustment, older age [incidence rate ratio (IRR): 1.71 per 10 years older, 95% CI: 1.60 to 1.83], diabetes (IRR: 1.49, 95% CI: 1.22 to 1.82) and hypertension (IRR: 1.63, 95% CI: 1.43 to 1.87) were associated with non-AIDS events.
  • Compared with patients without an event, there was a 4-fold increased risk of death after an AIDS event (relative hazard: 4.14; 95% CI 3.47 to 4.94) and almost a 7-fold increased risk of death after a non-AIDS event (relative hazard: 6.72; 95% CI: 5.61 to 8.05).
  • CONCLUSIONS: Non-AIDS events were common in the combination antiretroviral therapy era and associated with considerably mortality.
  • Evidence on the impact of modifying immunodeficiency and lifestyle-related factors on the risk of non-AIDS events in HIV-infected persons is an important but unmet research need.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20700060.001).
  • [ISSN] 1944-7884
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Losso M; Elias C; Vetter N; Zangerle R; Karpov I; Vassilenko A; Suetnov O; Clumeck N; De Wit S; Poll B; Colebunders R; Vandekerckhove L; Hadziosmanovic V; Kostov K; Begovac J; Machala L; Rozsypal H; Sedlacek D; Gerstoft J; Kronborg G; Benfield T; Larsen M; Gerstoft J; Katzenstein T; Hansen AB; Skinhøj P; Pedersen C; Zilmer K; Ristola M; Katlama C; Viard JP; Girard PM; Livrozet JM; Vanhems P; Pradier C; Dabis F; Neau D; Rockstroh J; Schmidt R; van Lunzen J; Degen O; Stellbrink HJ; Staszewski S; Bogner J; Fätkenheuer G; Kosmidis J; Gargalianos P; Xylomenos G; Perdios J; Panos G; Filandras A; Karabatsaki E; Sambatakou H; Banhegyi D; Mulcahy F; Yust I; Turner D; Burke M; Pollack S; Hassoun G; Maayan S; Chiesi A; Esposito R; Mazeu I; Mussini C; Arici C; Pristera R; Mazzotta F; Gabbuti A; Vullo V; Lichtner M; Chirianni A; Montesarchio E; Gargiulo M; Antonucci G; Iacomi F; Narciso P; Vlassi C; Zaccarelli M; Lazzarin A; Finazzi R; Galli M; Ridolfo A; d'Arminio Monforte A; Rozentale B; Chaplinskas S; Hemmer R; Staub T; Reiss P; Bruun J; Maeland A; Ormaasen V; Knysz B; Gasiorowski J; Horban A; Bakowska E; Prokopowicz D; Flisiak R; Boron-Kaczmarska A; Pynka M; Beniowski M; Mularska E; Trocha H; Jablonowska E; Malolepsza E; Wojcik K; Antunes F; Valadas E; Mansinho K; Maltez F; Duiculescu D; Rakhmanova A; Vinogradova E; Buzunova S; Jevtovic D; Mokrá M; Stanekova D; Tomazic J; González-Lahoz J; Soriano V; Martin-Carbonero L; Labarga P; Moreno S; Clotet B; Carlos A 3rd; Moreno S; Clotet B; Jou A; Paredes R; Tural C; Puig J; Bravo I; Gatell JM; Miró JM; Domingo P; Gutierrez M; Mateo G; Sambeat MA; Karlsson A; Persson PO; Flamholc L; Ledergerber B; Weber R; Francioli P; Cavassini M; Hirschel B; Boffi E; Furrer H; Battegay M; Elzi L; Kravchenko E; Chentsova N; Kutsyna G; Servitskiy S; Antoniak S; Krasnov M; Barton S; Johnson AM; Mercey D; Phillips A; Johnson MA; Mocroft A; Murphy M; Weber J; Scullard G; Fisher M; Leen C; Clotet B; Paredes R; Antunes F; Clotet B; Duiculescu D; Gatell J; Gazzard B; Horban A; Karlsson A; Katlama C; Ledergerber B; D'Arminio Montforte A; Phillips A; Rakhmanova A; Reiss P; Rockstroh J; Lundgren J; Kirk O; Mocroft A; Friis-Møller N; Cozzi-Lepri A; Bannister W; Ellefson M; Borch A; Podlekareva D; Kjaer J; Peters L; Reekie J; Kowalska J
  •  go-up   go-down


86. Heyns CF, Groeneveld AE, Sigarroa NB: Urologic complications of HIV and AIDS. Nat Clin Pract Urol; 2009 Jan;6(1):32-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urologic complications of HIV and AIDS.
  • Disease progression from HIV to AIDS and HIV-related mortality can be reduced effectively by several years of treatment with highly active antiretroviral therapy (HAART).
  • For patients who do not have access to HAART, HIV infection continues to be a lethal disorder characterized by opportunistic infection with uncommon organisms (e.g. mycobacteria, fungi, parasites and viruses), as well as lethal malignancies such as Kaposi sarcoma, non-Hodgkin lymphoma and squamous cell carcinoma of the penis or cervix.
  • In patients receiving HAART, urologic complications are likely to be caused by adverse effects of antiretroviral medication (e.g. indinavir urolithiasis) or disorders associated with aging, such as benign prostatic hyperplasia and prostate cancer.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Nat Clin Pract Urol. 2010 Apr;7(4):178
  • (PMID = 19132004.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 134
  •  go-up   go-down


87. Greene W, Kuhne K, Ye F, Chen J, Zhou F, Lei X, Gao SJ: Molecular biology of KSHV in relation to AIDS-associated oncogenesis. Cancer Treat Res; 2007;133:69-127
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular biology of KSHV in relation to AIDS-associated oncogenesis.
  • KSHV has been established as the causative agent of KS, PEL, and MCD, malignancies occurring more frequently in AIDS patients.
  • KSHV latent infection and lytic reactivation are characterized by distinct gene expression profiles, and both latency and lytic reactivation seem to be required for malignant progression.
  • As a sophisticated oncogenic virus, KSHV has evolved to possess a formidable repertoire of potent mechanisms that enable it to target and manipulate host cell pathways, leading to increased cell proliferation, increased cell survival, dysregulated angiogenesis, evasion of immunity, and malignant progression in the immunocompromised host.
  • The complex interplay between the two viruses dramatically elevates the risk for development of KSHV-induced malignancies, KS, PEL, and MCD.
  • In fact, clinically significant immune deficiency is not necessary for the induction of KSHV-related malignancy.
  • Because of variables such as lack of access to therapy noncompliance with prescribed treatment, failure to respond to treatment and the development of drug-resistant strains of HIV, KSHV-induced malignancies will continue to present as major health concerns.